



(86) Date de dépôt PCT/PCT Filing Date: 2001/05/24
(87) Date publication PCT/PCT Publication Date: 2001/11/29
(85) Entrée phase nationale/National Entry: 2002/11/19
(86) N° demande PCT/PCT Application No.: US 2001/017158
(87) N° publication PCT/PCT Publication No.: 2001/090156
(30) Priorités/Priorities: 2000/05/24 (09/579,240) US;
2000/10/10 (09/686,347) US; 2001/03/14 (60/275,980) US;
2001/05/23 (09/864,921) US

(51) Cl.Int.⁷/Int.Cl.⁷ C12N 15/57, C12N 15/63, C07K 14/47,
C12N 5/10, C07K 16/00, C07K 14/00, C07H 21/00


(71) Demandeur/Applicant:
THE BURNHAM INSTITUTE, US

(72) Inventeurs/Inventors:
REED, JOHN C., US;
PIO, FREDERICK F., CA;
GODZIK, ADAM, US;
STEHLIK, CHRISTIAN, US;
DAMIANO, JASON S., US;
LEE, SUG HYUNG, US;
...

(74) Agent: SMART & BIGGAR


(54) Titre : POLYPEPTIDES CONTENANT UN DOMAINE CARD, ACIDES NUCLEIQUES DE CODAGE, ET METHODES D'UTILISATION

(54) Title: CARD DOMAIN CONTAINING POLYPEPTIDES, ENCODING NUCLEIC ACIDS, AND METHODS OF USE



(57) Abrégé/Abstract:

The invention provides caspase recruitment domain (CARD) -containing polypeptides, CARD, NB-ARC, ANGIO-R, LRR and SAM domains therefrom, as well as encoding nucleic acid molecules and specific antibodies. The invention also provides related screening, diagnostic and therapeutic methods.



(72) Inventeurs(suite)/Inventors(continued): OLIVEIRA, VASCO A.M., US; HAYASHI, HIDEKI, JP;
PAWLOWSKI, KRZYSZTOF, SE

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
29 November 2001 (29.11.2001)

PCT

(10) International Publication Number
WO 01/90156 A2

(51) International Patent Classification⁷: **C07K 14/00**

(21) International Application Number: PCT/US01/17158

(22) International Filing Date: 24 May 2001 (24.05.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/579,240 24 May 2000 (24.05.2000) US
09/686,347 10 October 2000 (10.10.2000) US
60/275,980 14 March 2001 (14.03.2001) US
09/864,921 23 May 2001 (23.05.2001) US

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier applications:
US 09/579,240 (CIP)
Filed on 24 May 2000 (24.05.2000)
US Not furnished (CIP)
Filed on 23 May 2001 (23.05.2001)
US 09/686,347 (CIP)
Filed on 10 October 2000 (10.10.2000)
US 60/275,980 (CIP)
Filed on 14 March 2001 (14.03.2001)

(71) Applicant (for all designated States except US): **THE BURNHAM INSTITUTE** [US/US]; 10901 North Torrey Pines Road, La Jolla, CA 92037 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **REED, John, C.** [US/US]; 17044 El Camino Real, Rancho Santa Fe, CA 92067 (US). **PIO, Frederick, F.** [FR/CA]; 2142 Venables Street, Vancouver, British Colombia V5L 2J4 (CA). **GODZIK, Adam** [US/US]; 9184 Buckwheat Street, San Diego, CA 92129 (US). **STEHLIK, Christian** [AT/US]; 7535 Charmant Drive, Apt. 304, San Diego,

CA 92122 (US). **DAMIANO, Jason, S.** [US/US]; 329 Bonair Street, La Jolla, CA 92037-5900 (US). **LEE, Sug, Hyung** [KR/US]; 3895 Nobel Drive, Apt. 129, San Diego, CA 92122 (US). **OLIVEIRA, Vasco, A., M.** [PT/US]; 3929 Nobel Drive, Apt. 317, San Diego, CA 92122 (US). **HAYASHI, Hideki** [JP/JP]; 4-2-202 Mihara-cho, Nagasaki City 852-8123 (JP). **PAWLOWSKI, Krzysztof** [PL/US]; 8444 Capricorn Way #67, San Diego, CA 92126 (US).

(74) Agents: **WEBSTER, Melanie, K.** et al.; Campbell & Flores LLP, 7th Floor, 4370 La Jolla Village Drive, San Diego, CA 92122 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AT (utility model), AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ (utility model), DE, DE (utility model), DK, DK (utility model), DM, DZ, EE, EE (utility model), ES, FI, FI (utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (utility model), SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.


(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: CARD DOMAIN CONTAINING POLYPEPTIDES, ENCODING NUCLEIC ACIDS, AND METHODS OF USE



(57) Abstract: The invention provides caspase recruitment domain (CARD) -containing polypeptides, CARD, NB-ARC, ANGIO-R, LRR and SAM domains therefrom, as well as encoding nucleic acid molecules and specific antibodies. The invention also provides related screening, diagnostic and therapeutic methods.



WO 01/90156 A2

CARD DOMAIN CONTAINING POLYPEPTIDES, ENCODING
NUCLEIC ACIDS, AND METHODS OF USE

This invention was made in part with U.S.
Government support under NIH Grant No. GM61694 awarded
5 by the National Institutes of Health. The U.S.
Government has certain rights in this invention.

BACKGROUND OF THE INVENTION

FIELD OF THE INVENTION

This invention relates generally to the
10 fields of molecular biology and molecular medicine and
more specifically to the identification of proteins
involved in programmed cell death, cytokine processing
and receptor signal transduction, and associations of
these proteins.

15

BACKGROUND INFORMATION

Programmed cell death is a physiologic
process that ensures homeostasis is maintained between
cell production and cell turnover in essentially all
self-renewing tissues. In many cases, characteristic
20 morphological changes, termed "apoptosis," occur in a
dying cell. Since similar changes occur in different
types of dying cells, cell death appears to proceed
through a common pathway in different cell types.

In addition to maintaining tissue
25 homeostasis, apoptosis also occurs in response to a
variety of external stimuli, including growth factor
deprivation, alterations in calcium levels, free-
radicals, cytotoxic lymphokines, infection by some
viruses, radiation and most chemotherapeutic agents.

Thus, apoptosis is an inducible event that likely is subject to similar mechanisms of regulation as occur, for example, in a metabolic pathway. In this regard, dysregulation of apoptosis also can occur and is
5 observed, for example, in some types of cancer cells, which survive for a longer time than corresponding normal cells, and in neurodegenerative diseases where neurons die prematurely. In viral infections, induction of apoptosis can figure prominently in the
10 pathophysiology of the disease process, because immune-based for eradication of viral infections depend on elimination of virus-producing host cells by immune cell attack resulting in apoptosis.

Some of the proteins involved in programmed
15 cell death have been identified and associations among some of these proteins have been described. However, additional apoptosis regulating proteins remain to be found and the mechanisms by which these proteins mediate their activity remains to be elucidated. The
20 identification of the proteins involved in cell death and an understanding of the associations between these proteins can provide a means for manipulating the process of apoptosis in a cell and, therefore, selectively regulating the relative lifespan of a cell
25 or its relative resistance to cell death stimuli.

The principal effectors of apoptosis are a family of intracellular proteases known as Caspases, representing an abbreviation for Cysteine Aspartyl
Proteases. Caspases are found as inactive zymogens in
30 essentially all animal cells. During apoptosis, the caspases are activated by proteolytic processing at specific aspartic acid residues, resulting in the production of subunits that assemble into an active protease typically consisting of a heterotetramer

containing two large and two small subunits. The phenomenon of apoptosis is produced directly or indirectly by the activation of caspases in cells, resulting in the proteolytic cleavage of specific
5 substrate proteins. Moreover, in many cases, caspases can cleave and activate themselves and each other, creating cascades of protease activation and mechanisms for "auto"-activation. Thus, knowledge about the proteins that interact with and regulate caspases is
10 important for devising strategies for manipulating cell life and death in therapeutically useful ways. In addition, because caspases can also participate in cytokine activation and other processes, knowledge about the proteins that interact with caspases can be
15 important for manipulating immune responses and other biochemical processes in useful ways.

One of the mechanisms for regulating caspase activation involves protein-protein interactions mediated by a family of protein domains known as
20 caspase recruitment domains (CARDs). The identification of proteins that contain CARD domains and the elucidation of the proteins with which they interact, therefore, can form the basis for strategies designed to alter apoptosis, cytokine production,
25 cytokine receptor signaling, and other cellular processes. Thus, a need exists to identify proteins that contain CARD domains. The present invention satisfies this need and provides additional advantages as well.

30

SUMMARY OF THE INVENTION

The invention provides caspase recruitment domain (CARD)-containing polypeptides, and CARD, NB-ARC, ANGIO-R, LRR and SAM domains therefrom. Also

provided are chimeric polypeptides containing a CARD, NB-ARC, ANGIO-R, LRR or SAM domain of a CARD-containing polypeptide. Methods of producing CARD-containing polypeptides, and compositions containing
5 CARD-containing polypeptides and a pharmaceutically acceptable carrier, are also provided.

The invention further provides nucleic acid molecules encoding CARD-containing polypeptides and CARD, NB-ARC, ANGIO-R, LRR and SAM domains therefrom.
10 Also provided are antibodies directed against such polypeptides.

The invention also provides methods for identifying a nucleic acid molecule encoding a CARD-containing polypeptide, and methods for detecting
15 the presence of a CARD-containing polypeptide in a sample.

Further provided are methods of identifying a CARD-associated polypeptide (CAP), and methods of identifying an effective agent that alters the
20 association of a CARD-containing polypeptide with a CAP. The invention also provides methods of identifying an effective agent that modulates an activity of a NB-ARC domain of a CARD-containing polypeptide.

25 The invention also provides methods of altering the level of a biochemical process modulated by a CARD-containing polypeptide.

The invention further provides methods of treating a pathology characterized by abnormal cell
30 proliferation, abnormal cell death, or inflammation.

Also provided are methods of diagnosing or predicting clinical prognosis of a pathology characterized by an increased or decreased level of a CARD-containing polypeptide in a subject.

5

BRIEF DESCRIPTION OF THE FIGURES

Figure 1A shows the genomic organization of the CLAN (CARD 4/5X) gene on chromosome 2 deduced from the BAC 164M19 sequence from the SPG4 candidate region at 2p21-2p22 (Accession No. AL121653) and Homo sapiens chromosome 2 working draft sequence (Accession No. NT_005194.1). Figure 1B shows mRNA splicing generating CLAN A, B, C and D. Figure 1C shows the deduced domain structure for the splice forms of CARD4/5X (CLAN A, B, C and D).

Figure 2 shows an alignment of the protein sequence of the isoforms of CLAN (designated CLAN A, B, C and D; SEQ ID NOS:97, 99, 103 and 101, respectively). Dark boxes indicate identical amino acids, and white boxes indicate conserved amino acids.

Figure 3 shows the amino acid sequences of the CARD-A, CARD-B and NB-ARC domains of CARD3X (SEQ ID NOS: 170, 172 and 174, respectively).

Figure 4 shows an alignment of COP-1 (SEQ ID NO:86) and caspase-1 (SEQ ID NO:87). The amino acids shaded in black are identical.

Figure 5 shows an alignment of COP-2 (SEQ ID NO:90) and caspase-1 (SEQ ID NO:87), with the consensus sequence (SEQ ID NO:91) shown above the aligned

sequences. The amino acids shaded in black are identical.

Figure 6 shows IL-1 β secretion by COS7 cells transfected with the indicated amounts of expression
5 vectors encoding the indicated proteins.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides novel polypeptides involved in programmed cell death, or apoptosis. The principal effectors of apoptosis are a
10 family of intracellular cysteine aspartyl proteases, known as caspases. Caspase activity in the cell is regulated by protein-protein interactions. Similarly, protein-protein interactions influence the activity of other proteins involved in apoptosis. Several protein
15 interaction domains have been implicated in interactions among some apoptosis-regulating proteins. Among these is the caspase recruitment domain, or CARD-containing polypeptide which are so named for the ability of the CARD-containing polypeptides to bind
20 caspases. In addition to their ability to bind caspases, numerous CARD-containing polypeptides bind other proteins, particularly, other CARD-containing polypeptides. Further, CARD-containing polypeptides influence a variety of cellular and biochemical
25 processes beyond apoptosis, including cell adhesion, inflammation and cytokine receptor signaling.

In accordance with the present invention, there are provided isolated CARD-containing polypeptides or functional fragments thereof,
30 comprising substantially the same amino acid sequence as set forth in any of SEQ ID NOS: 12, 168, 188, 170,

172, 174, 176, 97, 99, 101, 103, 178, 180, 182, 184, 86 and 90.

The sequence identifiers set forth above correspond to the molecules described herein as set forth in Table 1.

Table 1

	<u>Designation</u>	<u>Nucleotide</u>	<u>Polypeptide</u>
		<u>SEQ ID NO:</u>	<u>SEQ ID NO:</u>
	CARD2X	11	12
	CARD2X CARD Domain	167	168
10	CARD3X	187	188 and 189
	CARD3X CARDA Domain	169	170
	CARD3X CARDB Domain	171	172
	CARD3X NB-ARC Domain	173	174
	CARD3X ANGIO-R Domain	175	176
15	CLAN A	96	97
	CLAN B	98	99
	CLAN C	100	101
	CLAN D	102	103
	CLAN CARD	177	178
20	CLAN NACHT	179	180
	CLAN LRR	181	182
	CLAN SAM	183	184
	COP1	85	86
	COP2	89	90

25 The terms "CARD-containing protein" or "CARD-containing polypeptide" as used herein refer to a protein or polypeptide containing a CARD domain. As used herein, the term "CARD domain" refers to a Caspase Recruitment Domain. A CARD domain is a well known

protein domain of approximately 80 amino acids with characteristic sequence conservation as described, for example, in Hofmann et al., Trends Biochem. Sci. 22:155-156 (1997). CARD domains have been found in
5 some members of the Caspase family of cell death proteases. Caspases-1, 2, 4, 5, 9, and 11 contain CARD domains near their NH2-termini. These CARD domains mediate interactions of the zymogen inactive forms of caspases with other proteins which can either activate
10 or inhibit the activation of these enzymes.

For example, the CARD domain of pro-caspase-9 binds to the CARD domain of a caspase-activating protein called Apaf-1 (Apoptosis Protease Activating Factor-1). Similarly, the CARD domain of pro-caspase-1
15 permits interactions with another CARD protein known as Cardiac (also referred to as RIP2 and RICK), which results in activation of the caspase-1 protease (Thome et al., Curr. Biol. 16:885-888 (1998)). Additionally, pro-caspase-2 binds to the CARD protein Raidd (also
20 know as Cradd), which permits recruitment of pro-caspase-2 to Tumor Necrosis Factor (TNF) Receptor complexes and which results in activation of the caspase-2 protease (Ahmad et al., Cancer Res. 57:615-619 (1997)). CARD domains can also participate
25 in homotypic interactions with themselves, resulting in self-association of polypeptides that contain these protein-interaction domains and producing dimeric or possibly even oligomeric complexes.

CARD domains can be found in association with
30 other types of functional domains within a single polypeptide, thus providing a mechanism for bringing a functional domain into close proximity or contact with a target protein via CARD:CARD associations involving two CARD-containing polypeptides. For example, the

Caenorhabditis elegans cell death gene *ced-4* encodes a protein that contains a CARD domain and a ATP-binding oligomerization domain called an NB-ARC domain (van der Biezen and Jones, Curr. Biol. 8:R226-R227). The CARD
5 domain of the CED-4 protein interacts with the CARD domain of a pro-caspase called CED-3. The NB-ARC domain allows CED-4 to self-associate, thereby forming an oligomeric complex which brings associated pro-CED-3 molecules into close proximity to each other. Because
10 most pro-caspases possess at least a small amount of protease activity even in their unprocessed form, the assembly of a complex that brings the proforms of caspase into juxtaposition can result in trans-processing of zymogens, producing the
15 proteolytically processed and active caspase. Thus, CED-4 employs a CARD domain for binding a pro-caspase and an NB-ARC domain for self-oligomerization, resulting in caspase clustering, proteolytic processing and activation.

20 In addition to their role in caspase activation, CARD domains have been implicated in other cellular processes. Some CARD-containing polypeptides, for example, induce activation of the transcription factor NF-kB. NF-kB activation is induced by many
25 cytokines and plays an important role in cytokine receptor signal transduction mechanisms (DiDonato et al., Nature 388:548-554 (1997)). Moreover, CARD domains are found in some proteins that inhibit rather than activate caspases, such as the IAP (Inhibitor of
30 Apoptosis Protein) family members, cIAP1 and cIAP2 (Rothe et al., Cell 83:1243-1252 (1995)) and oncogenic mutants of the Bcl-10 protein (Willis et al., Cell 96:35-45 (1999)). Also, though caspase activation resulting from CARD domain interactions is often
35 involved in inducing apoptosis, other caspases are

primarily involved in proteolytic processing and activation of inflammatory cytokines (such as pro-IL-1b and pro-IL-18). Thus, CARD-containing polypeptides can also be involved in cytokine receptor signaling and
5 cytokine production, and, therefore, can be involved in regulation of immune and inflammatory responses.

In view of the function of the CARD domain within the invention CARD-containing polypeptides or functional fragments thereof, polypeptides of the
10 invention are contemplated herein for use in methods to alter biochemical processes such as apoptosis, NF-kB induction, cytokine processing, cytokine receptor signaling, caspase-mediated proteolysis, thus having modulating effects on cell life and death (i.e.,
15 apoptosis), inflammation, cell adhesion, and other cellular and biochemical processes.

Invention CARD-containing polypeptides or functional fragments thereof (including CARD domains) are also contemplated in methods to identify CARD-
20 binding agents and CARD-associated polypeptides (CAPs) that alter apoptosis, NF-kB induction, cytokine processing, cytokine receptor signaling, caspase-mediated proteolysis, thus having modulating effects on cell life and death (i.e., apoptosis), inflammation,
25 cell adhesion, and other cellular and biochemical processes.

It is also contemplated herein that invention CARD-containing polypeptides can associate with other CARD-containing polypeptides to form invention hetero-
30 oligomers or homo-oligomers, such as heterodimers or homodimers. In particular, the association of the CARD domain of invention polypeptides with other CARD-

containing polypeptides, such as Apaf-1, CED-4, caspases-1, 2, 9, 11, cIAPs-1 and 2, CARDIAK, Raidd, Dark, CLAN, other invention CARD-containing polypeptides, and the like, including homo-
5 oligomerization, is sufficiently specific such that the bound complex can form *in vivo* in a cell or *in vitro* under suitable conditions. Similarly therefore, an invention CARD-containing polypeptide can associate with another CARD-containing polypeptide by CARD:CARD
10 form invention hetero-oligomers or homo-oligomers, such as heterodimers or homodimers.

In accordance with the present invention, sequences for novel CARD-containing polypeptides have been determined. Thus, the present invention provides
15 novel CARD-containing polypeptides, including the newly identified CARD-containing polypeptides designated CARD2X, CARD3X, CLAN A, CLAN B, CLAN C, CLAN D, COP-1 and COP-2 (set forth in SEQ ID NOS: 12, 188, 97, 99, 101, 103, 86 and 90).

20 In addition to CARD domains, invention polypeptides can contain one or more additional domains. The locations within the reference sequence of the domains described herein are set forth in Table 2.

Table 2

	<u>Domain</u>	<u>Corresponding amino acids</u>	<u>SEQ ID NO:</u>
	CARD2X CARD Domain	4-78 of SEQ ID NO:12	167 (nt) 168 (aa)
5	CARD3X CARDA Domain	2-78 of SEQ ID NO:107	169 (nt) 170 (aa)
	CARD3X CARDB Domain	105-185 of SEQ ID NO:107	171 (nt) 172 (aa)
10	CARD3X NB-ARC Domain	265-560 of SEQ ID NO:107	173 (nt) 174 (aa)
	CARD3X ANGIO-R Domain	437-839 of SEQ ID NO:107	175 (nt) 176 (aa)
	CLAN CARD Domain	1-87 of SEQ ID NO:97	177 (nt) 178 (aa)
15	CLAN NACHT Domain	161-457 of SEQ ID NO:97	179 (nt) 180 (aa)
	CLAN LRR Domain	760-965 of SEQ ID NO:97	181 (nt) 182 (aa)
20	CLAN SAM Domain	642-696 of SEQ ID NO:97	183 (nt) 184 (aa)

CARD3X (SEQ ID NO:88) contains at least four distinct domains: two CARD domains, designated CARD-A and CARD-B, an NB-ARC domain and an angio-R domain. A second in-frame, open reading frame that begins after a stop codon encodes a domain with several leucine rich repeats (LRR) (SEQ ID NO:189) (see Example). An invention CARD3X polypeptide can thus contain the amino acid sequence designated SEQ ID NO:188 and the amino acid sequence designated SEQ ID NO:189; contain SEQ ID NO:188 but not SEQ ID NO:189; or contain SEQ ID NO:189 but not SEQ ID NO:188. A murine CARD3X polypeptide can contain the amino acid sequence designated SEQ ID

NO:193, which is homologous to a portion of the human CARD3X ANGIO-R domain, with or without one or more additional CARD3X domains.

CLAN exists in four isoforms (see Example),
5 each of which contains a CARD domain. The longest isoform, CLAN-A, also contains an NB-ARC (NACHT) domain, a LRR domain and a SAM domain. CLAN represents a new member of the CED-4 related protein family. Numerous CED-4-related proteins have recently been
10 identified. These proteins belong to the CED-4 family of proteins, and include CED-4 (Yuan and Horvitz, Development 116:309-320 (1992)), Apaf-1, (Zou et al., Cell 90:405-413 (1997)), Dark (Rodriguez et al., Nature Cell Biol. 1:272-279 (1999)), and CARD4/Nod1 (Bertin et
15 al., J. Biol. Chem. 274:12955-12958 (1999) and Inohara et al., J. Biol. Chem. 274:14560-14567 (1999)). As used herein, a "CED-4 family" member or "CED-4 protein family" member, also referred to herein as a "NAC" polypeptide, is a polypeptide that comprises a NB-ARC
20 domain and a CARD domain.

The CED-4 homolog in humans and rodents, referred to as Apaf-1, contains a (i) CARD domain, (ii) NB-ARC domain, and (iii) multiple copies of a WD-repeat domain. In contrast to CED-4 which can spontaneously
25 oligomerize, the mammalian Apaf-1 protein is an inactive monomer until induced to oligomerize by binding of a co-factor protein, cytochrome c (Li et al., Cell 91:479-489 (1997)). In Apaf-1, the WD repeat domains prevent oligomerization of the Apaf-1 protein,
30 until coming into contact with cytochrome c. Thus, the WD-repeats function as a negative-regulatory domain that maintains Apaf-1 in a latent state until cytochrome c release from damaged mitochondria triggers the assembly of an oligomeric Apaf-1 complex (Saleh, J.

Biol. Chem. 274:17941-17945 (1999)). By binding pro-caspase-9 through its CARD domain, Apaf-1 oligomeric complexes are thought to bring the zymogen forms of caspase-9 into close proximity, permitting
5 them to cleave each other and produce the proteolytic processed and active caspase-9 protease (Zou et al., J. Biol. Chem. 274:11549-11556 (1999)).

Another characteristic of the invention CARD-containing polypeptides is that they can associate
10 with pro-caspases, caspases or with caspase-associated proteins, thereby altering caspase proteolytic activity. Caspase proteolytic activity is associated with apoptosis of cells, and additionally with cytokine production. Therefore, an invention CARD-containing
15 polypeptide can alter apoptosis or cytokine production by altering caspase proteolytic activity. As used herein a "caspase" is any member of the cysteine aspartyl proteases. Typically, as caspase can associate with a CARD-containing polypeptide of the
20 invention such as a NAC polypeptide. Similarly, a "pro-caspase" is an inactive or less-active precursor form of a caspase, which is typically converted to the more active caspase form by a proteolytic event, and often a proteolytic event preceded by a protein:protein
25 interaction such as a CARD: CARD interaction, and the like.

As described in the Example, COP-1 interacts with the prodomain of pro-caspase-1 and also with RIP2, a protein previously demonstrated to bind the prodomain
30 of pro-caspase-1. COP-1 competes with RIP2 for binding to pro-caspase-1, thereby inhibiting RIP2-mediated caspase-1 oligomerization. Consequently, COP-1 interferes with the ability of RIP2 to enhance caspase-1-induced secretion of mature IL- 1 β .

Therefore, COP-1 is likely to play a role in controlling IL-1 β generation and thereby opposing IL-1 β -induced inflammation. IL-1 β plays a critical role in septic shock, which currently represents the most common cause of lethality in patients treated in the intensive care setting. Accordingly, COP-1 likely plays a role in IL-1 β homeostasis to prevent systemic inflammatory reactions when challenged with gram-negative bacteria or other inflammatory insults.

As also described in the Example, because of their interactions with diverse other CARD proteins, the isoforms of CLAN (A, B, C and D) likely influence apoptosis, cytokine processing, or NF-kB activity. Interactions of CLAN with pro-caspase-1 likely indicates a role for CLAN as a IL-1 β regulator. In this regard, different isoforms of CLAN likely have opposing effects on pro-caspase-1 activation. The longest isoform, CLAN-A, for example, can trigger pro-caspase-1 activation by the "induced proximity" mechanism as a result of oligomerization mediated by its NB-ARC (NACHT) domain. In contrast, the shorter isoforms of CLAN lacking this self-oligomerization can operate as competitive antagonists of pro-caspase-1 activation, analogous to ICEBERG, a CARD-containing protein that competes with CARDIAK (RIP2/RICK) for binding to pro-caspase-1. Interactions of CLAN with NAC also suggest this protein can have an influence on apoptosis mediated by Apaf-1, in as much as NAC binds Apaf-1 and enhances its ability to activate caspase-9 in response to cytochrome c. Finally, CLAN associations with NF-kB regulators such as Bcl-10 and Nod2 strongly suggest that at least some of the CLAN isoforms can influence the activity of this transcription factor.

In addition to the ability to bind caspases, invention CARD-containing polypeptides can contain a protease domain, such as a protease domain found in caspase, and the like. A caspase protease domain hydrolyzes amide bonds, particularly the amide bond of a peptide or polypeptide backbone. Typically, a caspase protease domain contains a P20/P10 domain in the active site region of the caspase protease domain. Thus, a caspase protease domain has proteolytic activity.

CARD-containing polypeptides are also known to induce activation of the transcription factor NF-kB. Thus, an invention CARD-containing polypeptide can also alter transcription by, for example, modulation of NF-kB activity, and the like.

The NB-ARC (NACHT) domain of invention NAC polypeptides such as CLAN and CARD3X (see Example) associates with other polypeptides, particularly with polypeptides comprising NB-ARC domains. Thus, a functional NB-ARC domain associates with NB-ARC domain-containing polypeptides by way of NB-ARC:NACHT association. As used herein, the term "associate" or "association" means that CARD-containing polypeptide such as a NAC polypeptide can bind to a polypeptide relatively specifically and, therefore, can form a bound complex. For example, the association of a CARD domain of an invention CARD-containing polypeptide with another CARD-containing polypeptide or the association of a NB-ARC domain of NAC with another NB-ARC domain-containing polypeptides is sufficiently specific such that the bound complex can form *in vivo* in a cell or *in vitro* under suitable conditions.

Further, a NB-ARC domain demonstrates both nucleotide-binding (e.g., ATP-binding) and hydrolysis activities, which is typically required for its ability to associate with NB-ARC domain-containing

5 polypeptides. Thus, an NB-ARC domain of the invention NAC comprises one or more nucleotide binding sites. As used herein, a nucleotide binding site is a portion of a polypeptide that specifically binds a nucleotide such as, e.g., ADP, ATP, and the like. Typically, the

10 nucleotide binding site of NB-ARC will comprise a P-loop, a kinase 2 motif, or a kinase 3a motif of the invention NAC (these motifs are defined, for example, in van der Biezen and Jones, supra). Preferably, the nucleotide binding site of NB-ARC comprises a P-loop of

15 the invention NAC. The NB-ARC domain of the an invention CARD-containing polypeptide, therefore, is capable of associating with other NB-ARC domains in homo- or hetero-oligomerization. Additionally, the NB-ARC domain is characterized by nucleotide hydrolysis

20 activity, which can influence the ability of an NB-ARC domain to associate with another NB-ARC domain.

An invention NAC, therefore, is capable of CARD:CARD association and/or NB-ARC:NB-ARC association, resulting in a multifunctional polypeptide capable of

25 one or more specific associations with other polypeptides. An invention NAC can alter cell processes such as apoptosis, cytokine production, and the like. For example, it is contemplated herein that an invention NAC polypeptide can increase the level of

30 apoptosis in a cell. It is also contemplated herein that an invention NAC can decrease the level of apoptosis in a cell. For example, a NAC which does not induce apoptosis may form hetero-oligomers with a NAC which is apoptotic, thus interfering with the

35 apoptosis-inducing activity of NAC.

In another embodiment of the invention, a CARD-containing polypeptide of the invention, such as CLAN (SEQ ID NOS:96, 98, 100 and 102) and an isoform of CARD3X (containing SEQ ID NO:189) also contains
5 Leucine-Rich Repeats (LRR) domain. LRR domains are well known in the art and, in one embodiment, the LRR domain of an invention CARD-containing polypeptide has substantially the same sequence as a LRR described in another CARD-containing polypeptide known as Nod1
10 (Inohara et al., J. Biol. Chem. 274:14560-14567 (1999)). The function of the LRR domain is to mediate specific interactions with other polypeptides.

In another embodiment of the invention, there are provided CARD-containing polypeptides that contain
15 an NB-ARC domain and a CARD domain. NAC polypeptide sequences disclosed herein, for example, CARD4/5X (CLAN), modulate a variety of biochemical processes such as apoptosis. NAC polypeptides can also have other domains that modulate biochemical processes such
20 as an LRR domain or a WD domain.

Those of skill in the art will recognize that numerous residues of the above-described sequences can be substituted with other, chemically, sterically and/or electronically similar residues without
25 substantially altering the biological activity of the resulting CARD-containing polypeptide species. In addition, larger polypeptide sequences comprising substantially the same sequence as amino acids set forth in SEQ ID NOS:12, 168, 188, 170, 172, 174, 176,
30 97, 99, 101, 103, 178, 180, 182, 184, 86 and 90, therein are contemplated within the scope of the invention.

As employed herein, the term "substantially the same amino acid sequence" refers to amino acid sequences having at least about 70% or 75% identity with respect to the reference amino acid sequence, and retaining comparable functional and biological activity characteristic of the polypeptide defined by the reference amino acid sequence. Preferably, polypeptides having "substantially the same amino acid sequence" will have at least about 80%, 82%, 84%, 86% or 88%, more preferably 90%, 91%, 92%, 93% or 94% amino acid identity with respect to the reference amino acid sequence; with greater than about 95%, 96%, 97%, 98% or 99% amino acid sequence identity being especially preferred. It is recognized, however, that polypeptides or nucleic acids containing less than the described levels of sequence identity arising as splice variants or that are modified by conservative amino acid substitutions, or by substitution of degenerate codons are also encompassed within the scope of the present invention.

In accordance with the invention, specifically included within the definition of substantially the same amino acid sequence is the predominant amino acid sequence of a particular invention CARD-containing polypeptide or domain disclosed herein. The predominant amino acid sequence refers to the most commonly expressed naturally occurring amino acid sequence in a species population. A predominant polypeptide with multiple isoforms will have the most commonly expressed amino acid sequence for each isoform. A predominant CARD-containing polypeptide of the invention refers to an amino acid sequence having sequence identity to an amino acid sequence disclosed herein that is greater than that of

any other naturally occurring protein of a particular species (e.g., human).

Given the teachings herein of the location and nucleic acid or amino acid sequences corresponding to the invention CARD-containing polypeptides, one of skill in the art can readily confirm and, if necessary, revise the nucleic acid or amino acid sequences associated with the CARD-containing polypeptides of the invention. For example, the sequences can be confirmed by probing a cDNA library with a nucleic acid probe corresponding to a nucleic acid of the invention using PCR or other known methods. Further, an appropriate bacterial artificial chromosome containing the region of the genome encoding an invention CARD-containing polypeptide can be commercially obtained and probed using PCR, restriction mapping, sequencing, and other known methods.

The term "biologically active" or "functional", when used herein as a modifier of invention CARD-containing polypeptides, or polypeptide fragments thereof, refers to a polypeptide that exhibits functional characteristics similar to a CARD-containing polypeptide of the invention. Biological activities of a CARD-containing polypeptide include, for example, the ability to bind, preferably *in vivo*, to a nucleotide, to a CARD-associated polypeptide, to a NB-ARC-containing polypeptide, or to homo-oligomerize, or to alter protease activation, particularly caspase activation, or to catalyze reactions such as proteolysis or nucleotide hydrolysis, or to alter NF-kB activity, or to alter apoptosis, cytokine processing, cytokine receptor signaling, inflammation, immune response, and other biological activities described herein.

The ability of a CARD-containing polypeptide to bind another polypeptide such as a CARD-associated polypeptide can be assayed, for example, using the methods well known in the art such as yeast two-hybrid
5 assays, co-immunoprecipitation, GST fusion co-purification, and other methods provided in standard technique manuals such as Sambrook, supra, and Ausubel et al., supra. Another biological activity of a CARD-containing polypeptide is the ability to act as an
10 immunogen for the production of polyclonal and monoclonal antibodies that bind specifically to an invention CARD-containing polypeptide. Thus, an invention nucleic acid encoding a CARD-containing polypeptide can encode a polypeptide specifically
15 recognized by an antibody that also specifically recognizes a CARD-containing polypeptide (preferably human) including the amino acid set forth in SEQ ID NOS: 12, 168, 188, 170, 172, 174, 176, 97, 99, 101, 103, 178, 180, 182, 184, 86 and 90. Such immunologic
20 activity may be assayed by any method known to those of skill in the art. For example, a test-polypeptide can be used to produce antibodies, which are then assayed for their ability to bind to an invention polypeptide. If the antibody binds to the test-polypeptide and to
25 the reference polypeptide with substantially the same affinity, then the polypeptide possesses the requisite immunologic biological activity.

As used herein, the term "substantially purified" means a polypeptide that is in a form that is
30 relatively free from contaminating lipids, polypeptides, nucleic acids or other cellular material normally associated with a polypeptide in a cell. A substantially purified CARD-containing polypeptide can be obtained by a variety of methods well-known in the
35 art, e.g., recombinant expression systems described

herein, chemical synthesis or purification from native sources. Purification methods can include, for example, precipitation, gel filtration, ion-exchange, reverse-phase and affinity chromatography, and the like. Other well-known methods are described in Deutscher et al., "Guide to Protein Purification" Methods in Enzymology Vol. 182, (Academic Press, (1990)). Alternatively, the isolated polypeptides of the present invention can be obtained using well-known recombinant methods as described, for example, in Sambrook et al., supra, (1989) and Ausubel et al., supra (2000). The methods and conditions for biochemical purification of a polypeptide of the invention can be chosen by those skilled in the art, and purification monitored, for example, by an immunological assay, binding assay, or a functional assay.

In addition to the ability of invention CARD-containing polypeptides, or functional fragments thereof, to interact with other, heterologous proteins (e.g., CARD-containing polypeptides), invention CARD-containing polypeptides have the ability to self-associate to form invention homo-oligomers such as homodimers. This self-association is possible through interactions between CARD domains, and also through interactions between NB-ARC domains. Further, self-association can take place as a result of interactions between LRR domains.

In accordance with the invention, there are also provided mutations and fragments of CARD-containing polypeptides which have activity different than a predominant naturally occurring CARD-containing polypeptide activity. As used herein, a "mutation" can be any deletion, insertion, or change of one or more

amino acids in the predominant naturally occurring protein sequence (e.g., wild-type), and a "fragment" is any truncated form, either carboxy-terminal, amino-terminal, or both, of the predominant naturally occurring protein. Preferably, the different activity of the mutation or fragment is a result of the mutant polypeptide or fragment maintaining some but not all of the activities of the respective predominant naturally occurring CARD-containing polypeptide.

10 For example, a functional fragment of an invention polypeptide can contain or consist of one or more of the following: a CARD domain, a NB-ARC domain, a LRR domain, a SAM domain, or an angio-R domain. In a specific example, a fragment of a CARD-containing
15 polypeptide such as CLAN can contain a CARD domain and LRR domain, but lack a functional NB-ARC domain. Such a fragment will maintain a portion of the predominant naturally occurring CLAN activity (e.g., CARD domain functionality), but not all such activities (e.g.,
20 lacking an active NB-ARC domain). The resultant fragment will therefore have an activity different than the predominant naturally occurring CLAN activity. In another example, the CLAN polypeptide might have only the NB-ARC domain, allowing it to interact with other
25 NB-ARC domain proteins in forming homo-oligomers or hetero-oligomers. In one embodiment, the activity of the fragment will be "dominant-negative." A dominant-negative activity will allow the fragment to reduce or inactivate the activity of one or more isoforms of a
30 predominant naturally occurring CARD-containing polypeptide. Another functional fragment can include an angio-R domain (see Example), or any of the domains disclosed herein (see, for example, Table 2).

Isoforms of the CARD-containing polypeptides are also provided which arise from alternative mRNA splicing and may alter or modify the interactions of the CARD-containing polypeptide with other

5 polypeptides. For example, four isoforms of CLAN and three isoforms of CARD3X are disclosed herein. Additional isoforms of the CARD-containing polypeptides designated SEQ ID NOS: 12, 188, 97, 99, 101, 103, 86 and 90, are contemplated herein and therefore, are

10 encompassed within the scope of the invention CARD-containing polypeptides.

Methods to identify polypeptides containing a functional fragment of a CARD-containing polypeptide of the invention are well known in the art and are

15 disclosed herein. For example, genomic or cDNA libraries, including universal cDNA libraries can be probed according to methods disclosed herein or other methods known in the art. Full-length polypeptide encoding nucleic acids such as full-length cDNAs can be

20 obtained by a variety of methods well-known in the art. For example, 5' and 3' RACE, methodology is well known in the art and described in Ausubel et al., supra, and the like.

In another embodiment of the invention,

25 chimeric polypeptides are provided comprising a CARD-containing polypeptide, or a functional fragment thereof, fused with another protein or functional fragment thereof. Functional fragments of a CARD-containing polypeptide include, for example, NB-ARC

30 (NACHT), CARD, LRR, and ANGIO-R domains or other fragments that retain a biological activity of an invention CARD-containing polypeptide. Polypeptides with which the CARD-containing polypeptide or functional fragment thereof are fused will include, for

example, glutathione-S-transferase, an antibody, or other proteins or functional fragments thereof which facilitate recovery of the chimera. Further, polypeptides with which a CARD-containing polypeptide
5 or functional fragment thereof are fused will include, for example, luciferase, green fluorescent protein, an antibody, or other proteins or functional fragments thereof which facilitate identification of the chimera. Still further polypeptides with which a CARD-containing
10 polypeptide or functional fragment thereof are fused will include, for example, the LexA DNA binding domain, ricin, a-sarcin, an antibody or fragment thereof, or other polypeptides which have therapeutic properties or other biological activity.

15 Further invention chimeric polypeptides contemplated herein are chimeric polypeptides wherein a functional fragment of a CARD-containing polypeptide is fused with a catalytic domain or a protein interaction domain from a heterologous polypeptide. For example,
20 the NB-ARC domain of CLAN, as disclosed herein, can be replaced by the NB-ARC domain of other CARD polypeptides, such as CARD3X, and the like. Another example of such a chimera is a polypeptide wherein the CARD domain of CLAN is replaced by the CARD domain from
25 CARD2X or CARD3X, and the like. In a further example, an NB-ARC domain can be fused with a caspase catalytic P20 domain to form a novel chimera with caspase activity. One of skill in the art will appreciate that a large number of chimeric polypeptides are readily
30 available by combining domains of two or more CARD-containing polypeptides of the invention. Further, chimeric polypeptides can contain a functional fragment of a CARD-containing polypeptide of the invention fused with a domain of a protein known in the art, such as
35 CED-4, Apaf-1, caspase-1, and the like.

In another embodiment of the invention, polypeptides are provided comprising 10 or more contiguous amino acids selected from the group consisting of SEQ ID NOS:12, 188, 97, 99, 101, 103, 86
5 and 90.

As used herein, the term "polypeptide" when used in reference to a CARD-containing polypeptide or fragment is intended to refer to a peptide or polypeptide of two or more amino acids. The term
10 "polypeptide analog" includes any polypeptide having an amino acid residue sequence substantially the same as a sequence specifically described herein in which one or more residues have been conservatively substituted with a functionally similar residue and which displays the
15 ability to functionally mimic a CARD-containing polypeptide as described herein. A "modification" of an invention polypeptide also encompasses conservative substitutions of an invention polypeptide amino acid sequence. Conservative substitutions of encoded amino
20 acids include, for example, amino acids that belong within the following groups: (1) non-polar amino acids (Gly, Ala, Val, Leu, and Ile); (2) polar neutral amino acids (Cys, Met, Ser, Thr, Asn, and Gln); (3) polar acidic amino acids (Asp and Glu); (4) polar basic amino
25 acids (Lys, Arg and His); and (5) aromatic amino acids (Phe, Trp, Tyr, and His). Other groupings of amino acids can be found, for example in Taylor, J. Theor. Biol. 119:205-218 (1986), which is incorporated herein by reference. Other minor modifications are included
30 within invention polypeptides so long as the polypeptide retains some or all of its function as described herein.

The amino acid length of functional fragments or polypeptide analogs of the present invention can

range from about 5 amino acids up to the full-length protein sequence of an invention CARD-containing polypeptide. In certain embodiments, the amino acid lengths include, for example, at least about 10 amino acids, at least about 15, at least about 20, at least about 25, at least about 30, at least about 35, at least about 40, at least about 45, at least about 50, at least about 55, at least about 60, at least about 65, at least about 70, at least about 75, at least about 80, at least about 85, at least about 90, at least about 95, at least about 100, at least about 125, at least about 150, at least about 175, at least about 200, at least about 250 or more amino acids in length up to the full-length CARD-containing polypeptide sequence. The functional fragments can be contiguous amino acid sequences of an invention polypeptide, including contiguous amino acid sequences of SEQ ID NOS: 12, 188, 97, 99, 101, 103, 86 and 90. A peptide of at least about 10 amino acids can be used, for example, as an immungen to raise antibodies specific for an invention CARD-containing polypeptide.

A modification of a polypeptide can also include derivatives, analogues and functional mimetics thereof, provided that such polypeptide displays a CARD-containing polypeptide biological activity. For example, derivatives can include chemical modifications of the polypeptide such as alkylation, acylation, carbamylation, iodination, or any modification that derivatizes the polypeptide. Such derivatized molecules include, for example, those molecules in which free amino groups have been derivatized to form amine hydrochlorides, p-toluene sulfonyl groups, carbobenzoxy groups, t-butyloxycarbonyl groups, chloroacetyl groups or formyl groups. Free carboxyl groups can be derivatized to form salts, methyl and

ethyl esters or other types of esters or hydrazides. Free hydroxyl groups can be derivatized to form O-acyl or O-alkyl derivatives. The imidazole nitrogen of histidine can be derivatized to form

5 N-im-benzylhistidine. Also included as derivatives or analogues are those peptides which contain one or more naturally occurring amino acid derivatives of the twenty standard amino acids, for example, 4-hydroxyproline, 5-hydroxylysine, 3-methylhistidine,

10 homoserine, ornithine or carboxyglutamate, and can include amino acids that are not linked by peptide bonds. Polypeptides of the present invention also include any polypeptide having one or more additions and/or deletions of residues, relative to the sequence

15 of a polypeptide whose sequence is shown herein, so long as CARD-containing polypeptide activity is maintained.

A modification of an invention polypeptide includes functional mimetics thereof. Mimetics

20 encompass chemicals containing chemical moieties that mimic the function of the polypeptide. For example, if a polypeptide contains two charged chemical moieties having functional activity, a mimetic places two charged chemical moieties in a spatial orientation and

25 constrained structure so that the charged chemical function is maintained in three-dimensional space. Thus, a mimetic, which orients functional groups that provide a function of a CARD-containing polypeptide, are included within the meaning of a CARD-containing

30 polypeptide derivative. All of these modifications are included within the term "polypeptide" so long as the invention polypeptide or functional fragment retains its function. Exemplary mimetics are peptidomimetics, peptoids, or other peptide-like polymers such as

35 poly(b-amino acids), and also non-polymeric compounds

upon which functional groups that mimic a peptide are positioned.

Another embodiment of the invention provides a CARD-containing polypeptide, or a functional fragment thereof, fused with a moiety to form a conjugate. As used herein, a "moiety" can be a physical, chemical or biological entity which contributes functionality to a CARD-containing polypeptide or a functional fragment thereof. Functionalities contributed by a moiety include therapeutic or other biological activity, or the ability to facilitate identification or recovery of a CARD-containing polypeptide. Therefore, a moiety will include molecules known in the art to be useful for detection of the conjugate by, for example, by fluorescence, magnetic imaging, detection of radioactive emission. A moiety may also be useful for recovery of the conjugate, for example a His tag or other known tags used for protein isolation and/or purification, or a physical substance such as a bead. A moiety can be a therapeutic compound, for example, a cytotoxic drug which can be useful to effect a biological change in cells to which the conjugate localizes.

An example of the means for preparing the invention polypeptide(s) is to express nucleic acids encoding a CARD-containing polypeptide in a suitable host cell, such as a bacterial cell, a yeast cell, an amphibian cell such as an oocyte, or a mammalian cell, using methods well known in the art, and recovering the expressed polypeptide, again using well-known purification methods. Invention polypeptides can be isolated directly from cells that have been transformed with expression vectors as known in the art. Recombinantly expressed polypeptides of the invention

can also be expressed as fusion proteins with appropriate affinity tags, such as glutathione S transferase (GST) or poly His, and affinity purified. The invention polypeptide, biologically functional fragments, and functional equivalents thereof can also be produced by *in vitro* transcription/translation methods known in the art, such as using reticulocyte lysates, as used for example, in the TNT system (Promega). The invention polypeptide, biologically functional fragments, and functional equivalents thereof can also be produced by chemical synthesis. For example, synthetic polypeptides can be produced using Applied Biosystems, Inc. Model 430A or 431A automatic peptide synthesizer (Foster City, CA) employing the chemistry provided by the manufacturer.

In accordance with another embodiment of the invention, there are provided isolated nucleic acids encoding a CARD-containing polypeptide or functional fragment thereof. The isolated nucleic acids can be selected from:

- (a) DNA encoding a polypeptide containing the amino acid sequence set forth in SEQ ID NOs: 12, 168, 188, 170, 172, 174, 176, 97, 99, 101, 103, 178, 180, 182, 184, 86 and 90, or
- (b) DNA that hybridizes to the DNA of (a) under moderately stringent conditions, where the DNA encodes biologically active CARD-containing polypeptide, or
- (c) DNA degenerate with respect to (b), where the DNA encodes biologically active CARD-containing polypeptide.

The nucleic acid molecules described herein are useful for producing invention polypeptides, when

such nucleic acids are incorporated into a variety of protein expression systems known to those of skill in the art. In addition, such nucleic acid molecules or fragments thereof can be labeled with a readily
5 detectable substituent and used as hybridization probes for assaying for the presence and/or amount of an invention CARD-encoding gene or mRNA transcript in a given sample. The nucleic acid molecules described herein, and fragments thereof, are also useful as
10 primers and/or templates in a PCR reaction for amplifying genes encoding invention polypeptides described herein.

The term "nucleic acid" (also referred to as polynucleotides) encompasses ribonucleic acid (RNA) or
15 deoxyribonucleic acid (DNA), probes, oligonucleotides, and primers and can be single stranded or double stranded. DNA can be either complementary DNA (cDNA) or genomic DNA, e.g. a CARD-encoding gene, and can represent the sense strand, the anti-sense strand, or
20 both. Examples of nucleic acids are RNA, cDNA, or isolated genomic DNA encoding a CARD-containing polypeptide. One means of isolating a CARD-encoding nucleic acid is to probe a mammalian genomic or cDNA library with a natural or artificially designed DNA
25 probe using methods well known in the art. DNA probes derived from the CARD-encoding gene are particularly useful for this purpose. DNA and cDNA molecules that encode CARD-containing polypeptides can be used to obtain complementary genomic DNA, cDNA or RNA from
30 mammalian (e.g., human, mouse, rat, rabbit, pig, and the like), or other animal sources, or to isolate related cDNA or genomic clones by screening cDNA or genomic libraries, using methods described in more detail below. Such nucleic acids include, but are not
35 limited to, nucleic acids comprising substantially the

same nucleotide sequence as set forth in SEQ ID NOS:
11, 167, 187, 169, 171, 173, 175, 96, 98, 100, 102,
177, 179, 181, 183, 85 and 89. In general, a genomic
sequence of the invention includes regulatory regions
5 such as promoters, enhancers, and introns that are
outside of the exons encoding a CARD-containing
polypeptide but does not include proximal genes that do
not encode a CARD-containing polypeptide.

Thus a CARD-encoding nucleic acid as used
10 herein refers to a nucleic acid encoding a CARD-
containing polypeptide of the invention, or a
functional fragment thereof.

Use of the terms "isolated" and/or "purified"
and/or "substantially purified" in the present
15 specification and claims as a modifier of DNA, RNA,
polypeptides or proteins means that the DNA, RNA,
polypeptides or proteins so designated have been
produced in such form by the hand of man, and thus are
separated from their native in vivo cellular
20 environment, and are substantially free of any other
species of nucleic acid or protein. As a result of
this human intervention, the recombinant DNAs, RNAs,
polypeptides and proteins of the invention are useful
in ways described herein that the DNAs, RNAs,
25 polypeptides or proteins as they naturally occur are
not.

Invention nucleic acids encoding CARD-
containing polypeptides and invention CARD-containing
polypeptides can be obtained from any species of
30 organism, such as prokaryotes, eukaryotes, plants,
fungi, vertebrates, invertebrates, and the like. A
particular species can be mammalian, As used herein,
"mammalian" refers to a subset of species from which an

invention CARD-encoding nucleic acid is derived, e.g., human, rat, mouse, rabbit, monkey, baboon, bovine, porcine, ovine, canine, feline, and the like. A preferred CARD-encoding nucleic acid herein, is human
5 CARD-encoding nucleic acid.

In one embodiment of the present invention, cDNAs encoding the invention CARD-containing polypeptides disclosed herein comprise substantially the same nucleotide sequence as the coding region set
10 forth in any of SEQ ID NOS: 11, 167, 187, 169, 171, 173, 175, 96, 98, 100, 102, 177, 179, 181, 183, 85 and 89.

As employed herein, the term "substantially the same nucleotide sequence" refers to a nucleic acid molecule (DNA or RNA) having sufficient identity to the
15 reference polynucleotide, such that it will hybridize to the reference nucleotide under moderately or highly stringent hybridization conditions. In one embodiment, a nucleic acid molecule having substantially the same
20 nucleotide sequence as the reference nucleotide sequence encodes substantially the same amino acid sequence as that set forth in any of SEQ ID NOS: 12, 168, 188, 170, 172, 174, 176, 97, 99, 101, 103, 178, 180, 182, 184, 86 and 90. In another embodiment, a
25 nucleic acid molecule having "substantially the same nucleotide sequence" as the reference nucleotide sequence has at least 60%, or at least 65% identity with respect to the reference nucleotide sequence, such as at least 70%, 72%, 74%, 76%, 78%, 80%, 82%, 84%,
30 86%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to the reference nucleotide sequence.

In accordance with the invention, specifically included within the definition of substantially the same nucleotide sequence is the predominant nucleotide sequence of a particular invention CARD-containing polypeptide described herein. The predominant nucleotide sequence refers to the most commonly present naturally occurring nucleotide sequence in a species population. A predominant CARD-encoding nucleic acid of the invention refers to a nucleotide sequence having sequence identity to a nucleotide sequence disclosed herein that is greater than that of any other naturally occurring nucleotide sequence of a particular species (e.g., human).

In one embodiment, a nucleic acid molecule that has substantially the same nucleotide sequence as a reference sequence is a modification of the reference sequence. As used herein, a "modification" of a nucleic acid can include one or several nucleotide additions, deletions, or substitutions with respect to a reference sequence. A modification of a nucleic acid can include substitutions that do not change the encoded amino acid sequence due to the degeneracy of the genetic code. Such modifications can correspond to variations that are made deliberately, or which occur as mutations during nucleic acid replication.

Exemplary modifications of the recited nucleotide sequences include sequences that correspond to homologs of other species, including mammalian species such as mouse, primates, including monkey and baboon, rat, rabbit, bovine, porcine, ovine, canine, feline, or other animal species. The corresponding nucleotide sequences of non-human species can be determined by methods known in the art, such as by PCR or by screening genomic, cDNA or expression libraries.

Another exemplary modification of the invention CARD-encoding nucleic acid or CARD-containing polypeptide can correspond to splice variant forms of the CARD-encoding nucleotide sequence. Additionally, a
5 modification of a nucleotide sequence can include one or more non-native nucleotides, having, for example, modifications to the base, the sugar, or the phosphate portion, or having a modified phosphodiester linkage. Such modifications can be advantageous in increasing
10 the stability of the nucleic acid molecule.

Furthermore, a modification of a nucleotide sequence can include, for example, a detectable moiety, such as a radiolabel, a fluorochrome, a ferromagnetic substance, a luminescent tag or a detectable binding
15 agent such as biotin. Such modifications can be advantageous in applications where detection of a CARD-encoding nucleic acid molecule is desired.

In another embodiment, a nucleic acid molecule that has substantially the same nucleotide
20 sequence as a reference sequence is a functionally equivalent nucleic acid, which indicates that it is phenotypically similar to the reference nucleic acid. As used herein, the phrase "functionally equivalent nucleic acids" encompasses nucleic acids characterized
25 by slight and non-consequential sequence variations that will function in substantially the same manner to produce the same polypeptide product(s) as the nucleic acids disclosed herein. In particular, functionally equivalent nucleic acids encode polypeptides that are
30 the same as those encoded by the nucleic acids disclosed herein or that have conservative amino acid variations, as described above. These variations include those recognized by skilled artisans as those

that do not substantially alter the tertiary structure of the protein.

Further provided are nucleic acids encoding CARD-containing polypeptides that, by virtue of the degeneracy of the genetic code, do not necessarily hybridize to the invention nucleic acids under specified hybridization conditions. Preferred nucleic acids encoding the invention CARD-containing polypeptides are comprised of nucleotides that encode substantially the same amino acid sequence as set forth in SEQ ID NOS:12, 168, 188, 170, 172, 174, 176, 97, 99, 101, 103, 178, 180, 182, 184, 86 and 90.

Hybridization refers to the binding of complementary strands of nucleic acid (i.e., sense:antisense strands or probe:target-DNA) to each other through hydrogen bonds, similar to the bonds that naturally occur in chromosomal DNA. Stringency levels used to hybridize a given probe with target-DNA can be readily varied by those of skill in the art.

The phrase "stringent hybridization" is used herein to refer to conditions under which polynucleic acid hybrids are stable. As known to those of skill in the art, the stability of hybrids is reflected in the melting temperature (T_m) of the hybrids. In general, the stability of a hybrid is a function of sodium ion concentration and temperature. Typically, the hybridization reaction is performed under conditions of lower stringency, followed by washes of varying, but higher, stringency. Reference to hybridization stringency relates to such washing conditions.

As used herein, the phrase "moderately stringent hybridization" refers to conditions that

permit target-nucleic acid to bind a complementary nucleic acid. The hybridized nucleic acids will generally have at least about 60% identity, at least about 75% identity, such as at least about 85% identity; or at least about 90% identity. Moderately stringent conditions are conditions equivalent to hybridization in 50% formamide, 5X Denhart's solution, 5X SSPE, 0.2% SDS at 42°C, followed by washing in 0.2X SSPE, 0.2% SDS, at 42°C.

10 The phrase "high stringency hybridization" refers to conditions that permit hybridization of only those nucleic acid sequences that form stable hybrids in 0.018M NaCl at 65°C, for example, if a hybrid is not stable in 0.018M NaCl at 65°C, it will not be stable
15 under high stringency conditions, as contemplated herein. High stringency conditions can be provided, for example, by hybridization in 50% formamide, 5X Denhart's solution, 5X SSPE, 0.2% SDS at 42°C, followed by washing in 0.1X SSPE, and 0.1% SDS at 65°C.

20 The phrase "low stringency hybridization" refers to conditions equivalent to hybridization in 10% formamide, 5X Denhart's solution, 6X SSPE, 0.2% SDS at 22°C, followed by washing in 1X SSPE, 0.2% SDS, at 37°C. Denhart's solution contains 1% Ficoll, 1%
25 polyvinylpyrrolidone, and 1% bovine serum albumin (BSA). 20X SSPE (sodium chloride, sodium phosphate, ethylene diamide tetraacetic acid (EDTA)) contains 3M sodium chloride, 0.2M sodium phosphate, and 0.025 M (EDTA). Other suitable moderate stringency and high stringency
30 hybridization buffers and conditions are well known to those of skill in the art and are described, for example, in Sambrook et al., supra (1989); and Ausubel et al., supra, 2000). Nucleic acids encoding polypeptides hybridize under moderately stringent or

high stringency conditions to substantially the entire sequence, or substantial portions, for example, typically at least 15-30 nucleotides of the nucleic acid sequence set forth in SEQ ID NOS:11, 167, 187, 5 169, 171, 173, 175, 96, 98, 100, 102, 177, 179, 181, 183, 85 and 89.

As used herein, the term "degenerate" refers to codons that differ in at least one nucleotide from a reference nucleic acid, e.g., SEQ ID NOS:11, 167, 187, 10 169, 171, 173, 175, 96, 98, 100, 102, 177, 179, 181, 183, 85 and 89, but encode the same amino acids as the reference nucleic acid. For example, codons specified by the triplets "UCU", "UCC", "UCA", and "UCG" are degenerate with respect to each other since all four of 15 these codons encode the amino acid serine.

The invention also provides a modification of a nucleotide sequence that hybridizes to a CARD-encoding nucleic acid molecule, for example, a nucleic acid molecule referenced as any of SEQ ID NOS:11, 167, 20 187, 169, 171, 173, 175, 96, 98, 100, 102, 177, 179, 181, 183, 85 and 89 under moderately stringent conditions. Modifications of nucleotide sequences, where the modification has at least 60% identity to a CARD-encoding nucleotide sequence, are also provided. 25 The invention also provides modification of a CARD-encoding nucleotide sequence having at least 65% identity, at least 70% identity, at least 72% identity, at least 74% identity, at least 76% identity, at least 78% identity, at least 80% identity, at least 82% 30 identity, at least 84% identity, at least 86% identity, at least 88% identity, at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity,

at least 96% identity, at least 97% identity, at least 98% identity or at least 99% identity.

Identity of any two nucleic acid or amino acid sequences can be determined by those skilled in the art based, for example, on a BLAST 2.0 computer alignment, using default parameters. BLAST 2.0 searching is known in the art and is publicly available, for example, at <http://www.ncbi.nlm.nih.gov/BLAST/>, as described by Tatiana et al., FEMS Microbiol Lett. 174:247-250 (1999); Altschul et al., Nucleic Acids Res., 25:3389-3402 (1997).

One means of isolating a nucleic acid encoding a CARD-containing polypeptide is to probe a cDNA library or genomic library with a natural or artificially designed nucleic acid probe using methods well known in the art. Nucleic acid probes derived from a CARD-encoding gene are particularly useful for this purpose. DNA and cDNA molecules that encode CARD-containing polypeptides can be used to obtain complementary genomic DNA, cDNA or RNA from mammals, for example, human, mouse, rat, rabbit, pig, and the like, or other animal sources, or to isolate related cDNA or genomic clones by the screening of cDNA or genomic libraries, by methods well known in the art (see, for example, the Examples set forth hereinafter; and Sambrook et al., supra, 1989; Ausubel et al., supra, 2000).

Another useful method for producing a CARD-encoding nucleic acid molecule of the invention involves amplification of the nucleic acid molecule using PCR and invention oligonucleotides and, optionally, purification of the resulting product by

gel electrophoresis. Either PCR or RT-PCR can be used to produce a CARD-encoding nucleic acid molecule having any desired nucleotide boundaries as described in the Examples. Desired modifications to the nucleic acid sequence can also be introduced by choosing an appropriate oligonucleotide primer with one or more additions, deletions or substitutions. Such nucleic acid molecules can be amplified exponentially starting from as little as a single gene or mRNA copy, from any cell, tissue or species of interest.

The invention additionally provides a nucleic acid that hybridizes under high stringency conditions to the CARD coding portion of any of SEQ ID NOS:11, 187, 96, 98, 100, 102, 85 and 89, such as to any of SEQ ID NOS: 168, 170, 172 and 178. The invention also provides a nucleic acid having a nucleotide sequence substantially the same as set forth in any of SEQ ID 11, 167, 187, 169, 171, 173, 175, 96, 98, 100, 102, 177, 179, 181, 183, 85 and 89.

The invention also provides a method for identifying nucleic acids encoding a mammalian CARD-containing polypeptide by contacting a sample containing nucleic acids with one or more invention nucleic acid molecules or oligonucleotides, wherein the contacting is effected under high stringency hybridization conditions, and identifying a nucleic acid that hybridizes to the oligonucleotide. The invention additionally provides a method of detecting a CARD-encoding nucleic acid molecule in a sample by contacting the sample with two or more invention oligonucleotides, amplifying a nucleic acid molecule, and detecting the amplification. The amplification can be performed, for example, using PCR. The invention further provides oligonucleotides that function as

single stranded nucleic acid primers for amplification of a CARD-encoding nucleic acid, wherein the primers comprise a nucleic acid sequence derived from the nucleic acid sequences set forth as SEQ ID NOS:11, 187,
5 96, 98, 100, 102, 85 and 89.

In accordance with a further embodiment of the present invention, optionally labeled CARD-encoding cDNAs, or fragments thereof, can be employed to probe library(ies) such as cDNA, genomic, BAC, and the like
10 for predominant nucleic acid sequences or additional nucleic acid sequences encoding novel CARD-containing polypeptides. Construction and screening of suitable mammalian cDNA libraries, including human cDNA libraries, is well-known in the art, as demonstrated,
15 for example, in Ausubel et al., supra. Screening of such a cDNA library is initially carried out under low-stringency conditions, which comprise a temperature of less than about 42°C, a formamide concentration of less than about 50%, and a moderate to low salt
20 concentration.

Probe-based screening conditions can comprise a temperature of about 37°C, a formamide concentration of about 20%, and a salt concentration of about 5X standard saline citrate (SSC; 20X SSC contains 3M
25 sodium chloride, 0.3M sodium citrate, pH 7.0). Such conditions will allow the identification of sequences which have a substantial degree of similarity with the probe sequence, without requiring perfect homology. The phrase "substantial similarity" refers to sequences
30 which share at least 50% homology. Hybridization conditions are selected which allow the identification of sequences having at least 70% homology with the probe, while discriminating against sequences which have a lower degree of homology with the probe. As a

result, nucleic acids having substantially the same nucleotide sequence as any of SEQ ID NOS:11, 167, 187, 169, 171, 173, 175, 96, 98, 100, 102, 177, 179, 181, 183, 85 and 89 are obtained.

5 As used herein, a nucleic acid "probe" is single-stranded nucleic acid, or analog thereof, that has a sequence of nucleotides that includes at least 15, at least 20, at least 50, at least 100, at least 200, at least 300, at least 400, or at least 500
10 contiguous bases that are substantially the same as, or the complement of, any contiguous bases set forth in any of SEQ ID NOS:11, 187, 96, 98, 100, 102, 85 and 89. In addition, the entire cDNA encoding region of an invention CARD-containing polypeptide, or an entire
15 sequence substantially the same as SEQ ID NOS:11, 187, 96, 98, 100, 102, 85 and 89 can be used as a probe. Probes can be labeled by methods well-known in the art, as described hereinafter, and used in various diagnostic kits.

20 The invention additionally provides an oligonucleotide comprising between 15 and 300 contiguous nucleotides of any of SEQ ID NOS:11, 187, 96, 98, 100, 102, 85 and 89 or the anti-sense strand thereof. As used herein, the term "oligonucleotide"
25 refers to a nucleic acid molecule that includes at least 15 contiguous nucleotides from a reference nucleotide sequence, can include at least 16, 17, 18, 19, 20 or at least 25 contiguous nucleotides, and often includes at least 30, 40, 50, 60, 70, 80, 90, 100, 125,
30 150, 175, 200, 225, 250, 275, 300, 325, up to 350 contiguous nucleotides from the reference nucleotide sequence. The reference nucleotide sequence can be the sense strand or the anti-sense strand.

The oligonucleotides of the invention that contain at least 15 contiguous nucleotides of a reference CARD-encoding nucleotide sequence are able to hybridize to CARD-encoding nucleotide sequences under
5 moderately stringent hybridization conditions and thus can be advantageously used, for example, as probes to detect CARD-encoding DNA or RNA in a sample, and to detect splice variants thereof; as sequencing or PCR primers; as antisense reagents to block transcription
10 of CARD-encoding RNA in cells; or in other applications known to those skilled in the art in which hybridization to a CARD-encoding nucleic acid molecule is desirable.

In accordance with another embodiment of the
15 invention, a method is provided for identifying nucleic acids encoding a CARD-containing polypeptide. The method comprises contacting a sample containing nucleic acids with an invention probe or an invention oligonucleotide, wherein said contacting is effected
20 under high stringency hybridization conditions, and identifying nucleic acids which hybridize thereto. Methods for identification of nucleic acids encoding a CARD-containing polypeptide are disclosed herein and exemplified in the Examples.

25 Also provided in accordance with present invention is a method for identifying a CARD-encoding nucleotide sequence comprising the steps of using a CARD-encoding nucleotide sequence selected from SEQ ID NOS:11, 167, 187, 169, 171, 173, 175, 96, 98, 100, 102,
30 177, 179, 181, 183, 85 and 89 to identify a candidate CARD-encoding nucleotide sequence and verifying the candidate CARD-encoding nucleotide sequence by aligning the candidate sequence with known CARD-encoding nucleotide sequences, where a conserved CARD domain

sequence or a predicted three dimensional polypeptide structure similar to a known CARD domain three dimensional structure confirms the candidate sequence as a CARD-encoding sequence. Methods for identifying
5 CARD-encoding sequences are provided herein (See Examples).

It is understood that a CARD-encoding nucleic acid molecule of the invention, as used herein, specifically excludes previously known nucleic acid
10 molecules consisting of nucleotide sequences having identity with the CARD-encoding nucleotide sequence (SEQ ID NOS:11, 167, 187, 169, 171, 173, 175, 96, 98, 100, 102, 177, 179, 181, 183, 85 and 89), such as Expressed Sequence Tags (ESTs), Sequence Tagged Sites
15 (STSs) and genomic fragments, deposited in public databases such as the nr, dbest, dbsts, gss and htgs databases, which are available for searching at <http://www.ncbi.nlm.nih.gov/blast/>.

In particular, an invention CARD-encoding
20 nucleic acid molecule excludes the exact, specific and complete nucleic acid molecule sequence corresponding to any of the nucleotide sequences having the Genbank (gb), EMBL (emb) or DDBJ (dbj) accession numbers described below. Accession numbers specifically
25 excluded include GI:6165147 (Phase-1), AC007728 (Phase-1), NT-002476 (Phase-1), AC010968 (Phase-1), AP001153, AC022468 (Phase-1), GI:6253000 (Phase-1), AC0097959 (Phase-1), GI:6497652 (Phase-1) (contig:23086:40635), GI:6497652 (Phase-1) (contig:41136:57024), AC023068
30 (Phase-1), W58453, AA257158, AA046000, AW085161, AI189838, AA418021, AA046105, W58488, AA418193, AA257066, AI217611, AW295205, AI023795, AL389934, AA070591, AA070591, AC027011, AP002787, AQ889169, AV719179, AI263294, AV656315, AW337918, BF207840,

AW418826, BK903662, AI023795, H25984, AL121653 and
NT_005194.1. The human contig referenced as GenBank
accession No. AC007608 is also specifically excluded
from a CARD encoding nucleic acid molecule. The
5 genomic contigs referenced as GenBank accession numbers
GI 5001450, GI 8575872 and GI 9795562 are also
specifically excluded from invention nucleic acid
molecules. Since one of skill in the art will realize
that the above-recited excluded sequences may be
10 revised at a later date, the skilled artisan will
recognize that the above-recited sequences are excluded
as they stand on the priority date of this application.

The isolated nucleic acid molecules of the
invention can be used in a variety of diagnostic and
15 therapeutic applications. For example, the isolated
nucleic acid molecules of the invention can be used as
probes, as described above; as templates for the
recombinant expression of CARD-containing polypeptides;
or in screening assays such as two-hybrid assays to
20 identify cellular molecules that bind CARD-containing
polypeptides.

The invention thus provides methods for
detecting a CARD-encoding nucleic acid in a sample.
The methods of detecting a CARD-encoding nucleic acid
25 in a sample can be either qualitative or quantitative,
as desired. For example, the presence, abundance,
integrity or structure of a CARD-encoding nucleic acid
can be determined, as desired, depending on the assay
format and the probe used for hybridization or primer
30 pair chosen for application.

Useful assays for detecting a CARD-containing
nucleic acid based on specific hybridization with an
isolated invention oligonucleotide are well known in

the art and include, for example, *in situ* hybridization, which can be used to detect altered chromosomal location of the nucleic acid molecule, altered gene copy number, and RNA abundance, depending
5 on the assay format used. Other hybridization assays include, for example, Northern blots and RNase protection assays, which can be used to determine the abundance and integrity of different RNA splice variants, and Southern blots, which can be used to
10 determine the copy number and integrity of DNA. A hybridization probe can be labeled with any suitable detectable moiety, such as a radioisotope, fluorochrome, chemiluminescent marker, biotin, or other detectable moiety known in the art that is detectable
15 by analytical methods.

As used herein, the terms "label" and "indicating means" in their various grammatical forms refer to single atoms and molecules that are either directly or indirectly involved in the production of a
20 detectable signal. Any label or indicating means can be linked to invention nucleic acid probes, expressed proteins, polypeptide fragments, or antibody molecules. These atoms or molecules can be used alone or in conjunction with additional reagents. Such labels are
25 themselves well-known in clinical diagnostic chemistry.

Useful assays for detecting a CARD-encoding nucleic acid in a sample based on amplifying a CARD-encoding nucleic acid with two or more invention oligonucleotides are also well known in the art, and
30 include, for example, qualitative or quantitative polymerase chain reaction (PCR); reverse-transcription PCR (RT-PCR); single strand conformational polymorphism (SSCP) analysis, which can readily identify a single point mutation in DNA based on differences in the

secondary structure of single-strand DNA that produce an altered electrophoretic mobility upon non-denaturing gel electrophoresis; and coupled PCR, transcription and translation assays, such as a protein truncation test, 5 in which a mutation in DNA is determined by an altered protein product on an electrophoresis gel. Additionally, the amplified CARD-encoding nucleic acid can be sequenced to detect mutations and mutational hot-spots, and specific assays for large-scale 10 screening of samples to identify such mutations can be developed.

Also provided are antisense-nucleic acids having a sequence capable of binding specifically with full-length or any portion of an mRNA that encodes 15 CARD-containing polypeptides so as to prevent translation of the mRNA. The antisense-nucleic acid can have a sequence capable of binding specifically with any portion of the sequence of the cDNA encoding CARD-containing polypeptides. As used herein, the 20 phrase "binding specifically" encompasses the ability of a nucleic acid sequence to recognize a complementary nucleic acid sequence and to form double-helical segments therewith via the formation of hydrogen bonds between the complementary base pairs. An example of an 25 antisense-nucleic acid is an antisense-nucleic acid comprising chemical analogs of nucleotides.

The present invention provides means to alter levels of expression of CARD-containing polypeptides by recombinantly expressing CARD-containing anti-sense 30 nucleic acids or employing synthetic anti-sense nucleic acid compositions (hereinafter SANC) that inhibit translation of mRNA encoding these polypeptides. Synthetic oligonucleotides, or other antisense-nucleic

acid chemical structures designed to recognize and selectively bind to mRNA are constructed to be complementary to full-length or portions of a CARD-encoding strand, including nucleotide sequences

5 substantially the same as SEQ ID NOS:11, 187, 96, 98, 100, 102, 85 and 89.

The SANC is designed to be stable in the blood stream for administration to a subject by injection, or in laboratory cell culture conditions.

10 The SANC is designed to be capable of passing through the cell membrane in order to enter the cytoplasm of the cell by virtue of physical and chemical properties of the SANC, which render it capable of passing through cell membranes, for example, by designing small,

15 hydrophobic SANC chemical structures, or by virtue of specific transport systems in the cell which recognize and transport the SANC into the cell. In addition, the SANC can be designed for administration only to certain selected cell populations by targeting the SANC to be

20 recognized by specific cellular uptake mechanisms which bind and take up the SANC only within select cell populations. In a particular embodiment the SANC is an antisense oligonucleotide.

For example, the SANC may be designed to bind

25 to a receptor found only in a certain cell type, as discussed above. The SANC is also designed to recognize and selectively bind to target mRNA sequence, which can correspond to a sequence contained within the sequences shown in SEQ ID NOS:11, 187, 96, 98, 100,

30 102, 85 and 89. The SANC is designed to inactivate target mRNA sequence by either binding thereto and inducing degradation of the mRNA by, for example, RNase I digestion, or inhibiting translation of mRNA target sequence by interfering with the binding of

translation-regulating factors or ribosomes, or inclusion of other chemical structures, such as ribozyme sequences or reactive chemical groups which either degrade or chemically modify the target mRNA.

- 5 SANCs have been shown to be capable of such properties when directed against mRNA targets (see Cohen et al., TIPS, 10:435 (1989) and Weintraub, Sci. American, January (1990), pp.40).

The invention further provides a method of
10 altering the level of a biochemical process modulated by a CARD-containing polypeptide by introducing an antisense nucleotide sequence into the cell, wherein the antisense nucleotide sequence specifically hybridizes to a CARD-encoding nucleic acid molecule,
15 wherein the hybridization reduces or inhibits the expression of the CARD-containing polypeptide in the cell. The use of anti-sense nucleic acids, including recombinant anti-sense nucleic acids or SANCs, can be advantageously used to inhibit cell death.

20 Compositions comprising an amount of the antisense-nucleic acid of the invention, effective to reduce expression of CARD-containing polypeptides by entering a cell and binding specifically to CARD-encoding mRNA so as to prevent translation and an
25 acceptable hydrophobic carrier capable of passing through a cell membrane are also provided herein. Suitable hydrophobic carriers are described, for example, in U.S. Patent Nos. 5,334,761; 4,889,953; 4,897,355, and the like. The acceptable hydrophobic
30 carrier capable of passing through cell membranes may also comprise a structure which binds to a receptor specific for a selected cell type and is thereby taken up by cells of the selected cell type. For example,

the structure can be part of a protein known to bind to a cell-type specific receptor such as a tumor.

Antisense-nucleic acid compositions are useful to inhibit translation of mRNA encoding invention polypeptides. Synthetic oligonucleotides, or other antisense chemical structures are designed to bind to CARD-encoding mRNA and inhibit translation of mRNA and are useful as compositions to inhibit expression of CARD-encoding genes or CARD-associated polypeptide genes in a tissue sample or in a subject.

The invention also provides vectors containing the CARD-encoding nucleic acids of the invention. Suitable expression vectors are well-known in the art and include vectors capable of expressing nucleic acid operatively linked to a regulatory sequence or element such as a promoter region or enhancer region that is capable of regulating expression of such nucleic acid. Appropriate expression vectors include those that are replicable in eukaryotic cells and/or prokaryotic cells and those that remain episomal or those which integrate into the host cell genome.

Promoters or enhancers, depending upon the nature of the regulation, can be constitutive or regulated. The regulatory sequences or regulatory elements are operatively linked to a nucleic acid of the invention such that the physical and functional relationship between the nucleic acid and the regulatory sequence allows transcription of the nucleic acid.

Suitable vectors for expression in prokaryotic or eukaryotic cells are well known to those

skilled in the art (see, for example, Ausubel et al.,
supra, 2000). Vectors useful for expression in
eukaryotic cells can include, for example, regulatory
elements including the SV40 early promoter, the
5 cytomegalovirus (CMV) promoter, the mouse mammary tumor
virus (MMTV) steroid-inducible promoter, Moloney
murine leukemia virus (MMLV) promoter, and the like.
The vectors of the invention are useful for subcloning
and amplifying a CARD-encoding nucleic acid molecule
10 and for recombinantly expressing a CARD-containing
polypeptide. A vector of the invention can include,
for example, viral vectors such as a bacteriophage, a
baculovirus or a retrovirus; cosmids or plasmids; and,
particularly for cloning large nucleic acid molecules,
15 bacterial artificial chromosome vectors (BACs) and
yeast artificial chromosome vectors (YACs). Such
vectors are commercially available, and their uses are
well known in the art. One skilled in the art will
know or can readily determine an appropriate promoter
20 for expression in a particular host cell.

The invention additionally provides
recombinant cells containing CARD-encoding nucleic
acids of the invention. The recombinant cells are
generated by introducing into a host cell a vector
25 containing a CARD-encoding nucleic acid molecule. The
recombinant cells are transduced, transfected or
otherwise genetically modified. Exemplary host cells
that can be used to express recombinant CARD molecules
include mammalian primary cells; established mammalian
30 cell lines, such as COS, CHO, HeLa, NIH3T3, HEK 293 and
PC12 cells; amphibian cells, such as *Xenopus* embryos
and oocytes and other vertebrate cells. Exemplary host
cells also include insect cells such as *Drosophila*,
yeast cells such as *Saccharomyces cerevisiae*,
35 *Saccharomyces pombe*, or *Pichia pastoris*, and

prokaryotic cells such as *Escherichia coli*. Additional host cells can be obtained, for example, from ATCC (Manassas, VA).

In one embodiment, CARD-encoding nucleic acids can be delivered into mammalian cells, either *in vivo* or *in vitro* using suitable vectors well-known in the art. Suitable vectors for delivering a CARD-containing polypeptide, or a functional fragment thereof to a mammalian cell, include viral vectors such as retroviral vectors, adenovirus, adeno-associated virus, lentivirus, herpesvirus, as well as non-viral vectors such as plasmid vectors. Such vectors are useful for providing therapeutic amounts of a CARD-containing polypeptide (see, for example, U.S. Patent No. 5,399,346, issued March 21, 1995). Delivery of CARD polypeptides or nucleic acids therapeutically can be particularly useful when targeted to a tumor cell, thereby inducing apoptosis in tumor cells. In addition, where it is desirable to limit or reduce the *in vivo* expression of a CARD-containing polypeptide, the introduction of the antisense strand of the invention nucleic acid is contemplated.

Viral based systems provide the advantage of being able to introduce relatively high levels of the heterologous nucleic acid into a variety of cells. Suitable viral vectors for introducing an invention CARD-encoding nucleic acid into mammalian cells are well known in the art. These viral vectors include, for example, Herpes simplex virus vectors (Geller et al., Science, 241:1667-1669 (1988)); vaccinia virus vectors (Piccini et al., Meth. Enzymology, 153:545-563 (1987)); cytomegalovirus vectors (Mocarski et al., in Viral Vectors, Y. Gluzman and S.H. Hughes, Eds., Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.,

1988, pp. 78-84)); Moloney murine leukemia virus vectors (Danos et al., Proc. Natl. Acad. Sci. USA, 85:6460-6464 (1988); Blaese et al., Science, 270:475-479 (1995); Onodera et al., J. Virol., 72:1769-1774 (1998)); adenovirus vectors (Berkner, Biotechniques, 6:616-626 (1988); Cotten et al., Proc. Natl. Acad. Sci. USA, 89:6094-6098 (1992); Graham et al., Meth. Mol. Biol., 7:109-127 (1991); Li et al., Human Gene Therapy, 4:403-409 (1993); Zabner et al., Nature Genetics, 6:75-83 (1994)); adeno-associated virus vectors (Goldman et al., Human Gene Therapy, 10:2261-2268 (1997); Greelish et al., Nature Med., 5:439-443 (1999); Wang et al., Proc. Natl. Acad. Sci. USA, 96:3906-3910 (1999); Snyder et al., Nature Med., 5:64-70 (1999); Herzog et al., Nature Med., 5:56-63 (1999)); retrovirus vectors (Donahue et al., Nature Med., 4:181-186 (1998); Shackelford et al., Proc. Natl. Acad. Sci. USA, 85:9655-9659 (1988); U.S. Patent Nos. 4,405,712, 4,650,764 and 5,252,479, and WIPO publications WO 92/07573, WO 90/06997, WO 89/05345, WO 92/05266 and WO 92/14829; and lentivirus vectors (Kafri et al., Nature Genetics, 17:314-317 (1997)).

For example, in one embodiment of the present invention, adenovirus-transferrin/polylysine-DNA (TfAdpl-DNA) vector complexes (Wagner et al., Proc. Natl. Acad. Sci., USA, 89:6099-6103 (1992); Curiel et al., Hum. Gene Ther., 3:147-154 (1992); Gao et al., Hum. Gene Ther., 4:14-24 (1993)) are employed to transduce mammalian cells with heterologous CARD-encoding nucleic acid. Any of the plasmid expression vectors described herein may be employed in a TfAdpl-DNA complex.

Vectors useful for therapeutic administration of a CARD-encoding nucleic acid can contain a

regulatory element that provides tissue specific or inducible expression of an operatively linked nucleic acid. One skilled in the art can readily determine an appropriate tissue-specific promoter or enhancer that
5 allows expression of a CARD polypeptide or nucleic acid in a desired tissue. Any of a variety of inducible promoters or enhancers can also be included in the vector for regulatable expression of a CARD polypeptide or nucleic acid. Such inducible systems, include, for
10 example, tetracycline inducible system (Gossen & Bizard, Proc. Natl. Acad. Sci. USA, 89:5547-5551 (1992); Gossen et al., Science, 268:1766-1769 (1995); Clontech, Palo Alto, CA); metalothionein promoter induced by heavy metals; insect steroid hormone
15 responsive to ecdysone or related steroids such as muristerone (No et al., Proc. Natl. Acad. Sci. USA, 93:3346-3351 (1996); Yao et al., Nature, 366:476-479 (1993); Invitrogen, Carlsbad, CA); mouse mammary tumor virus (MMTV) induced by steroids such as glucocorticoid
20 and estrogen (Lee et al., Nature, 294:228-232 (1981); and heat shock promoters inducible by temperature changes.

An inducible system particularly useful for therapeutic administration utilizes an inducible
25 promoter that can be regulated to deliver a level of therapeutic product in response to a given level of drug administered to an individual and to have little or no expression of the therapeutic product in the absence of the drug. One such system utilizes a Gal4
30 fusion that is inducible by an antiprogesterin such as mifepristone in a modified adenovirus vector (Burien et al., Proc. Natl. Acad. Sci. USA, 96:355-360 (1999)). Another such inducible system utilizes the drug rapamycin to induce reconstitution of a transcriptional
35 activator containing rapamycin binding domains of

FKBP12 and FRAP in an adeno-associated virus vector (Ye et al., Science, 283:88-91 (1999)). It is understood that any combination of an inducible system can be combined in any suitable vector, including those
5 disclosed herein. Such a regulatable inducible system is advantageous because the level of expression of the therapeutic product can be controlled by the amount of drug administered to the individual or, if desired, expression of the therapeutic product can be terminated
10 by stopping administration of the drug.

The invention also provides a method for expression of a CARD-containing polypeptide by culturing cells containing a CARD-encoding nucleic acid under conditions suitable for expression of a CARD-
15 containing polypeptide. Thus, there is provided a method for the recombinant production of a CARD-containing polypeptide of the invention by expressing the CARD-encoding nucleic acid sequences in suitable host cells. Recombinant DNA expression systems that
20 are suitable to produce a CARD-containing polypeptide described herein are well-known in the art (see, for example, Ausubel et al., supra, 2000). For example, the above-described nucleotide sequences can be incorporated into vectors for further manipulation. As
25 used herein, vector refers to a recombinant DNA or RNA plasmid or virus containing discrete elements that are used to introduce heterologous DNA into cells for either expression or replication thereof.

The invention additionally provides an
30 isolated anti-CARD antibody having specific reactivity with a invention CARD-containing polypeptide. The anti-CARD antibody can be a monoclonal antibody or a polyclonal antibody. The invention further provides cell lines producing monoclonal antibodies having

specific reactivity with an invention CARD-containing protien.

The invention thus provides antibodies that specifically bind a CARD-containing polypeptide. As
5 used herein, the term "antibody" is used in its broadest sense to include polyclonal and monoclonal antibodies, as well as antigen binding fragments of such antibodies. With regard to an anti-CARD antibody of the invention, the term "antigen" means a native or
10 synthesized CARD-containing polypeptide or fragment thereof. An anti-CARD antibody, or antigen binding fragment of such an antibody, is characterized by having specific binding activity for a CARD polypeptide or a peptide portion thereof of at least about
15 $1 \times 10^5 \text{ M}^{-1}$. Thus, Fab, F(ab')₂, Fd and Fv fragments of an anti-CARD antibody, which retain specific binding activity for a CARD-containing polypeptide, are included within the definition of an antibody. Specific binding activity of a CARD-containing
20 polypeptide can be readily determined by one skilled in the art, for example, by comparing the binding activity of an anti-CARD antibody to a CARD-containing polypeptide versus a reference polypeptide that is not a CARD-containing polypeptide. Methods of preparing
25 polyclonal or monoclonal antibodies are well known to those skilled in the art (see, for example, Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press (1988)).

In addition, the term "antibody" as used
30 herein includes naturally occurring antibodies as well as non-naturally occurring antibodies, including, for example, single chain antibodies, chimeric, bifunctional and humanized antibodies, as well as antigen-binding fragments thereof. Such non-naturally

occurring antibodies can be constructed using solid phase peptide synthesis, can be produced recombinantly or can be obtained, for example, by screening combinatorial libraries consisting of variable heavy
5 chains and variable light chains as described by Huse et al., Science 246:1275-1281 (1989)). These and other methods of making, for example, chimeric, humanized, CDR-grafted, single chain, and bifunctional antibodies are well known to those skilled in the art (Winter and
10 Harris, Immunol. Today 14:243-246 (1993); Ward et al., Nature 341:544-546 (1989) ; Harlow and Lane, supra, 1988); Hilyard et al., Protein Engineering: A practical approach (IRL Press 1992); Borrabeck, Antibody Engineering, 2d ed. (Oxford University Press
15 1995)).

Anti-CARD antibodies can be raised using a CARD immunogen such as an isolated CARD-containing polypeptide having substantially the same amino acid sequence as SEQ ID NOS:12, 188, 97, 99, 101, 103, 86
20 and 90, or a fragment thereof, which can be prepared from natural sources or produced recombinantly, or a peptide portion of the CARD-containing polypeptide. Such peptide portions of a CARD-containing polypeptide are functional antigenic fragments if the antigenic
25 peptides can be used to generate a CARD-specific antibody. A non-immunogenic or weakly immunogenic CARD-containing polypeptide or portion thereof can be made immunogenic by coupling the hapten to a carrier molecule such as bovine serum albumin (BSA) or keyhole
30 limpet hemocyanin (KLH). Various other carrier molecules and methods for coupling a hapten to a carrier molecule are well known in the art (see, for example, Harlow and Lane, supra, 1988). An immunogenic CARD-containing polypeptide fragment can also be
35 generated by expressing the peptide as a fusion

protein, for example, to glutathione S transferase (GST), polyHis or the like. Methods for expressing peptide fusions are well known to those skilled in the art (Ausubel et al., supra, (2000)).

5 The invention further provides a method for detecting the presence of a human CARD-containing polypeptide in a sample by contacting a sample with a CARD-specific antibody, and detecting the presence of specific binding of the antibody to the sample, thereby
10 detecting the presence of a human CARD-containing polypeptide in the sample. CARD-specific antibodies can be used in diagnostic methods and systems to detect the level of CARD-containing polypeptide present in a sample. As used herein, the term "sample" is intended
15 to mean any biological fluid, cell, tissue, organ or portion thereof, that includes or potentially includes CARD nucleic acids or polypeptides. The term includes samples present in an individual as well as samples obtained or derived from the individual. For example,
20 a sample can be a histologic section of a specimen obtained by biopsy, or cells that are placed in or adapted to tissue culture. A sample further can be a subcellular fraction or extract, or a crude or substantially pure nucleic acid or polypeptide
25 preparation.

CARD-specific antibodies can also be used for the immunoaffinity or affinity chromatography purification of an invention CARD-containing polypeptide. In addition, methods are contemplated
30 herein for detecting the presence of an invention CARD-containing polypeptide in a cell, comprising contacting the cell with an antibody that specifically binds to CARD-containing polypeptides under conditions permitting binding of the antibody to the CARD-

containing polypeptides, detecting the presence of the antibody bound to the CARD-containing polypeptide, and thereby detecting the presence of invention polypeptides in a cell. With respect to the detection
5 of such polypeptides, the antibodies can be used for *in vitro* diagnostic or *in vivo* imaging methods.

Immunological procedures useful for *in vitro* detection of target CARD-containing polypeptides in a sample include immunoassays that employ a detectable
10 antibody. Such immunoassays include, for example, immunohistochemistry, immunofluorescence, ELISA assays, radioimmunoassay, FACS analysis, immunoprecipitation, immunoblot analysis, Pandex microfluorimetric assay, agglutination assays, flow cytometry and serum
15 diagnostic assays, which are well known in the art (Harlow and Lane, *supra*, 1988; Harlow and Lane, Using Antibodies: A Laboratory Manual, Cold Spring Harbor Press (1999)).

An antibody can be made detectable by various
20 means well known in the art. For example, a detectable marker can be directly attached to the antibody or indirectly attached using, for example, a secondary agent that recognizes the CARD specific antibody. Useful markers include, for example, radionucleotides,
25 enzymes, binding proteins such as biotin, fluorogens, chromogens and chemiluminescent labels.

An antibody can also be detectable by, for example, a fluorescent labeling agent that chemically binds to antibodies or antigens without denaturation to
30 form a fluorochrome (dye) that is a useful immunofluorescent tracer. A description of immunofluorescent analytic techniques is found in DeLuca, "Immunofluorescence Analysis", in Antibody As a

Tool, Marchalonis et al., eds., John Wiley & Sons, Ltd., pp. 189-231 (1982), which is incorporated herein by reference.

In one embodiment, the indicating group is an
5 enzyme, such as horseradish peroxidase (HRP), glucose oxidase, and the like. In another embodiment, radioactive elements are employed labeling agents. The linking of a label to a substrate, i.e., labeling of
10 nucleic acid probes, antibodies, polypeptides, and proteins, is well known in the art. For instance, an invention antibody can be labeled by metabolic incorporation of radiolabeled amino acids provided in the culture medium. See, for example, Galfre et al.,
Meth. Enzymol., 73:3-46 (1981). Conventional means of
15 protein conjugation or coupling by activated functional groups are particularly applicable. See, for example, Aurameas et al., Scand. J. Immunol., Vol. 8, Suppl. 7:7-23 (1978), Rodwell et al., Biotech., 3:889-894 (1984), and U.S. Patent No. 4,493,795.

20 In addition to detecting the presence of a CARD-containing polypeptide, invention anti-CARD antibodies are contemplated for use herein to alter the activity of the CARD-containing polypeptide in living animals, in humans, or in biological tissues or fluids
25 isolated therefrom. The term "alter" refers to the ability of a compound such as a CARD-containing polypeptide, a CARD-encoding nucleic acid, an agent or other compound to increase or decrease biological activity which is modulated by the compound, by
30 functioning as an agonist or antagonist of the compound. Accordingly, compositions comprising a carrier and an amount of an antibody having specificity for CARD-containing polypeptides effective to block

naturally occurring ligands or other CARD-associated polypeptides from binding to invention CARD-containing polypeptides are contemplated herein. For example, a monoclonal antibody directed to an epitope of an invention CARD-containing polypeptide, including an amino acid sequence substantially the same as SEQ ID 12, 188, 97, 99, 101, 103, 86 and 90, can be useful for this purpose.

The present invention further provides transgenic non-human mammals that are capable of expressing exogenous nucleic acids encoding CARD-containing polypeptides. As employed herein, the phrase "exogenous nucleic acid" refers to nucleic acid sequence which is not native to the host, or which is present in the host in other than its native environment, for example, as part of a genetically engineered DNA construct. In addition to naturally occurring CARD-containing polypeptide levels, a CARD-containing polypeptide of the invention can either be overexpressed or underexpressed in transgenic mammals, for example, underexpressed in a knock-out animal.

Also provided are transgenic non-human mammals capable of expressing CARD-encoding nucleic acids so mutated as to be incapable of normal activity. Therefore, the transgenic non-human mammals do not express native CARD-containing polypeptide or have reduced expression of native CARD-containing polypeptide. The present invention also provides transgenic non-human mammals having a genome comprising antisense nucleic acids complementary to CARD-encoding nucleic acids, placed so as to be transcribed into antisense mRNA complementary to CARD-encoding mRNA, which hybridizes to the mRNA and, thereby, reduces the

translation thereof. The nucleic acid can additionally comprise an inducible promoter and/or tissue specific regulatory elements, so that expression can be induced, or restricted to specific cell types.

5 Animal model systems useful for elucidating the physiological and behavioral roles of CARD-containing polypeptides are also provided, and are produced by creating transgenic animals in which the expression of the CARD-containing polypeptide is
10 altered using a variety of techniques. Examples of such techniques include the insertion of normal or mutant versions of nucleic acids encoding a CARD-containing polypeptide by microinjection, retroviral infection or other means well known to those skilled in
15 the art, into appropriate fertilized embryos to produce a transgenic animal, see, for example, Hogan et al., Manipulating the Mouse Embryo: A Laboratory Manual (Cold Spring Harbor Laboratory, (1986)). Transgenic animal model systems are useful for *in vivo* screening
20 of compounds for identification of specific ligands, such as agonists or antagonists, which activate or inhibit a biological activity.

 Also contemplated herein, is the use of homologous recombination of mutant or normal versions
25 of CARD-encoding genes with the native gene locus in transgenic animals, to alter the regulation of expression or the structure of CARD-containing polypeptides by replacing the endogeneous gene with a recombinant or mutated CARD-encoding gene. Methods for
30 producing a transgenic non-human mammal including a gene knock-out non-human mammal, are well known to those skilled in the art (see, Capecchi et al., Science 244:1288 (1989); Zimmer et al., Nature 338:150 (1989);

Shastri, Experientia, 51:1028-1039 (1995); Shastri, Mol. Cell. Biochem., 181:163-179 (1998); and U.S. Patent No. 5,616,491, issued April 1, 1997, No. 5,750,826, issued May 12, 1998, and No. 5,981,830, issued November 9, 5 1999).

In addition to homologous recombination, additional methods such as microinjection can be used which add genes to the host genome without removing host genes. Microinjection can produce a transgenic 10 animal that is capable of expressing both endogenous and exogenous CARD-containing polypeptides. Inducible promoters can be linked to the coding region of nucleic acids to provide a means to regulate expression of the transgene. Tissue specific regulatory elements can be 15 linked to the coding region to permit tissue-specific expression of the transgene. Transgenic animal model systems are useful for *in vivo* screening of compounds for identification of specific ligands, i.e., agonists and antagonists, which activate or inhibit CARD- 20 containing polypeptide responses.

In accordance with another embodiment of the invention, a method is provided for identifying a CARD-associated polypeptide (CAP). The method is carried out by contacting an invention CARD-containing 25 polypeptide with a candidate CAP and detecting association of the CARD-containing polypeptide with the CAP.

As used herein, the term "CARD-associated polypeptide" or "CAP" means a polypeptide that can 30 specifically bind to the CARD-containing polypeptides of the invention, or to any functional fragment of a CARD-containing polypeptide of the invention. Because

CARD-containing polypeptides of the invention contain domains which can self-associate, CARD-containing polypeptides are encompassed by the term CAP. An exemplary CAP is a protein or a polypeptide portion of a protein that can bind an NB-ARC (NACHT), CARD, LRR or ANGIO-R domain of an invention CARD-containing polypeptide. A CAP can be identified, for example, using *in vitro* protein binding assays similar to those described in, for example, Ausubel et al., supra, 2000, and by *in vivo* methods including methods such as yeast two-hybrid assays, or other protein-interaction assays and methods known in the art.

Normal association of CARD-containing polypeptide and a CAP polypeptide in a cell can be altered due, for example, to the expression in the cell of a variant CAP or CARD-containing polypeptide, respectively, either of which can compete with the normal binding function of a CARD-containing polypeptide and, therefore, can decrease the association of CAP and CARD-containing polypeptides in a cell. The term "variant" is used generally herein to mean a polypeptide that is different from the CAP or CARD-containing polypeptide that normally is found in a particular cell type. Thus, a variant can include a mutated protein or a naturally occurring protein, such as an isoform, that is not normally found in a particular cell type.

CARD-containing polypeptides and CARD-associated polypeptides of the invention can be characterized, for example, using *in vitro* binding assays or the yeast two hybrid system. An *in vivo* transcription activation assay such as the yeast two hybrid system is particularly useful for identifying

and manipulating the association of proteins. In addition, the results observed in such an assay likely mirror the events that naturally occur in a cell.

Thus, the results obtained in such an *in vivo* assay can
5 be predictive of results that can occur in a cell in a subject such as a human subject.

A transcription activation assay such as the yeast two hybrid system is based on the modular nature of transcription factors, which consist of functionally
10 separable DNA-binding and trans-activation domains. When expressed as separate proteins, these two domains fail to mediate gene transcription. However, transcription activation activity can be restored if the DNA-binding domain and the trans-activation domain
15 are bridged together due, for example, to the association of two proteins. The DNA-binding domain and trans-activation domain can be bridged, for example, by expressing the DNA-binding domain and trans-activation domain as fusion proteins (hybrids),
20 provided that the proteins that are fused to the domains can associate with each other. The non-covalent bridging of the two hybrids brings the DNA-binding and trans-activation domains together and creates a transcriptionally competent complex. The
25 association of the proteins is determined by observing transcriptional activation of a reporter gene.

The yeast two hybrid systems exemplified herein use various strains of *S. cerevisiae* as host cells for vectors that express the hybrid proteins. A
30 transcription activation assay also can be performed using, for example, mammalian cells. However, the yeast two hybrid system is particularly useful due to the ease of working with yeast and the speed with which

the assay can be performed. For example, yeast host cells containing a lacZ reporter gene linked to a LexA operator sequence can be used to demonstrate that a CARD domain of an invention CARD-containing polypeptide
5 can interact with itself or other CARD-containing polypeptides. For example, the DNA-binding domain can consist of the LexA DNA-binding domain, which binds the LexA promoter, fused to the CARD domain of a CARD-containing polypeptide of the invention and the
10 trans-activation domain can consist of the B42 acidic region separately fused to several cDNA sequences which encode known CARD-containing polypeptides. When the LexA domain is non-covalently bridged to a trans-activation domain fused to a CARD-containing
15 polypeptide, the association can activate transcription of the reporter gene.

A CAP, for example, a CARD-containing polypeptide, an NB-ARC-containing polypeptide or a LRR-containing polypeptide, also can be identified using
20 well known *in vitro* assays, for example, an assay utilizing a glutathione-S-transferase (GST) fusion protein. Such an *in vitro* assay provides a simple, rapid and inexpensive method for identifying and isolating a CAP. Such an *in vitro* assay is
25 particularly useful in confirming results obtained *in vivo* and can be used to characterize specific binding domains of a CAP. For example, a GST can be fused to a CARD-containing polypeptide of the invention, and expressed and purified by binding to an affinity matrix
30 containing immobilized glutathione. If desired, a sample that can contain a CAP or active fragments of a CAP can be passed over an affinity column containing bound GST/CARD and a CAP that binds to a CARD-containing polypeptide can be obtained. In addition,

GST/CARD can be used to screen a cDNA expression library, wherein binding of the GST/CARD fusion protein to a clone indicates that the clone contains a cDNA encoding a CAP.

5 Thus, one of skill in the art will recognize that using the CARD-containing polypeptides described herein, a variety of methods, such as protein purification, protein interaction cloning, or protein mass-spectrometry, can be used to identify a CAP.

10 Although the term "CAP" is used generally, it should be recognized that a CAP that is identified using the novel polypeptides described herein can be a fragment of a protein. Thus, as used herein, a CAP also includes a polypeptide that specifically
15 associates to a portion of an invention CARD-containing polypeptide that does not include a CARD domain. For example, a CAP can associate with the NB-ARC domain of CLAN or CARD3X. As used herein, a "candidate CAP" refers to a polypeptide containing a polypeptide
20 sequence know or suspected of binding one or more CARD-containing polypeptides of the invention. Thus, a CAP can represent a full-length protein or a CARD-associating fragment thereof. Since a CAP polypeptide can be a full-length protein or a CARD-associating
25 fragment thereof, one of skill in the art will recognize that a CAP-encoding nucleic acid, such as the genomic sequence, an mRNA sequence or a cDNA sequence need not encode the full-length protein. Thus, a cDNA can encode a polypeptide that is a fragment of a full-
30 length CAP which, nevertheless, binds one or more invention CARD-containing polypeptides. It is also within the scope of the invention that a full-length CAP can assume a conformation that does not, absent

some post-translational modification, bind a CARD-containing polypeptide of the invention, due, for example, to steric blocking of the binding site. Thus, a CAP can be a protein or a polypeptide portion of a
5 protein that can bind one of the CARD-containing polypeptides of the invention. Also, it should be recognized that a CAP can be identified by using a minimal polypeptide derived from the sequences of the CARD-containing polypeptides of the invention, and does
10 not necessarily require that the full-length molecules be employed for identifying such CAPs.

Since CARD-containing polypeptides can be involved in apoptosis, the association of a CAP with a CARD-containing polypeptide can affect the sensitivity
15 or resistance of a cell to apoptosis or can induce or block apoptosis induced by external or internal stimuli. The identification of various CAPs by use of known methods can be used to determine the function of these CAPs in cell death or signal transduction
20 pathways controlled by CARD-containing polypeptides, allowing for the development of assays that are useful for identifying agents that effectively alter the association of a CAP with a CARD-containing polypeptide. Such agents can be useful for providing
25 effective therapy for conditions caused, at least in part, by insufficient apoptosis, such as a cancer, autoimmune disease or certain viral infections. Such agents can also be useful for providing an effective therapy for diseases where excessive apoptosis is known
30 to occur, such as stroke, heart failure, or AIDS.

Assays of the invention can be used for identification of agents that alter the self-association of the CARD-containing polypeptides of the

invention. Thus, the methods of the invention can be used to identify agents that alter the self-association of CARD2X, CARD3X, CLAN A, CLAN B, CLAN C, CLAN D, COP-1 and COP-2 (set forth in SEQ ID NOS: 12, 188, 97, 99, 101, 103, 86 and 90) via their CARD domains, NB-ARC domains, LRR domains, or other domains within these polypeptides.

The ATP-binding and hydrolysis of the NB-ARC domains can be critical for function of a NAC polypeptide, for example, by altering the oligomerization of the NAC. Thus, agents that interfere with or enhance ATP or nucleotide binding and/or hydrolysis by the NB-ARC domain of a NAC polypeptide of the invention, such as CLAN (SEQ ID NOS:97, 99, 101 or 103) can also be useful for altering the activity of these polypeptides in cells.

A further embodiment of the invention provides a method to identify agents that can effectively alter CARD-containing polypeptide activity, for example the ability of CARD-containing polypeptides to associate with one or more heterologous proteins. Thus, the present invention provides a screening assay useful for identifying an effective agent, which can alter the association of a CARD-containing polypeptide with a CARD-associated polypeptide (CAP), such as a heterologous CARD-containing polypeptide. Since CARD-containing polypeptides are involved in biochemical processes such as apoptosis, the identification of such effective agents can be useful for altering the level of a biochemical process such as apoptosis in a cell, for example in a cell of a subject having a pathology characterized by an increased or decreased level of apoptosis.

Further, effective agents can be useful for alteration of other biochemical process modulated by a CARD-containing polypeptide of the invention.

Additional biochemical processes modulated by CARD-
5 containing polypeptide include, for example, NF- κ B induction, cytokine processing, cytokine receptor signaling, cJUN N-terminal kinase induction, and caspase-mediated proteolysis activation/inhibition, transcription, inflammation and cell adhesion.

10 As used herein, the term "agent" means a chemical or biological molecule such as a simple or complex organic molecule, a peptide, a peptido-mimetic, a polypeptide, a protein or an oligonucleotide that has the potential for altering the association of a CARD-
15 containing polypeptide with a heterologous protein or altering the ability of a CARD-containing polypeptide to self-associate or altering the ligand binding or catalytic activity of a CARD-containing polypeptide. An exemplary ligand binding activity is nucleotide
20 binding activity, such as ADP or ATP binding activity; and exemplary catalytic activities are nucleotide hydrolytic activity and proteolytic activity. In addition, the term "effective agent" is used herein to mean an agent that is confirmed as capable of altering
25 the association of a CARD-containing polypeptide with a heterologous protein or altering the ability of a CARD-containing polypeptide to self-associate or altering the ligand binding or catalytic activity of a CARD-containing polypeptide. For example, an effective
30 agent may be an anti-CARD antibody, a CARD-associated polypeptide, a caspase inhibitor, and the like.

As used herein, the term "alter the association" means that the association between two

specifically interacting polypeptides either is increased or decreased due to the presence of an effective agent. As a result of an altered association of CARD-containing polypeptide with another polypeptide
5 in a cell, the activity of the CARD-containing polypeptide or the CAP can be increased or decreased, thereby altering a biochemical process, for example, the level of apoptosis in the cell. As used herein, the term "alter the activity" means that the agent can
10 increase or decrease the activity of a CARD-containing polypeptide in a cell, thereby modulating a biochemical process in a cell, for example, the level of apoptosis in the cell. Similarly, the term "alter the level" of a biological process modulated by a CARD-containing
15 polypeptide refers to an increase or decrease a biochemical process which occurs upon altering the activity of a CARD-containing polypeptide. For example, an effective agent can increase or decrease the CARD:CARD-associating activity of a CARD-containing
20 polypeptide, which can result in decreased apoptosis. In another example, alteration of the ATP hydrolysis activity can modulate the ability of the NB-ARC domain of a CARD-containing polypeptide to associate with other NB-ARC-containing polypeptides, such as Apaf-1,
25 thereby altering any process effected by such association between a CARD-containing polypeptide and an NB-ARC-containing polypeptide.

An effective agent can act by interfering with the ability of a CARD-containing polypeptide to
30 associate with another polypeptide, or can act by causing the dissociation of a CARD-containing polypeptide from a complex with a CARD-associated polypeptide, wherein the ratio of bound CARD-containing polypeptide to free CARD-containing polypeptide is

related to the level of a biochemical process, such as, apoptosis, in a cell. For example, binding of a ligand to a CAP can allow the CAP, in turn, to bind a specific CARD-containing polypeptide such that all of the
5 specific CARD-containing polypeptide is bound to a CAP, and can result in decreased apoptosis. The association, for example, of a CARD-containing polypeptide and a CARD-containing polypeptide can result in activation or inhibition of the NB-ARC:NB-
10 ARC-associating activity of a CARD-containing polypeptide. In the presence of an effective agent, the association of a CARD-containing polypeptide and a CAP can be altered, which can, for example, alter the activation of caspases in the cell. As a result of the
15 altered caspase activation, the level of apoptosis in a cell can be increased or decreased. Thus, the identification of an effective agent that alters the association of a CARD-containing polypeptide with another polypeptide can allow for the use of the
20 effective agent to increase or decrease the level of a biological process such as apoptosis.

An effective agent can be useful, for example, to increase the level of apoptosis in a cell such as a cancer cell, which is characterized by having
25 a decreased level of apoptosis as compared to its normal cell counterpart. An effective agent also can be useful, for example, to decrease the level of apoptosis in a cell such as a T lymphocyte in a subject having a viral disease such as acquired
30 immunodeficiency syndrome, which is characterized by an increased level of apoptosis in an infected T cell as compared to a normal T cell. Thus, an effective agent can be useful as a medicament for altering the level of apoptosis in a subject having a pathology characterized

by increased or decreased apoptosis. In addition, an effective agent can be used, for example, to decrease the level of apoptosis and, therefore, increase the survival time of a cell such as a hybridoma cell in culture. The use of an effective agent to prolong the survival of a cell *in vitro* can significantly improve bioproduction yields in industrial tissue culture applications.

A CARD-containing polypeptide that lacks the ability to bind the NB-ARC domain or LRR domain of another polypeptide but retains the ability to self-associate via its CARD domain or to bind to other CARD-containing polypeptides is an example of an effective agent, since the expression of a non-NB-ARC-associating or non-catalytically active CARD-containing polypeptide in a cell can alter the association of a the endogenous CARD-containing polypeptide with itself or with CAPs.

Thus, it should be recognized that a mutation of a CARD-containing polypeptide can be an effective agent, depending, for example, on the normal levels of CARD-containing polypeptide and CARD-associated polypeptide that occur in a particular cell type. In addition, an active fragment of a CARD-containing polypeptide can be an effective agent, provided the active fragment can alter the association of a CARD-containing polypeptide and another polypeptide in a cell. Such active fragments, which can be peptides as small as about five amino acids, can be identified, for example, by screening a peptide library (see, for example, Ladner et al., U.S. Patent No: 5,223,409) to identify peptides that can bind a CARD-associated polypeptide.

Similarly, a fragment of a CARD-associated polypeptide also can be an effective agent. A fragment of CARD-associated polypeptide can be useful, for example, for decreasing the association of a CARD-containing polypeptide with a CAP in a cell by competing for binding to the CARD-containing polypeptide. A non-naturally occurring peptido-mimetic also can be useful as an effective agent. Such a peptido-mimetic can include, for example, a peptoid, which is peptide-like sequence containing N-substituted glycines, or an oligocarbamate. A peptido-mimetic can be particularly useful as an effective agent due, for example, to having an increased stability to enzymatic degradation *in vivo*.

In accordance with another embodiment of the present invention, there is provided a method of identifying an effective agent that alters the association of an invention CARD-containing polypeptide with a CARD-associated polypeptide (CAP), by the steps of:

(a) contacting a CARD-containing polypeptide and a CAP polypeptide, under conditions that allow the CARD-containing polypeptide and CAP polypeptide to associate, with an agent suspected of being able to alter the association of the CARD-containing polypeptide and CAP polypeptides; and

(b) detecting the altered association of the CARD-containing polypeptide and CAP polypeptide, where the altered association identifies an effective agent.

Methods well-known in the art for detecting the altered association of the CARD-containing polypeptide and CAP polypeptides, for example, measuring protein:protein binding, protein degradation
5 or apoptotic activity can be employed in bioassays described herein to identify agents as agonists or antagonists of CARD-containing polypeptides. As described herein, CARD-containing polypeptides have the ability to self-associate. Thus, methods for
10 identifying effective agents that alter the association of a CARD-containing polypeptide with a CAP are useful for identifying effective agents that alter the ability of a CARD-containing polypeptide to self-associate.

As used herein, "conditions that allow said
15 CARD-containing polypeptide and CAP polypeptide to associate" refers to environmental conditions in which a CARD-containing polypeptide and CAP specifically associate. Such conditions will typically be aqueous conditions, with a pH between 3.0 and 11.0, and
20 temperature below 100°C. Preferably, the conditions will be aqueous conditions with salt concentrations below the equivalent of 1 M NaCl, and pH between 5.0 and 9.0, and temperatures between 0°C and 50°C. Most preferably, the conditions will range from
25 physiological conditions of normal yeast or mammalian cells, or conditions favorable for carrying out *in vitro* assays such as immunoprecipitation and GST protein:protein association assays, and the like.

In another embodiment of the invention, a method is provided for identifying agents that modulate a ligand binding or catalytic activity of an invention CARD-containing polypeptide. The method contains the

5 steps of contacting an invention CARD-containing polypeptide with an agent suspected of modulating a ligand binding or catalytic activity of the CARD-containing polypeptide and measuring a ligand binding or catalytic activity of the CARD-containing

10 polypeptide, where modulated ligand binding or catalytic activity identifies the agent as an agent that alters the ligand binding or catalytic activity of a CARD-containing polypeptide.

As used herein in regard to ligand binding or

15 catalytic activity, "modulate" refers to an increase or decrease in ligand binding or catalytic activity. Thus, modulation encompasses inhibition of ligand binding or catalytic activity as well as activation or enhancement of ligand binding or catalytic activity.

20 Exemplary ligand binding activities include nucleotide binding activity. Exemplary catalytic binding activities include nucleotide hydrolysis and proteolysis activities.

Methods for measuring ligand binding or

25 catalytic activities are well known in the art, as disclosed herein. For example, an agent known or suspected of modulating ligand binding or catalytic activity can be contacted with an invention CARD-containing polypeptide in vivo or in vitro, and the

30 ligand binding or catalytic activity can be measured using known methods. For example, enzymatic activity can be measured using a cleavable reporter, where the

cleavable reporter generates or alters a measurable signal such as absorption, fluorescence or radioactive decay. Exemplary agents that can modulate ligand binding or catalytic activity include peptides, peptidomimetics and other peptide analogs, non-peptide organic molecules such as naturally occurring protease inhibitors and derivatives thereof, nucleotides and nucleotide analogs, and the like. Such inhibitors can be either reversible or irreversible, as is well known in the art.

Agents that modulate the ligand binding or catalytic activity of a CARD-containing polypeptide identified using the invention methods can be used to modulate the activity of a CARD-containing polypeptide. For example, an agent can modulate the nucleotide binding or nucleotide hydrolytic activity of an NB-ARC domain of a CARD-containing polypeptide. In another example, an agent can modulate the catalytic activity of a protease domain such as a caspase domain. Methods of modulating the ligand binding or catalytic activities of invention CARD-containing proteins can be used in methods of altering biochemical processes modulated by CARD-containing proteins, such as the biochemical processes disclosed herein.

In yet another embodiment of the present invention, there are provided methods for altering ligand binding or catalytic activity of a CARD-containing polypeptide of the invention, the method comprising:

contacting an CARD-containing polypeptide with an effective amount of an agent identified by the herein-described bioassays.

The present invention also provides *in vitro* screening assays. Such screening assays are particularly useful in that they can be automated, which allows for high through-put screening, for
5 example, of randomly or rationally designed agents such as drugs, peptidomimetics or peptides in order to identify those agents that effectively alter the association of a CARD-containing polypeptide and a CAP or the catalytic or ligand binding activity of a CARD-
10 containing polypeptide and, thereby, alter a biochemical process modulated by a CARD-containing polypeptide such as apoptosis. An *in vitro* screening assay can utilize, for example, a CARD-containing polypeptide including a CARD-containing fusion protein
15 such as a CARD-glutathione-S-transferase fusion protein. For use in the *in vitro* screening assay, the CARD-containing polypeptide should have an affinity for a solid substrate as well as the ability to associate with a CARD-associated polypeptide. For example, when
20 a CARD-containing polypeptide is used in the assay, the solid substrate can contain a covalently attached anti-CARD antibody. Alternatively, a GST/CARD fusion protein can be used in the assay and the solid substrate can contain covalently attached glutathione,
25 which is bound by the GST component of the GST/CARD fusion protein. Similarly, a CARD-associated polypeptide, or GST/NB-ARC-containing polypeptide fusion protein can be used in any of a variety of *in vitro* enzymatic or *in vitro* binding assays known in the
30 art and described in texts such as Ausubel et al., supra, 2000.

An *in vitro* screening assay can be performed by allowing a CARD-containing polypeptide, for example, to bind to the solid support, then adding a CARD-associated polypeptide and an agent to be tested.

5 Reference reactions, which do not contain an agent, can be performed in parallel. Following incubation under suitable conditions, which include, for example, an appropriate buffer concentration and pH and time and temperature that permit binding of the particular CARD-
10 containing polypeptide and CARD-associated polypeptide, the amount of protein that has associated in the absence of an agent and in the presence of an agent can be determined. The association of a CARD-associated polypeptide with a CARD-containing polypeptide can be
15 detected, for example, by attaching a detectable moiety such as a radionuclide or a fluorescent label to a CARD-associated polypeptide and measuring the amount of label that is associated with the solid support, wherein the amount of label detected indicates the
20 amount of association of the CARD-associated polypeptide with a CARD-containing polypeptide. An effective agent is determined by comparing the amount of specific binding in the presence of an agent as compared to a reference level of binding, wherein an
25 effective agent alters the association of CARD-containing polypeptide with the CARD-associated polypeptide. Such an assay is particularly useful for screening a panel of agents such as a peptide library in order to detect an effective agent.

30 Various binding assays to identify cellular proteins that interact with protein binding domains are known in the art and include, for example, yeast two-hybrid screening assays (see, for example, U.S.

Patent Nos. 5,283,173, 5,468,614 and 5,667,973; Ausubel et al., supra, 2000; Luban et al., Curr. Opin. Biotechnol. 6:59-64 (1995)) and affinity column chromatography methods using cellular extracts. By
5 synthesizing or expressing polypeptide fragments containing various CARD-associating sequences or deletions, the CARD binding interface can be readily identified.

Another assay for screening of agents that
10 alter the activity of a CARD-containing polypeptide is based on altering the phenotype of yeast by expressing a CARD-containing polypeptide. In one embodiment, expression of a CARD-containing polypeptide can be inducible (Tao et al., J. Biol. Chem. 273:23704-23708
15 (1998), and the compounds can be screened when CARD-containing polypeptide expression is induced. CARD-containing polypeptides of the invention can also be co-expressed in yeast with CAP polypeptides used to screen for compounds that antagonize the activity of
20 the CARD-containing polypeptide.

Also provided with the present invention are assays to identify agents that alter CARD-containing polypeptide expression. Methods to determine CARD-containing polypeptide expression can involve detecting
25 a change in CARD-containing polypeptide abundance in response to contacting the cell with an agent that modulates CARD-containing polypeptide expression. Assays for detecting changes in polypeptide expression include, for example, immunoassays with CARD-specific
30 antibodies, such as immunoblotting, immunofluorescence, immunohistochemistry and immunoprecipitation assays, as described herein.

As understood by those of skill in the art, assay methods for identifying agents that alter CARD-containing polypeptide activity generally require comparison to a reference. One type of a "reference" is a cell or culture that is treated substantially the same as the test cell or test culture exposed to the agent, with the distinction that the "reference" cell or culture is not exposed to the agent. Another type of "reference" cell or culture can be a cell or culture that is identical to the test cells, with the exception that the "reference" cells or culture do not express a CARD-containing polypeptide. Accordingly, the response of the transfected cell to an agent is compared to the response, or lack thereof, of the "reference" cell or culture to the same agent under the same reaction conditions.

Methods for producing pluralities of agents to use in screening for compounds that alter the activity of a CARD-containing polypeptide, including chemical or biological molecules such as simple or complex organic molecules, metal-containing compounds, carbohydrates, peptides, proteins, peptidomimetics, glycoproteins, lipoproteins, nucleic acids, antibodies, and the like, are well known in the art and are described, for example, in Huse, U.S. Patent No. 5,264,563; Francis et al., Curr. Opin. Chem. Biol. 2:422-428 (1998); Tietze et al., Curr. Biol., 2:363-371 (1998); Sofia, Mol. Divers. 3:75-94 (1998); Eichler et al., Med. Res. Rev. 15:481-496 (1995); and the like. Libraries containing large numbers of natural and synthetic agents also can be obtained from commercial sources. Combinatorial libraries of molecules can be prepared using well known combinatorial chemistry methods (Gordon et al., J. Med. Chem. 37: 1233-1251

(1994); Gordon et al., J. Med. Chem. 37: 1385-1401
(1994); Gordon et al., Acc. Chem. Res. 29:144-154
(1996); Wilson and Czarnik, eds., Combinatorial
Chemistry: Synthesis and Application, John Wiley &
5 Sons, New York (1997)).

The invention further provides a method of
diagnosing or predicting clinical prognosis of a
pathology characterized by an increased or decreased
level of a CARD-containing polypeptide in a subject.
10 The method includes the steps of (a) obtaining a test
sample from the subject; (b) contacting the sample with
an agent that can bind a CARD-containing polypeptide of
the invention under suitable conditions, wherein the
conditions allow specific binding of the agent to the
15 CARD-containing polypeptide; and (c) comparing the
amount of the specific binding in the test sample with
the amount of specific binding in a reference sample,
wherein an increased or decreased amount of the
specific binding in the test sample as compared to the
20 reference sample is diagnostic of, or predictive of the
clinical prognosis of, a pathology. The agent can be,
for example, an anti-CARD antibody, a CARD-associated-
polypeptide (CAP), or a CARD-encoding nucleic acid.

Exemplary pathologies for diagnosis or the
25 prediction of clinical prognosis include any of the
pathologies described herein, such as neoplastic
pathologies (e.g. cancer), autoimmune diseases, and
other pathologies related to abnormal cell
proliferation or abnormal cell death (e.g. apoptosis),
30 as disclosed herein.

The invention also provides a method of
diagnosing cancer or monitoring cancer therapy by

contacting a test sample from a patient with a CARD-specific antibody. The invention additionally provides a method of assessing prognosis (e.g., predicting the clinical prognosis) of patients with cancer comprising
5 contacting a test sample from a patient with a CARD-specific antibody.

The invention additionally provides a method of diagnosing cancer or monitoring cancer therapy by contacting a test sample from a patient with a
10 oligonucleotide that selectively hybridizes to a CARD-encoding nucleic acid molecule. The invention further provides a method of assessing prognosis (e.g., predicting the clinical prognosis) of patients with cancer by contacting a test sample from a patient with
15 a oligonucleotide that selectively hybridizes to a CARD-encoding nucleic acid molecule.

The methods of the invention for diagnosing cancer or monitoring cancer therapy using a CARD-specific antibody or oligonucleotide or nucleic acid
20 that selectively hybridizes to a CARD-encoding nucleic acid molecule can be used, for example, to segregate patients into a high risk group or a low risk group for diagnosing cancer or predicting risk of metastasis or risk of failure to respond to therapy. Therefore, the
25 methods of the invention can be advantageously used to determine, for example, the risk of metastasis in a cancer patient, or the risk of an autoimmune disease of a patient, or as a prognostic indicator of survival or disease progression in a cancer patient or patient with
30 an autoimmune disease. One of ordinary skill in the art would appreciate that the prognostic indicators of survival for cancer patients suffering from stage I cancer can be different from those for cancer patients

suffering from stage IV cancer. For example, prognosis for stage I cancer patients can be oriented toward the likelihood of continued growth and/or metastasis of the cancer, whereas prognosis for stage IV cancer patients
5 can be oriented toward the likely effectiveness of therapeutic methods for treating the cancer.

Accordingly, the methods of the invention directed to measuring the level of or determining the presence of a CARD-containing polypeptide or CARD-encoding nucleic
10 acid can be used advantageously as a prognostic indicator for the presence or progression of a cancer or response to therapy.

The invention further provides methods for introducing a CARD-encoding nucleic acid into a cell in
15 a subject, for example, for gene therapy. Viruses are specialized infectious agents that can elude host defense mechanisms and can infect and propagate in specific cell types. Viral based systems provide the advantage of being able to introduce relatively high
20 levels of the heterologous nucleic acid into a variety of cells. Suitable viral vectors for introducing an invention CARD-encoding nucleic acid into mammalian cells (e.g., vascular tissue segments) are well known in the art. These viral vectors include, for example,
25 Herpes simplex virus vectors (e.g., Geller et al., Science, 241:1667-1669 (1988)), Vaccinia virus vectors (e.g., Piccini et al., Meth. in Enzymology, 153:545-563 (1987); Cytomegalovirus vectors (Mocarski et al., in Viral Vectors, Y. Gluzman and S.H. Hughes, Eds., Cold
30 Spring Harbor Laboratory, Cold Spring Harbor, N.Y., 1988, pp. 78-84), Moloney murine leukemia virus vectors (Danos et al., Proc. Natl. Acad. Sci., USA, 85:6469 (1980)), adenovirus vectors (e.g., Logan et al., Proc. Natl. Acad. Sci., USA, 81:3655-3659 (1984);

Jones et al., Cell, 17:683-689 (1979); Berkner, Biotechniques, 6:616-626 (1988); Cotten et al., Proc. Natl. Acad. Sci., USA, 89:6094-6098 (1992); Graham et al., Meth. Mol. Biol., 7:109-127 (1991)),

5 adeno-associated virus vectors, retrovirus vectors (see, e.g., U.S. Patent 4,405,712 and 4,650,764), and the like. Especially preferred viral vectors are the adenovirus and retroviral vectors.

Suitable retroviral vectors for use herein
10 are described, for example, in U.S. Patent 5,252,479, and in WIPO publications WO 92/07573, WO 90/06997, WO 89/05345, WO 92/05266 and WO 92/14829, incorporated herein by reference, which provide a description of methods for efficiently introducing nucleic acids into
15 human cells using such retroviral vectors. Other retroviral vectors include, for example, the mouse mammary tumor virus vectors (e.g., Shackelford et al., Proc. Natl. Acad. Sci. USA, 85:9655-9659 (1988)), and the like.

20 In particular, the specificity of viral vectors for particular cell types can be utilized to target predetermined cell types. Thus, the selection of a viral vector will depend, in part, on the cell type to be targeted. For example, if a
25 neurodegenerative disease is to be treated by increasing the level of a CARD-containing polypeptide in neuronal cells affected by the disease, then a viral vector that targets neuronal cells can be used. A vector derived from a herpes simplex virus is an
30 example of a viral vector that targets neuronal cells (Battleman et al., J. Neurosci. 13:941-951 (1993), which is incorporated herein by reference). Similarly, if a disease or pathological condition of the

hematopoietic system is to be treated, then a viral vector that is specific for a particular blood cell or its precursor cell can be used. A vector based on a human immunodeficiency virus is an example of such a viral vector (Carroll et al., J. Cell. Biochem. 17E:241 (1993), which is incorporated herein by reference). In addition, a viral vector or other vector can be constructed to express a CARD-encoding nucleic acid in a tissue specific manner by incorporating a tissue-specific promoter or enhancer into the vector (Dai et al., Proc. Natl. Acad. Sci. USA 89:10892-10895 (1992), which is incorporated herein by reference).

For gene therapy, a vector containing a CARD-encoding nucleic acid or an antisense nucleotide sequence can be administered to a subject by various methods. For example, if viral vectors are used, administration can take advantage of the target specificity of the vectors. In such cases, there is no need to administer the vector locally at the diseased site. However, local administration can be a particularly effective method of administering a CARD-encoding nucleic acid. In addition, administration can be via intravenous or subcutaneous injection into the subject. Following injection, the viral vectors will circulate until they recognize host cells with the appropriate target specificity for infection. Injection of viral vectors into the spinal fluid also can be an effective mode of administration, for example, in treating a neurodegenerative disease.

Receptor-mediated DNA delivery approaches also can be used to deliver a CARD-encoding nucleic acid molecule into cells in a tissue-specific manner using a tissue-specific ligand or an antibody that is

non-covalently complexed with the nucleic acid molecule via a bridging molecule (Curiel et al., Hum. Gene Ther. 3:147-154 (1992); Wu and Wu, J. Biol. Chem. 262:4429-4432 (1987), each of which is incorporated
5 herein by reference). Direct injection of a naked or a nucleic acid molecule encapsulated, for example, in cationic liposomes also can be used for stable gene transfer into non-dividing or dividing cells *in vivo* (Ulmer et al., Science 259:1745-1748 (1993), which is
10 incorporated herein by reference). In addition, a CARD-encoding nucleic acid molecule can be transferred into a variety of tissues using the particle bombardment method (Williams et al., Proc. Natl. Acad. Sci. USA 88:2726-2730 (1991), which is incorporated
15 herein by reference). Such nucleic acid molecules can be linked to the appropriate nucleotide sequences required for transcription and translation.

A particularly useful mode of administration of a CARD-encoding nucleic acid is by direct
20 inoculation locally at the site of the disease or pathological condition. Local administration can be advantageous because there is no dilution effect and, therefore, the likelihood that a majority of the targeted cells will be contacted with the nucleic acid
25 molecule is increased. Thus, local inoculation can alleviate the targeting requirement necessary with other forms of administration and, if desired, a vector that infects all cell types in the inoculated area can be used. If expression is desired in only a specific
30 subset of cells within the inoculated area, then a promoter, an enhancer or other expression element specific for the desired subset of cells can be linked to the nucleic acid molecule. Vectors containing such nucleic acid molecules and regulatory elements can be

viral vectors, viral genomes, plasmids, phagemids and the like. Transfection vehicles such as liposomes also can be used to introduce a non-viral vector into recipient cells. Such vehicles are well known in the art.

The present invention also provides therapeutic compositions useful for practicing the therapeutic methods described herein. Therapeutic compositions of the present invention, such as pharmaceutical compositions, contain a physiologically compatible carrier together with an invention CARD-containing polypeptide (or functional fragment thereof), an invention CARD-encoding nucleic acid, an agent that alters CARD activity or expression identified by the methods described herein, or an anti-CARD antibody, as described herein, dissolved or dispersed therein as an active ingredient. In a preferred embodiment, the therapeutic composition is not immunogenic when administered to a mammal or human patient for therapeutic purposes.

As used herein, the terms "pharmaceutically acceptable", "physiologically compatible" and grammatical variations thereof, as they refer to compositions, carriers, diluents and reagents, are used interchangeably and represent that the materials are capable of administration to a mammal without the production of undesirable physiological effects.

The preparation of a pharmacological composition that contains active ingredients dissolved or dispersed therein is well known in the art. Typically such compositions are prepared as injectibles either as liquid solutions or suspensions; however,

solid forms suitable for solution, or suspension, in liquid prior to use can also be prepared. The preparation can also be emulsified.

The active ingredient can be mixed with
5 excipients which are pharmaceutically acceptable and compatible with the active ingredient in amounts suitable for use in the therapeutic methods described herein. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol, or the like, as
10 well as combinations of any two or more thereof. In addition, if desired, the composition can contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, and the like, which enhance the effectiveness of the active
15 ingredient.

The therapeutic composition of the present invention can include pharmaceutically acceptable salts of the components therein. Pharmaceutically acceptable nontoxic salts include the acid addition salts (formed
20 with the free amino groups of the polypeptide) that are formed with inorganic acids such as, for example, hydrochloric acid, hydrobromic acid, perchloric acid, nitric acid, thiocyanic acid, sulfuric acid, phosphoric acid, acetic acid, propionic acid, glycolic acid,
25 lactic acid, pyruvic acid, oxalic acid, malonic acid, succinic acid, maleic acid, fumaric acid, anthranilic acid, cinnamic acid, naphthalene sulfonic acid, sulfanilic acid, and the like.

Salts formed with the free carboxyl groups
30 can also be derived from inorganic bases such as, for example, sodium hydroxide, ammonium hydroxide, potassium hydroxide, and the like; and organic bases

such as mono-, di-, and tri-alkyl and -aryl amines
(e.g., triethylamine, diisopropyl amine, methyl amine,
dimethyl amine, and the like) and optionally
substituted ethanolamines (e.g., ethanolamine,
5 diethanolamine, and the like).

Physiologically tolerable carriers are well
known in the art. Exemplary liquid carriers are
sterile aqueous solutions that contain no materials in
addition to the active ingredients and water, or
10 contain a buffer such as sodium phosphate at
physiological pH, physiological saline or both, such as
phosphate-buffered saline. Still further, aqueous
carriers can contain more than one buffer salt, as well
as salts such as sodium and potassium chlorides,
15 dextrose, polyethylene glycol and other solutes.

Liquid compositions can also contain liquid
phases in addition to and to the exclusion of water.
Exemplary additional liquid phases include glycerin,
vegetable oils such as cottonseed oil, and water-oil
20 emulsions.

As described herein, an "effective amount" is
a predetermined amount calculated to achieve the
desired therapeutic effect, i.e., to alter the protein
binding activity of a CARD-containing polypeptide or
25 the catalytic activity of a CARD-containing
polypeptide, resulting in altered biochemical process
modulated by a CARD-containing polypeptide. The
required dosage will vary with the particular treatment
and with the duration of desired treatment; however, it
30 is anticipated that dosages between about 10 micrograms
and about 1 milligram per kilogram of body weight per
day will be used for therapeutic treatment. It may be

particularly advantageous to administer such agents in depot or long-lasting form as discussed herein. A therapeutically effective amount is typically an amount of an agent identified herein that, when administered
5 in a physiologically acceptable composition, is sufficient to achieve a plasma concentration of from about 0.1 µg/ml to about 100 µg/ml, preferably from about 1.0 µg/ml to about 50 µg/ml, more preferably at least about 2 µg/ml and usually 5 to 10 µg/ml.

10 Therapeutic invention anti-CARD antibodies can be administered in proportionately appropriate amounts in accordance with known practices in this art.

Also provided herein are methods of treating pathologies characterized by abnormal cell
15 proliferation, abnormal cell death, or inflammation said method comprising administering an effective amount of an invention therapeutic composition. Such compositions are typically administered in a physiologically compatible composition.

20 Exemplary abnormal cell proliferation diseases associated with CARD-containing polypeptides contemplated herein for treatment according to the present invention include cancer pathologies, keratinocyte hyperplasia, neoplasia, keloid, benign
25 prostatic hypertrophy, inflammatory hyperplasia, fibrosis, smooth muscle cell proliferation in arteries following balloon angioplasty (restenosis), and the like. Exemplary cancer pathologies contemplated herein for treatment include, gliomas, carcinomas,
30 adenocarcinomas, sarcomas, melanomas, hamartomas, leukemias, lymphomas, and the like. Further diseases associated with CARD-containing polypeptides contemplated herein for treatment according to the

present invention include inflammatory diseases and diseases of cell loss. Such diseases include allergies, inflammatory diseases including arthritis, lupus, Schrogen's syndrome, Crohn's disease, ulcerative
5 colitis, as well as allograft rejection, such as graft-versus-host disease, and the like. CARD-containing polypeptides can also be useful in design of strategies for preventing diseases related to abnormal cell death in conditions such as stroke, myocardial infarction,
10 heart failure, neurodegenerative diseases such as Parkinson's and Alzheimer's diseases, and for immunodeficiency associated diseases such as HIV infection, HIV-related disease, and the like.

Methods of treating pathologies can include
15 methods of modulating the activity of one or more oncogenic proteins, wherein the oncogenic proteins specifically interact with a CARD-containing polypeptide of the invention. Methods of modulating the activity of such oncogenic proteins will include
20 contacting the oncogenic protein with a substantially pure CARD-containing polypeptide or an active fragment (i.e., oncogenic protein-binding fragment) thereof. This contacting will alter the activity of the oncogenic protein, thereby providing a method of
25 treating a pathology caused by the oncogenic protein. Further methods of modulating the activity of oncogenic proteins will include contacting the oncogenic protein with an agent, wherein the agent alters interaction between a CARD-containing polypeptide and an oncogenic
30 protein.

Also contemplated herein, are therapeutic methods using invention pharmaceutical compositions for the treatment of pathological disorders in which there

is too little cell division, such as, for example, bone marrow aplasias, immunodeficiencies due to a decreased number of lymphocytes, and the like. Methods of treating a variety of inflammatory diseases with invention therapeutic compositions are also contemplated herein, such as treatment of sepsis, fibrosis (e.g., scarring), arthritis, graft versus host disease, and the like.

The present invention also provides methods for diagnosing a pathology that is characterized by an increased or decreased level of a biochemical process to determine whether the increased or decreased level of the biochemical process is due, for example, to increased or decreased expression of a CARD-containing polypeptide or to expression of a variant CARD-containing polypeptide. As disclosed herein, such biochemical processes include apoptosis, NF-kB induction, cytokine processing, caspase-mediated proteolysis, transcription, inflammation, cell adhesion, and the like. The identification of such a pathology, which can be due to altered association of a CARD-containing polypeptide with a CARD-associated polypeptide in a cell, or altered ligand binding or catalytic activity of a CARD-containing polypeptide, can allow for intervention therapy using an effective agent or a nucleic acid molecule or an antisense nucleotide sequence as described herein. In general, a test sample can be obtained from a subject having a pathology characterized by having or suspected of having increased or decreased apoptosis and can be compared to a reference sample from a normal subject to determine whether a cell in the test sample has, for example, increased or decreased expression of a CARD-encoding gene. The level of a CARD-containing

polypeptide in a cell can be determined by contacting a sample with a reagent such as an anti-CARD antibody or a CARD-associated polypeptide, either of which can specifically bind a CARD-containing polypeptide. For example, the level of a CARD-containing polypeptide in a cell can be determined by well known immunoassay or immunohistochemical methods using an anti-CARD antibody (see, for example, Reed et al., Anal. Biochem. 205:70-76 (1992); see, also, Harlow and Lane, supra, (1988)).

As used herein, the term "reagent" means a chemical or biological molecule that can specifically bind to a CARD-containing polypeptide or to a bound CARD/CARD-associated polypeptide complex. For example, either an anti-CARD antibody or a CARD-associated polypeptide can be a reagent for a CARD-containing polypeptide, whereas either an anti-CARD antibody or an anti-CARD-associated polypeptide antibody can be a reagent for a CARD/CARD-associated polypeptide complex.

As used herein, the term "test sample" means a cell or tissue specimen that is obtained from a subject and is to be examined for expression of a CARD-encoding gene in a cell in the sample. A test sample can be obtained, for example, during surgery or by needle biopsy and can be examined using the methods described herein to diagnose a pathology characterized by increased or decreased apoptosis. Increased or decreased expression of a CARD-encoding gene in a cell in a test sample can be determined, for example, by comparison to an expected normal level of CARD-containing polypeptide or CARD-encoding mRNA in a particular cell type. A normal range of CARD-containing polypeptide or CARD-encoding mRNA levels in various cell types can be determined by sampling a statistically significant number of normal subjects.

In addition, a reference sample can be evaluated in parallel with a test sample in order to determine whether a pathology characterized by increased or decreased apoptosis is due to increased or decreased expression of a CARD-encoding gene. The test sample can be examined using, for example, immunohistochemical methods as described above or the sample can be further processed and examined. For example, an extract of a test sample can be prepared and examined to determine whether a CARD-containing polypeptide in the sample can associate with a CARD-associated polypeptide in the same manner as a CARD-containing polypeptide from a reference cell or whether, instead, a variant CARD-containing polypeptide is expressed in the cell.

In accordance with another embodiment of the present invention, there are provided diagnostic systems, preferably in kit form, comprising at least one invention CARD-encoding nucleic acid, CARD-containing polypeptide, and/or anti-CARD antibody described herein, in a suitable packaging material. In one embodiment, for example, the diagnostic nucleic acids are derived from any of SEQ ID NOS:11, 187, 96, 98, 100, 102, 85 and 89. Invention diagnostic systems are useful for assaying for the presence or absence of CARD-encoding nucleic acid in either genomic DNA or in transcribed CARD-encoding nucleic acid, such as mRNA or cDNA.

A suitable diagnostic system includes at least one invention CARD-encoding nucleic acid, CARD-containing polypeptide, and/or anti-CARD antibody, preferably two or more invention nucleic acids, proteins and/or antibodies, as a separately packaged chemical reagent(s) in an amount sufficient for at

least one assay. Instructions for use of the packaged reagent are also typically included. Those of skill in the art can readily incorporate invention nucleic acid probes and/or primers into kit form in combination with
5 appropriate buffers and solutions for the practice of the invention methods as described herein.

As employed herein, the phrase "packaging material" refers to one or more physical structures used to house the contents of the kit, such as
10 invention nucleic acid probes or primers, and the like. The packaging material is constructed by well known methods, preferably to provide a sterile, contaminant-free environment. The packaging material has a label which indicates that the invention nucleic
15 acids can be used for detecting a particular CARD-encoding sequence including the nucleotide sequences set forth in SEQ ID NOS:11, 187, 96, 98, 100, 102, 85 and 89 or mutations or deletions therein, thereby diagnosing the presence of, or a predisposition for a
20 pathology such as cancer or an autoimmune disease. In addition, the packaging material contains instructions indicating how the materials within the kit are employed both to detect a particular sequence and diagnose the presence of, or a predisposition for a
25 pathology such as cancer or an autoimmune disease.

The packaging materials employed herein in relation to diagnostic systems are those customarily utilized in nucleic acid-based diagnostic systems. As used herein, the term "package" refers to a solid
30 matrix or material such as glass, plastic, paper, foil, and the like, capable of holding within fixed limits an isolated nucleic acid, oligonucleotide, or primer of the present invention. Thus, for example, a package

can be a glass vial used to contain milligram quantities of a contemplated nucleic acid, oligonucleotide or primer, or it can be a microtiter plate well to which microgram quantities of a contemplated nucleic acid probe have been operatively affixed.

"Instructions for use" typically include a tangible expression describing the reagent concentration or at least one assay method parameter, such as the relative amounts of reagent and sample to be admixed, maintenance time periods for reagent/sample admixtures, temperature, buffer conditions, and the like.

A diagnostic assay should include a simple method for detecting the amount of a CARD-containing polypeptide or CARD-encoding nucleic acid in a sample that is bound to the reagent. Detection can be performed by labeling the reagent and detecting the presence of the label using well known methods (see, for example, Harlow and Lane, supra, 1988; chap. 9, for labeling an antibody). A reagent can be labeled with various detectable moieties including a radiolabel, an enzyme, biotin or a fluorochrome. Materials for labeling the reagent can be included in the diagnostic kit or can be purchased separately from a commercial source. Following contact of a labeled reagent with a test sample and, if desired, a control sample, specifically bound reagent can be identified by detecting the particular moiety.

A labeled antibody that can specifically bind the reagent also can be used to identify specific binding of an unlabeled reagent. For example, if the

reagent is an anti-CARD antibody, a second antibody can be used to detect specific binding of the anti-CARD antibody. A second antibody generally will be specific for the particular class of the first antibody. For
5 example, if an anti-CARD antibody is of the IgG class, a second antibody will be an anti-IgG antibody. Such second antibodies are readily available from commercial sources. The second antibody can be labeled using a detectable moiety as described above. When a sample is
10 labeled using a second antibody, the sample is first contacted with a first antibody, then the sample is contacted with the labeled second antibody, which specifically binds to the first antibody and results in a labeled sample.

15 In accordance with another embodiment of the invention, there are provided methods for determining a prognosis of disease free or overall survival in a patient suffering from cancer. For example, it is contemplated herein that abnormal levels of CARD-
20 containing polypeptides (either higher or lower) in primary tumor tissue show a high correlation with either increased or decreased tumor recurrence or spread, and therefore indicates the likelihood of disease free or overall survival. Thus, the present
25 invention advantageously provides a significant advancement in cancer management because early identification of patients at risk for tumor recurrence or spread will permit aggressive early treatment with significantly enhanced potential for survival. Also
30 provided are methods for predicting the risk of tumor recurrence or spread in an individual having a cancer tumor; methods for screening a cancer patient to determine the risk of tumor metastasis; and methods for determining the proper course of treatment for a

patient suffering from cancer. These methods are carried out by collecting a sample from a patient and comparing the level of CARD-encoding gene expression in the patient to the level of expression in a control or
5 to a reference level of CARD-encoding gene expression as defined by patient population sampling, tissue culture analysis, or any other method known for determining reference levels for determination of disease prognosis. The level of CARD-encoding gene
10 expression in the patient is then classified as higher than the reference level or lower than the reference level, wherein the prognosis of survival or tumor recurrence is different for patients with higher levels than the prognosis for patients with lower levels.

15 All U.S. patents and all publications mentioned herein are incorporated in their entirety by reference thereto. The invention will now be described in greater detail by reference to the following non-limiting examples.

20 EXAMPLES

1.0 Identification of CARD-containing polypeptides.

The process of gene identification and assembling include the following steps:

A) Identification of new candidate CARD containing
25 polypeptides. A database search was performed using the TBLASTN program with the CARD domain of caspase-1 and caspase-12 as the query in the following NCBI databases: high throughput genome sequence (HTGS), genomic survey sequence (GSS) and expressed sequence
30 tag (EST) databases.

B) Verification that the new candidate CARD containing polypeptide is novel. Using PSI-BLAST, each new candidate CARD gene was queried in the annotated non-redundant (NR) database at NCBI. When the new candidate gene showed significant but not identical homology with other known CARD containing polypeptides during this search, the CARD containing polypeptide candidate was kept for further analysis.

C) 3-D-Model Building of new candidate CARD polypeptide: When the sequence homology was low (<25% identity), three-dimensional criteria was added to characterization of new CARD-containing polypeptides. The candidate CARD fragment was analyzed by a profile-profile sequence comparison method which aligns the candidate CARD domain with a database of sequences of known three-dimensional structure. From this analysis, a sequence alignment was produced and a three-dimensional model was built according to the known structure of CARD domain of IAP-1. In most cases, the best score was produced using CARD domain sequences having known three-dimensional structures. The quality of the three-dimensional model obtained from the alignments confirmed that novel CARD-domain containing polypeptides had been identified.

25

D) Identification of additional domains in the full length protein. Full length protein sequences were obtained using the closest full-length caspase homolog of the new CARD identified in step B as query. TBLASTN searches of the sequences containing the newly identified CARD domains were performed. Longer aligned fragments or multiple aligned fragments in the accession number corresponding to the newly identified

30

CARD containing polypeptides indicated a longer protein.

E) These additional domains were assembled using the following gene building procedure:

5 Genomic DNA fragments were identified by
T-BLAST-N analysis using mouse caspase-12 and human
caspase-1 full length protein as query and scanning
HTGS database from NCBI of incomplete DNA genomics
sequences. New fragments homologous to caspase-12 and
10 caspase-1 were further confirmed by psi-blast analysis
using the TBLASTN genomic DNA homolog fragment as query
and scanning NR database. The boundary of each
fragment was identified according to the following
criteria:

15 Disruption of sequence similarity between the
protein alignment of the target fragment and the query.

Extension of the protein sequence alignment
between query and target using ORF finder.

20 Protein sequence overlap between two
contiguous fragments in sequence relative to the query.

Conservation of exon-intron junction between
DNA sequence of the target and query.

Orientation of the ORF of the different
genomic DNA fragment.

25 Presence of contiguous fragments, based on
sequence alignment with the query, on the same contig.

Finally, the reconstituted sequences were aligned by CLUSTALW with the query and exon-intron junctions further refined by repeating the above process.

- 5 2.0 Identification of CARD2X, CARD3X and CLAN.
Nucleic acids encoding CARD containing proteins CARD2X, CARD3X and CLAN were identified from different CARD queries using tblastn and systematically scanning gss, htgs, and all EST databases at NCBI. Further analysis
10 using translated genomic fragment containing CARD domains larger than the CARD domain itself as query were performed to identify additional domains. Genomic DNA were translated in all reading frames and examined for additional domains using psi-blast and nr database.
- 15 3.0 *Cloning and sequencing of large cDNA.* For cDNA larger than 1500 bp, cloning is accomplished by amplification of multiple fragments of the cDNA. Jurkat total RNA is reverse-transcribed to complementary DNAs using MMLV reverse transcriptase
20 (Stratagene) and random hexanucleotide primers. Overlapping cDNA fragments of a CARD-containing polypeptide are amplified from the Jurkat complementary DNAs with Turbo *Pfu* DNA polymerase (Stratagene) using an oligonucleotide primer set for every 1500 bp of
25 cDNA, where the amplified cDNA fragment contains a unique restriction site near the end that is to be ligated with an adjacent amplified cDNA fragment.

- The resultant cDNA fragments are ligated into mammalian expression vector pcDNA-myc (Invitrogen,
30 modified as described in Roy et al., EMBO J. 16:6914-6925 (1997)) and assembled to full-length cDNA by consecutively ligating adjacent fragments at the unique

endonuclease sites form the full-length cDNA.

Sequencing analysis of the assembled full-length cDNA is carried out, and splice isoforms of CARD-containing polypeptides can be identified.

5 4.0 *Plasmid Constructions.* Complementary DNA encoding a CARD-containing polypeptide, or a functional fragment thereof is amplified from Jurkat cDNAs with Turbo Pfu DNA polymerase (Stratagene) and desired primers, such as those described above. The resultant
10 PCR fragments are digested with restriction enzymes such as *EcoRI* and *Xho I* and ligated into pGEX-4T1 (Pharmacia) and pcDNA-myc vectors.

5.0 *In vitro Protein Binding Assays.* CARD-containing or fragments thereof encoded in pGEX-4T1 are
15 expressed in XL-1 blue *E. coli* cells (Stratagene), and affinity-purified using glutathione (GSH)-sepharose according to known methods, such as those in Current Protocols in Molecular Biology, Ausubel et al. eds., John Wiley and Sons (1999). For GST pull-down assays,
20 purified CARD-GST fusion proteins and GST alone (0.1-0.5 µg immobilized on 10-15 µl GSH-sepharose beads) are incubated with 1 mg/ml of BSA in 100 µl Co-IP buffer (142.4 mM KCl, 5mM MgCl₂, 10 mM HEPES (pH 7.4), 0.5 mM EGTA, 0.2% NP-40, 1 mM DTT, and 1 mM PMSF)
25 for 30 min. at room temperature. The beads are then incubated with 1 µl of rat reticulocyte lysates (TnT-lysate; Promega, Inc.) containing ³⁵S-labeled, *in vitro* translated CARD-containing or control protein Skp-1 in 100 µl Co-IP buffer supplemented with 0.5
30 mg/ml BSA for overnight at 4°C. The beads are washed four times in 500 µl Co-IP buffer, followed by boiling in 20 µl Laemmli-SDS sample buffer. The eluted

proteins are analyzed by SDS-PAGE. The bands of SDS-PAGE gels are detected by fluorography.

The resultant oligomerization pattern will reveal that CARD:CARD and other protein:protein interactions occur with CARD-containing polypeptides or fragments thereof.

In vitro translated candidate CARD-associated polypeptides such as Apaf-1(lacking its WD domain), CED4, and control Skp-1 are subjected to GST pull-down assay using GSH-sepharose beads conjugated with GST and GST-CARD-containing polypeptides as described above. Lanes containing GST-CARD yield significant signals when incubated with a CARD-associated polypeptide whereas, the controls GST alone and Skp-1 yield negligible signals.

6.0 *Protein Interaction Studies in Yeast.* EGY48 yeast cells (*Saccharomyces cerevisiae*: MAT α , trp1, ura3, his, leu2::plexApo6-leu2) are transformed with pGilda-CARD plasmids (his marker) encoding the LexA DNA binding domain fused to: CARD-containing polypeptides, fragments thereof, or CARD-associated polypeptides. EGY48 are also transformed with a LexA-LacZ reporter plasmid pSH1840 (ura3 marker), as previously described (Durfee et al., 1993; Sato et al., 1995). Sources for cells and plasmids are described previously in U.S. Patent 5,632,994, and in Zervous et al., Cell 72:223-232 (1993); Gyuris et al., Cell 75:791-803 (1993); Golemis et al., In Current Protocols in Molecular Biology (ed. Ausubel et al.; Green Publ.; NY 1994), each of which is incorporated herein by reference. Transformants are replica-plated on Burkholder's minimal medium (BMM) plates supplemented with leucine

and 2% glucose as previously described (Sato et al.,
Gene 140:291-292 (1994)). Protein-protein interactions
are scored by growth of transformants on leucine
deficient BMM plates containing 2% galactose and 1%
5 raffinose.

Protein-protein interactions are also
evaluated using β -galactosidase activity assays.
Colonies grown on BMM/Leu/Glucose plates are
filter-lifted onto nitrocellulose membranes, and
10 incubated over-night on BMM/Leu/galactose plates.
Yeast cells are lysed by soaking filters in liquid
nitrogen and thawing at room temperature.
 β -galactosidase activity is measured by incubating the
filter in 3.2 ml Z buffer (60 mM, Na_2HPO_4 , 40 mM
15 Na_2HPO_4 , 10 mM KCl, 1 mM MgSO_4) supplemented with 50 μl
X-gal solution (20 mg/ml). Levels of β -galactosidase
activity are scaled according to the intensity of blue
color generated for each transformant.

The results of this experiment will show
20 colonies on leucine deficient plates for yeast
containing CARD/LexA fusions together with CARD-
associated polypeptide/B42. In addition, the
CARD/LexA:CARD-associated polypeptide/B42 cells will
have significant amounts of LacZ activity.

25 7.0 *Self-Association of NB-ARC domain of CARD-
containing polypeptides.* In vitro translated,
 ^{35}S -labeled rat reticulocyte lysates (1 μl) containing
NB-ARC or Skp-1 (used as a control) are incubated with
GSH-sepharose beads conjugated with purified GST-NB-ARC
30 or GST alone for GST pull-down assay, resolved on
SDS-PAGE and visualized by fluorography as described

above. One tenth of input is loaded for NB-ARC or Skp-1 as controls.

8.0 *Protein-Protein Interactions of CARD-containing polypeptides.* Transient transfection of 293T, a human embryonic kidney fibroblast cell line, are conducted using SuperFect reagents (Qiagen) according to manufacturer's instructions. The cDNA fragments encoding full-length CED4 and the truncated form of Apaf-1 (Apaf-1 Δ WD) comprising amino acids 1-420 of the human Apaf-1 protein are amplified by PCR and subcloned into pcDNA3HA at EcoRI and Xho I sites. Expression plasmids encoding catalytically inactive forms of caspases such as pro-Casp8 (pro-Casp8 (C/A)) are prepared by replacing Cys 377 with an Ala using site-directed mutagenesis and pro-Casp9 (pro-Casp9 (C/A)) has been described previously, Cardone et al., Science 282:1318-1321 (1998)). 293T cells are transiently transfected with an expression plasmid (2 μ g) encoding HA-tagged human Apaf-1 Δ WD, CED4, pro-Casp8 (C/A) or C-Terminal Flag-tagged pro-Casp9 (C/A) in the presence or absence of a plasmid (2 μ g) encoding myc-tagged CARD-containing polypeptide. After 24 hr growth in culture, transfected cells are collected and lysed in Co-IP buffer (142.4 mM KCl, 5 mM MgCl₂, 10 mM HEPES (pH 7.4), 0.5 mM EGTA, 0.1 % NP-40, and 1 mM DTT) supplemented with 12.5 mM β -glycerolphosphate, 2 mM NaF, 1 mM Na₃VO₄, 1 mM PMSF, and 1X protease inhibitor mix (Boehringer Mannheim). Cell lysates are clarified by microcentrifugation and subjected to immunoprecipitation using either a mouse monoclonal antibody to myc (Santa Cruz Biotechnologies, Inc) or a control mouse IgG. Proteins from the immune complexes are resolved by SDS-PAGE, transferred to nitrocellulose membranes, and subjected to immunoblot analysis using

anti-HA antibodies followed by anti-myc antibodies using a standard Western blotting procedure and ECL reagents from Amersham-Pharmacia Biotechnologies, Inc. (Krajewski et al., Proc. Natl. Acad. Sci. USA 96:5752-5 5757 (1999)).

9.0 *Cloning and characterization of CARD2X.* CARD2X-encoding cDNA was obtained by PCR using primers CGGAATTCATGGCTACCGAGAGTACTCC (SEQ ID NO:76) and GTAAAACGACGGCCAGT (SEQ ID NO:77) to amplify a 0.9 kb
10 cDNA molecule from a human skeletal muscle cDNA library (Clontech). The PCR products was then purified by agarose gel electrophoresis and the purified products subcloned into pBluescript II SK vector (Stratagene). Using the forward primers, the PCR fragments were
15 directly sequenced using the ABI PRISM Big Dye Terminal Cycle sequencing kit, according to manufacturer's instructions (Perkin Elmer). Based on the sequence obtained, a third CARD2X-specific primer was generated having the sequence GCAGAAGCCACTGTGGAAGAGGAGGTT (SEQ ID
20 NO:78). In identifying the 3' end of the CARD2X-encoding cDNA, this third CARD2X-specific primer was used in conjunction with a phage-specific primer having the sequence ATACGACTCACTATAGGGCGAATTGGCC (SEQ ID
25 NO:79) to amplify a 0.3 kb cDNA molecule using methods described above. The 0.3 kb cDNA molecule was cloned and sequenced as described above, and the sequences of the 0.3 and 0.9 kb cDNA molecules were merged to produce a 1.0 kb cDNA sequence.

The sequence of CARD2X was confirmed.
30 Additional 5' untranslated sequence was identified (nucleotide sequence of CARD2X including 5' untranslated sequence, SEQ ID NO:84). The CARD domain extends from amino acids 4 to 78 of SEQ ID NO:12.

The association between CARD2X and other CARD-containing proteins was determined. HEK 293T cells in 6-well plates were transfected using SuperFect (Qiagen) with pairwise combinations of Myc-tagged or
5 FLAG-tagged CARD2X, CARDIAK or NOD1 (total DNA 2 μ g). After 24 hours, cells were collected in 400 μ l of lysis buffer (20mM Tris, pH 7.4, 150mM NaCl, 1% NP-40, and 1mM EDTA supplemented with 1x protease inhibitors mix (Roche/Boehringer Mannheim)). Cell lysates were
10 clarified by centrifugation and subjected to immunoprecipitation using Agarose-beads conjugated with anti-FLAG M2 antibody (Sigma). Immune-complexes were washed three times with wash buffer (20mM Tris, pH 7.4, 100mM NaCl, 0.05% NP-40, and 1mM EDTA), and resolved on
15 SDS-PAGE gels. Proteins in the gels were transferred to nitrocellulose membranes, immunoblotted with anti-Myc antibodies, and detected with ECL (Amersham-Pharmacia Biotech). Epitope-specific antibodies for myc, FLAG, or HA tag were obtained from
20 Santa Cruz Biotech, Roche/Boehringer Mannheim, and Sigma. The results of these co-immunoprecipitation assays demonstrated that CARD2X specifically associates with both NOD1 and with CARDIAK.

The effect of CARDIAK on CARD2X
25 phosphorylation was next determined. HEK 293T cells transiently expressing FLAG-CARDIAK were lysed and immunoprecipitated with Agarose-beads conjugated with anti-FLAG M2 antibody. In vitro phosphorylation was performed in the immune complex with or without
30 purified Myc-CARD-2X as a substrate. The kinase reaction was initiated by adding 1 μ M of [γ -³²P]ATP in 10 μ l of kinase buffer (50mM Tris, pH7.4, 100mM NaCl, 6mM MgCl₂, 1mM MnCl, and 1mM EDTA). After 20min at 37°C, the reaction was stopped by adding 10 μ l of 2x SDS

sample buffer, and subjected to SDS-PAGE and autoradiography. The results of these assays indicated that CARD2X is not phosphorylated directly by CARDIAK.

Phosphatase assays were also performed to
5 examine phosphorylation of CARD2X. HEK 293 cells were transfected with plasmids encoding Myc-CARD-2X with or without FLAG-CARDIAK or FLAG-CARDIAK(K47M), which is a kinase deficient mutant of CARDIAK. The cleared
lysates were diluted 1:20 with 20µl of reaction buffer
10 (25mM Tris, pH8.0, 50mM NaCl, 5mM MgCl₂), and optionally treated with 2 units of calf intestine alkaline phosphatase (Gibco BRL) for 30min at 37°C. The reaction was terminated by adding 7µl 4x SDS sample
buffer, and subjected to SDS-PAGE and immunoblot. The
15 phosphorylated form of CARD2X migrates more slowly than CARD2X, and is not observed after phosphatase treatment. The results of these assays indicated that CARD2X is phosphorylated *in vivo* in the presence of either CARDIAK or kinase-deficient CARDIAK, but not in
20 their absence. Taken together with the *in vitro* phosphorylation results above, these results indicate that CARDIAK is indirectly involved in CARD2X phosphorylation.

The 30-35 residues at the carboxy terminus of
25 CARD2X have homology to human Alu family sequences and RhoGAP. Thus, this region can have activity similar to that observed in human Alu family sequences and RhoGAP.

10.0 *Cloning and characterization of CLAN.* CLAN
encoding cDNA was obtained by polymerase chain reaction
30 (PCR) using primers CXF1:TACTTACTTTGTCCCTTCA (SEQ ID NO:74) and CXR2:TATTGTCCCCATCTCGTC (SEQ ID NO:75) to amplify cDNA from a human genomic library. Thirty

cycles of PCR were carried out using Turbo *Pfu* DNA polymerase (Stratagene) at annealing temperature 47°C and extension temperature 72°C. The PCR product was then purified by agarose gel electrophoresis and the
5 purified product subcloned into pGEM-T vector (Promega).

The HTSG database of human genomic DNA sequence data was searched for regions capable of encoding CARDS using the CARD amino-acid sequence of
10 cIAP-1 as a query with the TBLASTn method. This search revealed strong homology with a human genomic clone (Accession number: AQ889169) that mapped to human chromosome 2p21-22. This locus was not recognized in the human genomic database and was not previously
15 annotated. In initial studies, two genes encoding CARD domain containing polypeptides, designated CARD4X and CARD5X, were identified. Upon further characterization, it was determined that CARD4X (also known as NAC-X or NAC-4) and CARD5X were actually
20 encoded by the same gene, which is therefore referenced as CARD4/5X. CARD4/5X was subsequently designated CLAN, which stands for "CARD, LRR and NACHT-containing protein," because at least one of the proteins encoded by it contains CARD, Leucine Rich Repeat (LRR) and
25 NACHT (NB-ARC) domains, as described below.

The CLAN gene locus lies in close proximity to the gene encoding Spastin (on chromosome 2p21-22), a AAA protein which is frequently mutated in autosomal dominant hereditary spastic paraplegia (AD-HSP). The
30 CLAN locus is found on the strand opposite the *SPG4* (*SPAST*) locus but with no overlapping regions. This result suggests that mutations in the CLAN gene

potentially occur in patients with this neurodegenerative disorder.

Using GENESCAN for exon prediction, additional regions potentially encoding a NACHT (NB-ARC) domain and regions corresponding to Leucine-Rich Repeat (LRR) domains were also recognized 3' to the potential CARD-encoding sequences, suggesting the presence of a CED4-like gene.

10.1 Cloning of CLAN cDNAs. CLAN-specific primers corresponding to sequences within the putative CARD and NACHT (NB-ARC) regions (as determined from genomic DNA sequence data) were used in conjunction with 2 universal primers to isolate CLAN cDNAs from first-strand liver and lung cDNA by nested PCR according to the manufacturer's protocol (SMART RACE, Clontech). Primers used for amplification are 5' RACE primers (5'-CATGTGAATGATCCCTCTAGCAG-3' (SEQ ID NO:153); nested 5'-GGGCTCGGCTATCGTGCTCTA-3' (SEQ ID NO:154)) and 3' RACE primers (5'-ACGATAGCCGAGCCCTTATTC-3' (SEQ ID NO:155); nested 5'-GTATGGAATGTTCTGAATCGC-3' (SEQ ID NO:156)). Amplification products were purified from agarose gels, ligated into the TA cloning vector (Promega), and sequenced. Four open reading frames were deduced and multiple clones of each isoform were sequenced to ensure fidelity of PCR products.

The longest transcript, termed CLAN-A, was 3.370 kilobasepairs (kbp) in length (SEQ ID NO:96) with an open reading frame (ORF) coding for a 1024 amino-acid protein (SEQ ID NO:97) containing a CARD, NACHT (NB-ARC), and LRR-domains, as well as a predicted SAM domain. A second transcript, termed CLAN-B, was 1.374 kbp in length (SEQ ID NO:98), with an ORF coding for a

359 amino-acid protein (SEQ ID NO:99) containing an identical CARD directly spliced to the LRRs. CLAN-C, the third transcript isolated, was 0.768 kbp in length (SEQ ID NO:102) and encoded a 156 amino acid protein (SEQ ID NO:103) containing the CARD and an additional region lacking homology to recognizable domains. Finally, the shortest transcript found, CLAN-D, was 0.578 kbp in length (SEQ ID NO:100) and contained an ORF encoding a 92 amino-acid protein (SEQ ID NO:101) encompassing only the CARD followed by 9 amino acids.

Comparisons of these cDNA sequence data with the genomic DNA sequence data found in the HTSG database suggested that the *CLAN* gene consists of 12 exons, spanning 41.3 kbp on chromosome 2p21-22 (Figure 1A). Six differences were found between the sequence of the *CLAN* cDNA and the sequence within the public database. Additionally, nucleotide regions 1-12 and 3372-3396 do not have equivalent fragments in the public database.

Southern blot analysis was also performed. For Southern blot analysis, 10 µg of restriction endonuclease (EcoRI or PstI) digested genomic DNA was loaded per lane and hybridized with the CARD domain of CLAN as a probe. The probe was derived from the CLAN A-isoform (see Figures 1 and 2), nucleotides 276 to 507 plus an additional 20 upstream nucleotides, which are not present in the cDNA but are present in the genomic DNA. CLAN was found to be a single copy gene.

Two different transcriptional start sites are utilized (corresponding to the beginning of either exon 1 or 2); however both are spliced to exon 3 at the beginning of the CARD. Exons 6 and 7 contain additional internal splice donor sites which are

utilized to generate CLAN-G. Figure 1B shows the pattern of mRNA splicing events predicted to give rise to the CLAN-A, CLAN-B, CLAN-C, and CLAN-D transcripts and encoded proteins. All the exon/intron splice
5 junctions follow the conserved GT/AG consensus rule.

As predicted by SMART (EMBL, Heidelberg, Germany), CLAN contains a CARD (amino acids 1-87 of SEQ ID NO:97). A ψ -BLAST search of the non-redundant database using the CLAN CARD as query identified
10 several homologous CARDS including those from cIAP1 and 2 (58%), caspase-1 and ICEBERG (50%), Nod1, Nod2, and Card8 (~38%) and caspase-13, Ced3, caspase-9, Bcl10 (CIPER) and CARKIAK/RIP2 (~30%).

Following the CARD, a domain containing
15 consensus sequences for Walker A and B boxes is present (Walker et al., EMBO J. 8:945-951 (1982)) as well as additional characteristics of the family of NTPases termed the NACHT family (Koonin et al., Trends. Biochem. Sci. 25:2230224 (2000)). By ψ -BLAST search
20 the NACHT domain of CLAN ("NB" in Figure 1, amino acids 161-457 of SEQ ID NO:97) shows highest similarity to the NACHT domain of NAIP (60%), followed by Nod1 (49%) and Nod2 (47%).

Leucine Rich Repeat (LRR) domains are also
25 found near the C-terminus of the A and B isoforms of the protein. The C-terminal end consists of four repeated LRRs, each containing a predicted β sheet and α helical structure, which is in agreement with the prototypical horseshoe-shaped structure of LRRs (Kobe
30 et al., Curr. Opin. Struct. Biol. 5:409-416 (1999)). LRR 1 (amino acids 760-791 of SEQ ID NO:97) represents a non-Kobe and Deisenhofer (non-K/D) LRR, whereas LRRs

2, 3, and 4 (amino acids 817-848; 845-876; and 934-965 of SEQ ID NO:97, respectively) are in accordance with Kobe and Deisenhofer (K/D) LRR. LRR 2 also shares sequence homology to a prototypical Ribonuclease Inhibitor type A (RI type A). By ψ -BLAST searches the LRRs show 49% sequence identity to the placental ribonuclease/angiogenin inhibitor (RAI).

Sequences located between the NACHT (NB-ARC) and LRR domains show some similarity to the sterile alpha motif (SAM) (amino acids 642-696 of SEQ ID NO:97), a domain built of five alpha helices originally found in proteins involved in numerous developmental processes. The SAM domain has been shown to function as a protein-protein interaction domain, with ability to homo- as well as hetero-oligomerize with other SAMs (Stapleton et al., Nat. Struct. Biol. 6:44-49 (1999)).

10.2 *In vivo* expression of CLAN. In order to determine which of the various splice variants of CLAN are expressed in adult human tissues, Northern blot analysis was performed. Hybridization probes corresponding to the common CARD domain of all 4 CLAN isoforms or the NACHT and LRR regions were radiolabeled by random priming with hexanucleotides (Roche) and α - ^{32}P -dCTP, or Digoxigenin-labeled with a commercially available kit (Roche), incubated with blots containing human poly(A)⁺ RNA derived from various human tissues (Origene), washed at high stringency, and exposed to X-ray film. Positive signals were detected by autoradiography or by immunoblotting with HRP-conjugated anti-DIG antibody and an enhanced chemiluminescence method (ECL) (Amersham).

Northern blot analysis with CARD of CLAN revealed expression of an approximately 1.5 kbp transcript corresponding to CLAN-B in nearly all tissues examined, with highest expression in lung and spleen. Northern blot analysis using the NACHT and LRR of CLAN-A as a probe revealed expression of an approximately 3.5 kbp mRNA corresponding to CLAN-A primarily in the lung.

To further explore the tissue-specific patterns of expression of CLAN splicing variants, RT-PCR assays were devised specific for the A, B, C, and D isoforms. A panel of cDNA specimens derived from various human tissues was utilized (Clontech), as well as blood cells, prepared as followed. Peripheral blood leukocytes were obtained from heparinized venous blood by Ficoll-Paque (Amersham) density-gradient centrifugation. Red blood cells were removed from granulocytes by short incubation in hypotonic lysis buffer. Monocytes were separated from lymphocytes by adherence to plastic dishes. Total RNA was isolated from cells using TRIZOL reagent (BRL) and 2 µg was used to generate cDNA in a reverse transcription reaction with Superscript II (BRL).

PCR was carried out on the cDNA samples in an Eppendorf thermal cycler using Taq polymerase (BRL) and the following isoform-specific primer pairs: CLAN-A 5'-GGTGGAGCAGGATGCTGCTAGAGG-3' (SEQ ID NO:159), 5'-CACAGTGGTCCAGGCTCCGAATGAAGTCA-3' (SEQ ID NO:160); CLAN-B 5'-CATCATTTGCTGCGAGAAGGTGGAG-3' (SEQ ID NO:161), 5'-TTAACTTGGATAACACTTGGCTAAG-3' (SEQ ID NO:162); CLAN-C 5'-GTAAACATCATTTGCTGCGAGAA-3' (SEQ ID NO:163), 5'-CCCGGGCAGGTAGAAGATGCTAT-3' (SEQ ID NO:164); CLAN-D

5' AATTTCATAAAGGACAATAGCCGAG-3' (SEQ ID NO:165), 5'-
TGTCTACTGTACTTTCTAAGCTGTT-3' (SEQ ID NO:166).

RT-PCR analysis showed that CLAN-B was
5 present throughout human tissues (brain, heart, kidney,
liver, lung, pancreas, placenta, skeletal muscle,
colon, ovary, leukocytes, prostate, small intestine,
spleen, testis, thymus), consistent with the Northern
blot analysis. In contrast, CLAN-A was restricted to
10 lung, colon, brain, prostate, spleen and leukocytes,
but not other tissues. Further analysis of leukocyte
sub-populations revealed expression of the CLAN-A
isoform predominantly in the monocyte cell fraction,
with lower expression found in granulocytes and no
15 expression in lymphocytes. Expression of CLAN-C was
absent in all normal tissues tested, however,
expression was evident in the cell line HEK293T,
suggesting this transcript can be produced under some
circumstances. CLAN-D transcripts were detected only in
20 brain by RT-PCR.

RT-PCR was also performed on cell lines.
RT-PCR was performed using the same CLAN primers as
used for RT-PCR in normal tissues, as described above.
RT-PCR was performed in various tumor derived cell
25 lines: M2, OVCAR3, HEY, HaCaT, 293T, SKOV-3, Jurkat,
BG-1, 697, HL-60, PC3, DU145, MDA-MB-231, MCF-7, MDA-
MB-4, HS578T, BT-549, and T-47D. Beta-actin primers
were used as a control. In contrast to normal tissue,
the transcript for CLAN was mostly absent in the cell
30 lines tested. Weak expression was found in the cell
lines 697, MDA-MB-231, MCF-7, MDA-MB-4, HS578T, and T-
47D.

10.3 *CLAN* protein interactions. Interactions between the CARD of CLAN and known CARD domains were tested *in vitro* and *in vivo*.

To test CLAN interactions with other molecules, an *in vitro* binding assay was performed. CLAN was *in vitro* translated in the absence of label (i.e., cold). Other cellular proteins were labeled *in vitro* with ³⁵S-Met: CLAN, caspase1, caspase2, caspase8, caspase9, caspase10, Apaf1, Apaf1-CARD, NACa, NAC-CARD, Bcl10, ASC, cIAP1, cIAP2, XIAP, Nod1, Ced4, RAIDD, and CARDIAK. The *in vitro* translated proteins were mixed separately with unlabeled CLAN and co-immunoprecipitated using an antibody against an epitope tag fused to CARD5X, either myc or hemagglutinin (HA). CLAN associated proteins were eluted by boiling in Laemmli denaturing buffer and separated by 12% SDS-PAGE. The radioactive bands were visualized by fluorography.

Weak binding to CLAN was observed with caspase2 and cIAP1, with stronger binding to Nod1 and Cardiak. The strongest binding was observed with Ced4. Caspase8 binding is possibly due to its stickiness. There was no association detected between CLAN and itself.

To prepare appropriate expression vectors for *in vivo* interaction studies, a cDNA encoding the CLAN CARD domain was amplified using PFU polymerase and specific primers (5'-CCCGGATCCATGAATTTTCATAAAGGACAATAGC-3' (SEQ ID NO:153); 5'-CCCTTCGAACAAGTCCTGAAATAGAGGATA-3' (SEQ ID NO:154)) containing BamHI and HindIII sites. The resulting PCR product was ligated into pCDNA3.1

(-)/Myc-His₆ A (Invitrogen) which places the myc-His₆ tag at the C-terminus of expressed proteins. pcDNA3/HA-CLAN (CARD) was created using a similar strategy. Authenticity of all vectors was confirmed by
5 DNA sequencing.

The CARD of CLAN was expressed as an epitope-tagged protein in HEK293T cells in co-transfections with a variety of other epitope-tagged CARD-containing proteins, and lysates derived from these cells were
10 used for co-immunoprecipitation assays. Briefly, HEK293T cells were seeded onto six-well plates (35mm wells) and transfected with 0.2-2 mg plasmid DNA using Superfect (Qiagen) 24 hr later. After culturing for a day, cells were collected and lysed in isotonic lysis
15 buffer (142.4 mM KCl, 5 mM MgCl₂, 10 mM HEPES (pH 7.4), 0.5 mM EGTA, 0.2% NP-40, 12.5 mM b-glycerophosphate, 2 mM NaF, 1 mM Na₃VO₄, 1 mM PMSF, and 1X protease inhibitor mix (Roche)). Lysates were clarified by centrifugation and subjected to immunoprecipitation
20 using agarose-conjugated anti-c-myc antibodies (Santa Cruz), or non-specific control antibodies and Protein G-agarose for 2-24hr at 4°C. Immune-complexes were washed four times with lysis buffer, boiled in Laemmli buffer, and separated by 12-15% PAGE. Immune-complexes
25 were then transferred to PVDF membranes and immunoblotted with anti-c-myc (Santa Cruz), anti-HA (Roche), or anti-flag (Sigma) antibodies. Membranes were washed, incubated with HRP-conjugated secondary antibodies, and reactive proteins were detected using
30 ECL.

Co-immunoprecipitation analysis indicated that the CARD of CLAN bound readily to full-length pro-caspase-1 but did not significantly bind another CARD-

containing caspase, caspase-9. Among the other CED-4 family members which contain a CARD in conjunction with a nucleotide-binding domain, CLAN interacted with the CARDS of Nod2 and NAC, but not with Apaf-1 or Nod-1.

5 Finally, the CLAN CARD was found to associate with Bcl-10, but not with another adapter protein, RAIDD.

11.0 *Cloning and characterization of CARD3X* Based on an analysis of the overlapping genomic contigs GI 8575872 and GI 5001450, a cDNA sequence for CARD3X was

10 predicted (SEQ ID NO:82), that encoded amino acid sequences designated SEQ ID NOS:83 and 107.

For identification of novel domains in CARD3X, the sequence of the CARD domain of polypeptide CARD3X was used as a query for a tblastn search in the

15 HTGS database, and two overlapping genomic contigs were found (GI numbers 5001450 and 8575872). This contig was analyzed using the GenScan server (<http://ccr-081.mit.edu/GENSCAN.html>) for the presence of exons. (Burge and Karlin, J. Mol. Biol. 268:78-94

20 (1997)). The predicted protein sequences coded by the exons were analyzed by comparison with the NCBI nr protein sequence database using PSI-BLAST. The predicted protein sequences coded by the exons were analyzed also by comparison with a database of proteins

25 with known three-dimensional structures and apoptosis related domains using the profile-profile comparison server at http://bioinformatics.burnham-inst.org/FFAS_apoptosis (Rychlewski, et al., Protein Science 9:232-241 (2000)).

30 CARD3X contains two CARD domains, a CARD-A and CARD-B domain (see Figure 3). An NB-ARC domain was also observed (see Figure 3). The NB-ARC is similar to

both the CLAN and APAF-1 NB-ARC domains and to NB-ARC domains from several plant disease resistance proteins (Aravind et al., Trends Biochem. Sci. 24:47-53 (1999); Young, Curr. Opin. Plant Biol. 4:285-289 (2000)).

5 An angio-R domain was also identified at amino acids 457-839 of SEQ ID NO:107. An "angio-R" is a new domain that can be defined as a region of a polypeptide chain that bears substantial similarity (e.g. 25, 30, 40% sequence identity) to the 514-reside
10 long protein "angiotensin II/vasopressin receptor" (described in Ruiz-Opazo et al., Nature Med. 1:1074-1081 (1995)). The "angio-R" domain has not been previously described in any protein.

To confirm the predicted sequences, cDNAs
15 were cloned and sequenced. The CARD3X cDNA was cloned using a Rapid-Screen™ Arrayed Placenta cDNA Library Panel from Origene Technologies, Inc. The library cDNAs had been pre-selected for long clones, unidirectionally cloned into the vector pCMV6-XL4, and
20 arrayed in a 96-well format. An initial Master Plate containing 500,000 cDNA clones was screened by PCR, using the forward primer 5'-GAAATGTGCTCGCAGGAGG- 3' (SEQ ID NO:185) and the reverse primer 5'-GATGAGCTTCTGACAGGCCC- 3' (SEQ ID NO:186). A set of
25 5000 clones that were initially positive by PCR were screened again with the same set of primers. Positive clones were plated on LB/Amp plates, and a further round of single colony PCRs was performed in order to obtain the desired clone.

30 Three independent clones were sequenced, each of which corresponded to the nucleotide sequence SEQ ID NO:187. The cDNA sequence differed at both the N- and

C-terminal ends from the CARD3X sequence predicted from analysis of genomic exons. SEQ ID NO:187 encodes a polypeptide of 795 amino acids (SEQ ID NO:188), followed by a stop codon. A second open reading frame
5 begins after the stop codon, and in the same reading frame, and encodes a polypeptide of 180 amino acids (SEQ ID NO:189). SEQ ID NO:189 contains several leucine rich repeats.

Subsequent to the identification of the two
10 polypeptides encoded by SEQ ID NO:187, a publication reported the cloning of a gene designated Nod2 cloned (Ogura et al., J. Biol. Chem. 276:4812-4818 (2001)). The published Nod2 sequence has additional N-terminal amino acids relative to SEQ ID NO:188 and, instead of
15 the stop codon between the residues that encode SEQ ID NO:188 and SEQ ID NO:189, additional coding sequence is present, which encodes several additional leucine rich repeats. The published Nod2 sequence is 1040 amino acids.

20 It is proposed that SEQ ID NO:188 is a splice variant form of CARD3X/Nod2 that does not contain an LRR domain. The LRR of Nod2 has been shown to interfere with the ability of the protein to activate NFkB (Ogura et al., supra (2001)). Therefore, SEQ ID
25 NO:188 is likely expressed under physiological conditions in which activation of NFkB is required.

Human CARD3X cDNA sequences were used as a query for BLAST searches of several mouse databases. A
30 genomic sequence, SEQ ID NO:190, was identified. Nucleotides 191-614 of SEQ ID NO:190 are homologous to the ANGIO-R coding region of human CARD3X. Nucleotides 193-612 of SEQ ID NO:191 were predicted to encode SEQ

ID NO:191, which is highly homologous to amino acids 214-341 of the ANGIO-R domain of human CARD3X (SEQ ID NO:176).

PCR was then performed on mouse genomic DNA obtained from C57B6 and NIH3T3 cell lines, using the following primers: Forward primer: 5'-CTGCAGAAGGCTGAGCCACACAACCT-3' (SEQ ID NO:194), Reverse primer: 5'-ACAGAGTTGTAATCCAGCTGTAGGGCCACA-3' (SEQ ID NO:195). The PCR product so obtained was sequenced (SEQ ID NO:192), and shown to have several nucleotide differences as compared to the corresponding region of SEQ ID NO:190. The predicted amino acid sequence encoded by SEQ ID NO:192 (designated SEQ ID NO:193) had a single amino acid difference in comparison with SEQ ID NO:191.

Both the CARD-A and CARD-B domains are independently cloned into pCDNA3 with epitope tags such as myc or HA, as described above, and binding of the CARD domains is tested with co-immunoprecipitation to test binding of CARD3X CARD domains with other known CARD domains, as described above.

The NB-ARC domain is cloned into a yeast two-hybrid vector and into pCDNA3 with two alternative epitope tags (e.g., myc and Flag) to determine whether the NB-ARC domain self-associates in an ATP-dependent manner/P-loop mutation. The P-loop, which binds the gamma phosphate of ATP in the NB-ARC domain, is mutated to remove a conserved Lys in the consensus P-loop sequence G-S/T-K, where Lys is generally mutated to Met. The NB-ARC domain is also tested for binding to the NB-domains of other CED-4 like proteins (e.g., apaf1, nod1, nac).

12.0 *Characterization of COP-1.* Using the amino-acid sequence of the caspase-1 prodomain as a query for BLASTn searches of the public databases, a
5 human EST clone (GenBank accession number AA070591) was identified containing an ORF encoding a 97 amino-acid protein (SEQ ID NO:86) predicted to share 92% sequence identity with the CARD of pro-caspase-1 (SEQ ID NO:87). The predicted protein contains a CARD
10 (residues 1-91), which is followed by 6 amino-acids and then a stop-codon. The CARD region of COP-1 showed 97% identity to the CARD of pro-caspase-1.

To confirm the predicted sequences, cDNAs were amplified from various adult human tissues and
15 sequenced. The sequenced COP-1 cDNA (SEQ ID NO:85) had the same nucleotide sequence as the original EST.

The start codon initiating the ORF in the COP-1 cDNA clones resides in a favorable context for translation, and is preceded by an in-frame stop codon.
20 The 3'- untranslated region contains TAAA and TATA motifs, typical of short-lived mRNAs which are subject to post-transcriptional regulation, and a candidate polyadenylation signal sequence (AATAAA). Thus, this protein contains essentially only a CARD, prompting the
25 moniker CARD Only Protein (COP-1).

To determine the genomic organization of the COP-1 gene, the COP-1 cDNA nucleotide sequence was employed for searches of the High Throughput Genomic Sequence (HTGS) database, resulting in identification
30 of three genomic clones containing the COP-1 gene (GenBank accessions numbers AC027011, AP001153 and AP002787). Comparison of the COP-1 cDNA and genomic

DNA sequences suggests a three exon structure, in which only the first two amino-acids are encoded in exon 1 and only the last 5 residues are encoded in exon 3, such that most of the coding regions (including the entire CARD) are derived from exon 2. The introns separating exons 1, 2, and 3 are 631 and 844 bp in length, respectively, containing consensus dinucleotide splice donor (GT) and splice acceptor (AG) motifs.

The COP-1 genomic clones identified in the HTSG database have been mapped to human chromosome 11q22, which is the same chromosomal region where the pro-caspase-1 gene resides, as well as pro-caspase-4, pro-caspase-5, and ICEBERG. To address the genomic localization of COP, pro-caspase-4, pro-caspase-5, and ICEBERG genes in chromosome 11, the public database of Human Genome Project Working Draft (www.genome.cse.ucsc.edu) was searched, and the order of these genes from centromere to telomere was determined to be pro-caspase-4, pro-caspase-5, pro-caspase-1, COP, and ICEBERG. This result suggests that COP-1 is a separate gene, presumably arising from duplication of other homologous genes in this locus.

14.1 COP-1 expression. To study the expression of COP-1, Northern blot analysis was performed using RNA derived from several adult human tissues and a ³²P-labeled COP-1 cDNA probe. Blots containing polyA-selected mRNA from various adult tissues (Clontech, Palo Alto, CA) were hybridized using a ³²P-labeled COP-1 cDNA probe. The probe represented a 570 bp length cDNA containing portions of the 5'-untranslated region, the complete ORF, and portions of the 3'-untranslated region of COP. The COP-1 probe (from the EST clone corresponding to AA070591 obtained

from the I.M.A.G.E. Consortium (Washington University School of Medicine, St. Louis, MO)) was excised from the plasmid by restriction digestion with EcoRI and XhoI, gel-purified, and radiolabeled by the random priming method using [α - ^{32} P] dCTP and a kit from Ambion (Austin, TX). After hybridization, heat-denatured probe was annealed for 1 hr at 68°C with QuickHyb Hybridization Solution (Stratagene, La Jolla, CA) and then blots were washed with solutions containing 2x SSC, 0.1% (w/v) SDS (twice each for 15 min at 25°C) followed by 0.1x SSC, 0.1% (w/v) SDS (twice for 10 min at 40°C). Bands were visualized by autoradiography.

Hybridizing bands of approximately 0.6 kbp, 1.5 kbp and 2.6 kbp were identified, with the 0.6 kbp band representing the most abundant of these transcripts and presumably corresponding to the fully-spliced COP-1 mRNA. The less abundant larger 1.5 kbp and 2.6 kbp transcripts could represent unspliced precursors. Alternatively, the 2.6 kbp mRNA could represent pro-caspase-1 mRNA, resulting from probe cross-hybridization. The 0.6 kbp COP-1 mRNA was most abundant in spleen, followed by liver, placenta, and peripheral blood leukocytes (PBL). However, most tissues (including heart, muscle, colon, kidney, intestine and lung) were shown to contain at least some detectable 0.6 kbp COP-1 mRNA.

To corroborate the Northern blot analysis, COP-1 mRNA expression in adult human tissues was also examined using RT-PCR and COP-specific primers. cDNA samples derived from multiple human adult tissues (Clontech, Palo Alto, CA) were amplified using a set of COP-specific primers (a forward primer 5'-GAAGACAGTTACCTGGCAGA-3' (SEQ ID NO:147) and a

reverse primer 5'-TTGTATTCTGAACATGGCACC-3' (SEQ ID NO:148)). The resulting PCR products were size-fractionated by electrophoresis in 1.5% agarose gels, then stained with ethidium bromide for UV-
5 photography. In some cases, bands were excised from gels, purified, and sequenced, thus verifying amplification of the correct product by the RT-PCR assay.

RT-PCR analysis showed that COP-1 mRNA was
10 expressed in all tissues analyzed (brain, heart, muscle, colon, spleen, kidney, liver, intestine, placenta, lung and PBL), except thymus. Parallel RT-PCR analysis of β -actin mRNA served as a control. In general, the relative levels of COP-1 mRNA detected
15 by RT-PCR were in agreement with the Northern blot data.

14.2 *COP-1 interactions.* The prodomain of pro-caspase-1 is required for dimerization and activation of this zymogen. Since the prodomain of
20 COP-1 shares a high-degree of amino-acid sequence identity with the prodomain of caspase-1, the possibility that COP-1 interacts with pro-caspase-1 in co-immunoprecipitation assays was tested. Interactions with several other CARD-containing proteins were also
25 tested, including COP-1 itself, RIP2, Bcl-10, cIAP1, cIAP2 and pro-caspase-9.

For these experiments, the entire open reading frame (ORF) of COP-1 was amplified by PCR using the primers (5'-CCAGAATTTCATGGCCGACAAGGTCCTGAAG-3' (SEQ
30 ID NO:145) (forward) and 5'-CCACTCGAGCTAATTTCCAGGTATCGGACC-3' (SEQ ID NO:146) (reverse). The COP-1 PCR product was digested with

EcoRI/XhoI and ligated into mammalian expression vectors pcDNA3-Myc, pcDNA3-HA and pcDNA3-Flag at the EcoRI/XhoI cloning sites. Plasmids encoding wild-type pro-caspase-1, RIP2, and pro-IL-1 β were as described in
5 Thome et al., Curr. Biol. 8:885-888 (1998); Nett-Fiordalisi et al., J. Leukoc. Biol. 58:717-724 (1995); and Wang et al., J. Biol. Chem. 271:20580-20587 (1996).

A pro-caspase-1 Cys 285 Ala mutant was made
10 from wild-type caspase-1 plasmid by site-directed mutagenesis, using a commercially available kit (Stratagene, La Jolla, CA) and the primers 5'-GATCATCATCCAGGCCGCCGTGGTGACAGCCCTGG-3' (SEQ ID NO:149) and 5'-CCAGGGCTGTCACCACGGGCGGCCTGGATGATGATC-3' (SEQ ID NO:150).
15 A truncation mutant of pro-caspase-1 in which a stop codon was introduced downstream of the CARD was created by PCR using primers 5'-CGGAATTCATGGCCGACAAGGTCCTG-3' (SEQ ID NO:151) and CGCTCGAGTTAGTCTTGCATATTAAGGTAATTTCCAGA-3' (SEQ ID
20 NO:152).

Human embryonic kidney 293T cells were cultured at 37°C in 5% CO₂ in Dulbecco's Modified Eagle's Medium (DMEM) with 10% heat-inactivated fetal bovine serum (FBS). Cells in log phase were
25 transfected in 60 mm diameter dishes with expression plasmids (5 μ g total DNA) using Superfect Transfection Reagent (Qiagen, Valencia, CA) according to the manufacturer's recommendations. Cells were harvested 2 days later and lysed in ice-cold NP-40 lysis buffer
30 (10 mM HEPES [pH 7.4], 142.5 mM KCl, 0.2% NP-40, 5 mM EGTA), supplemented with 1 mM DTT, 12.5 mM β -glycerophosphate, 1 μ M Na₃VO₄, 1mM PMSF, and 1X protease inhibitor mix (Roche, Indianapolis, IN). Cell

lysates (0.5 ml) were clarified by centrifugation at 16,000xg for 5 minutes, and subjected to immunoprecipitation using specific antibodies, including anti-Myc antibodies (Santa Cruz Biotechnology, Santa Cruz, CA), and anti-Flag antibodies (Sigma, St. Louis, MO), in combination with 15 µl Protein A- or G-Sepharose (Zymed, South San Francisco, CA).

Immune-complexes were fractionated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and transferred to nitrocellulose membranes. The resulting blots were incubated with various antibodies, including anti-HA antibodies (1:1000 v/v; Roche, Indianapolis, IN), anti-Myc antibodies (1:100 v/v; Santa Cruz Biotechnology, Santa Cruz, CA) and anti-Flag antibodies (1: 1000 v/v; Sigma, St. Louis, MO), followed by horseradish peroxidase-conjugated secondary antibodies, and detection by an enhanced chemiluminescence (ECL) method (Amersham-Pharmacia, Piscataway, NJ). Alternatively, lysates were analyzed directly by immunoblotting after normalization for total protein content.

The co-immunoprecipitation results showed that HA-COP-1 co-immunoprecipitated with Myc-COP, indicating that this protein can self-associate. In addition, HA-COP-1 co-immunoprecipitated with Myc-tagged pro-caspase-1 (C285A mutant) as well as with a fragment of pro-caspase-1 containing only its CARD-carrying prodomain. Thus, COP-1 binds pro-caspase-1 through its CARD domain. For these co-immunoprecipitation experiments, the active site cysteine of pro-caspase-1 was mutated to avoid induction of apoptosis, which can occur when

over-expressing this protease. Additionally, Myc-COP-1 co-immunoprecipitated with Flag-RIP2. In contrast, COP-1 did not co-immunoprecipitate with the CARD-containing proteins Bcl-10, cIAP1, cIAP2, or pro-caspase-9, thus demonstrating the specificity of these results.

RIP2 has been shown to bind and activate caspase-1 through the interaction of their CARDS, resulting in oligomerization of pro-caspase-1 and its activation via the "induced proximity" mechanism. The data demonstrating that COP-1 binds to both pro-caspase-1 and RIP2 therefore suggested that COP-1 might function as a modulator of RIP2-induced pro-caspase-1 oligomerization.

To test this hypothesis, experiments were performed in which 293T cells were transiently transfected with expression plasmids encoding Myc-tagged pro-caspase-1 (C285A mutant) and HA-tagged pro-caspase-1 (C285A mutant), with or without Flag-tagged RIP2 and COP, after which Myc-pro-caspase-1 and HA-pro-caspase-1 association was monitored by co-immunoprecipitation assays.

As determined by this co-immunoprecipitation assay, pro-caspase-1 self-associated and this was enhanced by co-expression of RIP2. However, when COP-1 was also co-expressed, this RIP2-mediated effect on pro-caspase-1 self-association was negated. These findings suggested the possibility of a competitive mechanism, in which COP-1 competes with RIP2 for binding to pro-caspase-1. To test this hypothesis, therefore, transfection experiments were performed in which Flag-RIP2 and Myc-tagged pro-caspase-1 (C285A

mutant) were expressed in 293T cells in the presence of increasing amounts of HA-tagged COP-1. The effects of COP-1 on association of RIP2 with pro-caspase-1 were then evaluated by co-immunoprecipitation assays in which immunoprecipitations were performed using anti-Flag antibody to recover Flag-RIP2 protein and the resulting immune-complexes were analyzed by SDS-PAGE/immunoblotting using anti-Myc antibody to detect associated Myc-pro-caspase- 1.

10 The results from these experiments indicated that COP-1 inhibited association of pro-caspase-1 with RIP2 in a dose-dependent manner. Immunoblot analysis of lysates from these same cells demonstrated that COP-1 did not affect the total levels of pro-caspase-1 or
15 RIP2, but rather just their association. These results therefore confirm that COP-1 can interfere with binding of pro-caspase-1 to RIP2.

14.3 *COP-1 inhibition of caspase-1-mediated activation of pro-IL-1 β .* Active caspase-1 cleaves
20 pro-IL-1 β , resulting in the generation of bioactive IL-1 β which is secreted from cells. It was hypothesized that COP-1 could suppress caspase-1-induced pro-IL-1 β processing and thus reduce secretion of IL-1 β .

25 To test this hypothesis, COS-7, 293T, or 293HEK cells were co-transfected in 12 well (22 mm in diameter) plates using Lipofectamine Plus Reagent (GIBCO BRL, Grand Island, NY) with plasmids encoding mouse pro-IL-1 β , human caspase-1, RIP2, or COP-1, in
30 various amounts (total DNA = 2.0 μ g). At 1 day after transfection, supernatants were collected and stored at -80°C or used immediately to quantify secretion of

mature murine IL-1 β into the culture medium by an ELISA assay, according to the manufacturer's protocol (R&D systems, Minneapolis, MN).

Co-expression of pro-caspase-1 and pro-IL-1 β in COS-7 cells resulted in secretion of mature IL-1 β ranging from 80 pg/ml to 250 pg/ml, which was proportional to the amount of pro-caspase-1 plasmid used (Figure 17). This IL-1 β secretion was enhanced by co-expression of RIP2 plasmid. In contrast, expression of COP-1 together with pro-caspase-1, pro-IL-1 β , and RIP2 resulted in a dose-dependent decrease in the amount of mature IL-1 β secretion, proportional to the amount of COP-1-encoding plasmid used (Figure 6). Similar results were obtained using 293T or 293HEK cells. These results indicate that COP-1 is capable of suppressing the caspase-1-mediated secretion of IL-1 β .

15.0 *Identification of COP-2.* A human CARD-containing proteins, designated COP-2, for CARD-only protein 2, was identified and the gene and cDNA cloned. The predicted protein of COP-2 has high sequence similarity to the CARD-domain of human caspase-1. For COP-2, two primers based on the caspase-15 genomic sequence were designed, one in the middle of the CARD domain (5'-aagaagagacggctgcttatcaat-3'; SEQ ID NO:104) and the other in the catalytic domain (5'-ccacagcaggcctcgaagatgatc-3'; SEQ ID NO:105). RT-RTR was performed, and a single band was observed, although the band size was smaller than expected for caspase-15. The PCR product was sequenced, and it was found that two exons were deleted and the catalytic domain was directly connected to the CARD domain. However, due to a frameshift, a stop codon occurs just after the CARD domain, resulting in truncated protein and no translation of the catalytic domain.

To clone the N-terminal region, a primer (5'-atgattcctcctgaagaagag-3'; SEQ ID NO:106) was designed with the genomic sequence in the most N-terminal portion of the CARD domain including ATG. RT-PCR was performed, and the PCR product was sequenced and found to be the same as in the genomic DNA. A merged construct containing both the N-terminal fragment and the CARD domain sequence was made by PCR.

The COP-2 cDNA sequence identified contained 321 nucleotides (SEQ ID NO:89), and the deduced amino acid sequence (SEQ ID NO:90) had a high level of identity with caspase-1. An alignment of COP-2 (SEQ ID NO:90) and caspase-1 (SEQ ID NO:87) is shown in Figure 5, with the consensus sequence (SEQ ID NO:91) shown above the aligned sequences. The amino acids shaded in black are identical. The stippled shading represents a match within 3 distance units. COP-2 is encoded by the caspase-15 gene (Figure 3), but COP-2 is a CARD only protein that lacks the caspase catalytic domain.

COP-2 cDNA encodes a polypeptide with downstream termination codons, which result in shorter proteins containing a CARD domain without associated catalytic protease domains. COP-2 is therefore expected to function as trans-dominant inhibitor that likely prevents caspase activation by binding to the CARD-domains (pro-domains) in pro-enzymes such as pro-caspase-1.

COP-2 polypeptide is expected to function as A regulator of caspase-1 activation by enhancing or suppressing the activation of caspase-1. COP-2 binding activity is tested, for example, by making epitope tagged fusions with COP-2 and caspase-1 and

co-immunoprecipitating to determine binding interactions with caspase-1. Antibodies specific for COP-2 are also made.

The effect of COP-2 on caspase-1 proteolytic activity is also tested. Methods for measuring caspase activity are well known (see, for example, Thornberry, Nature 356:768-774 (1992); Thornberry and Molineaux, Protein Science 4:3-12 (1995); Rano et al., Chem. Biol. 4:149-155 (1997); Fletcher et al., J. Interferon Cytokine Res. 15:243-248 (1995)), and are also described above.

All journal article, reference and patent citations provided above, in parentheses or otherwise, whether previously stated or not, are incorporated herein by reference in their entirety.

Although the invention has been described with reference to the examples provided above, it should be understood that various modifications can be made without departing from the spirit of the invention.

SEQUENCE LISTING

<110> The Burnham Institute

Reed, John C.

Pio, Frederick F.

Godzik, Adam

Stehlik, Christian

Damiano, Jason S.

Lee, Sug-Hyung

Oliveira, Vasco A.

Hayashi, Hideki

Pawlowski, Krzysztof

<120> Novel Card Domain Containing

Polypeptides, Encoding Nucleic Acids, and Methods of Use

<130> FP-LJ 4665

<150> US 09/579,240

<151> 2000-05-24

<150> US 09/686,347

<151> 2000-10-10

<150> US 60/275,980

<151> 2001-03-14

<160> 195

<170> FastSEQ for Windows Version 4.0

<210> 1

<400> 1

000

<210> 2

<400> 2

000

<210> 3

<400> 3

000

<210> 4

<400> 4

000

<210> 5

WO 01/90156

PCT/US01/17158

<400> 5
000

<210> 6

<400> 6
000

<210> 7

<400> 7
000

<210> 8

<400> 8
000

<210> 9

<400> 9
000

<210> 10

<400> 10
000

<210> 11
<211> 1038
<212> DNA
<213> Homo sapien

<220>
<221> CDS
<222> (1)...(930)

<400> 11
atg gct acc gag agt act ccc tca gag atc ata gaa aga gaa aga aaa 48
Met Ala Thr Glu Ser Thr Pro Ser Glu Ile Ile Glu Arg Glu Arg Lys
1 5 10 15

aag ttg ctt gaa atc ctt caa cat gat cct gat tct atc tta gac acg 96
Lys Leu Leu Glu Ile Leu Gln His Asp Pro Asp Ser Ile Leu Asp Thr
20 25 30

tta act tct cgg agg ctg att tct gag gaa gag tat gag act ctg gag 144
Leu Thr Ser Arg Arg Leu Ile Ser Glu Glu Glu Tyr Glu Thr Leu Glu
35 40 45

aat gtt aca gat ctc ctg aag aaa agt cgg aag ctg tta att ttg gta 192
Asn Val Thr Asp Leu Leu Lys Lys Ser Arg Lys Leu Leu Ile Leu Val
50 55 60

cag aaa aag gga gag gcg acc tgt cag cat ttt ctc aag tgt tta ttt 240

Gln	Lys	Lys	Gly	Glu	Ala	Thr	Cys	Gln	His	Phe	Leu	Lys	Cys	Leu	Phe	
65					70					75					80	
agt	act	ttt	cca	cag	tca	gct	gcc	att	tgc	ggc	tta	agg	cat	gaa	gtt	288
Ser	Thr	Phe	Pro	Gln	Ser	Ala	Ala	Ile	Cys	Gly	Leu	Arg	His	Glu	Val	
				85				90						95		
tta	aaa	cat	gag	aat	aca	gta	cct	cct	caa	tct	atg	ggg	gca	agc	agt	336
Leu	Lys	His	Glu	Asn	Thr	Val	Pro	Pro	Gln	Ser	Met	Gly	Ala	Ser	Ser	
			100				105						110			
aat	tca	gaa	gat	gct	ttt	tct	cct	gga	ata	aaa	cag	cct	gaa	gcc	cct	384
Asn	Ser	Glu	Asp	Ala	Phe	Ser	Pro	Gly	Ile	Lys	Gln	Pro	Glu	Ala	Pro	
		115					120					125				
gag	atc	aca	gtg	ttc	ttc	agt	gag	aag	gaa	cac	ttg	gat	ttg	gaa	acc	432
Glu	Ile	Thr	Val	Phe	Phe	Ser	Glu	Lys	Glu	His	Leu	Asp	Leu	Glu	Thr	
	130					135					140					
tct	gag	ttt	ttc	agg	gac	aag	aaa	act	agt	tat	agg	gaa	aca	gct	ttg	480
Ser	Glu	Phe	Phe	Arg	Asp	Lys	Lys	Thr	Ser	Tyr	Arg	Glu	Thr	Ala	Leu	
145					150					155					160	
tct	gcc	agg	aag	aat	gag	aag	gaa	tat	gac	aca	cca	gaa	gtc	aca	tta	528
Ser	Ala	Arg	Lys	Asn	Glu	Lys	Glu	Tyr	Asp	Thr	Pro	Glu	Val	Thr	Leu	
				165					170					175		
tca	tat	tca	gtt	gag	aaa	gtt	gga	tgt	gaa	gtt	cca	gca	act	att	aca	576
Ser	Tyr	Ser	Val	Glu	Lys	Val	Gly	Cys	Glu	Val	Pro	Ala	Thr	Ile	Thr	
			180				185						190			
tat	ata	aaa	gat	gga	cag	aga	tat	gag	gag	cta	gat	gat	tct	tta	tac	624
Tyr	Ile	Lys	Asp	Gly	Gln	Arg	Tyr	Glu	Glu	Leu	Asp	Asp	Ser	Leu	Tyr	
		195					200					205				
tta	gga	aaa	gag	gaa	tat	cta	gga	tct	gtt	gac	acc	cct	gaa	gat	gca	672
Leu	Gly	Lys	Glu	Glu	Tyr	Leu	Gly	Ser	Val	Asp	Thr	Pro	Glu	Asp	Ala	
	210					215					220					
gaa	gcc	act	gtg	gaa	gag	gag	gtt	tat	gat	gac	cca	gag	cac	gtt	gga	720
Glu	Ala	Thr	Val	Glu	Glu	Glu	Val	Tyr	Asp	Asp	Pro	Glu	His	Val	Gly	
225					230					235					240	
tat	gat	ggt	gaa	gag	gac	ttc	gag	aat	tca	gaa	acc	aca	gag	ttc	tct	768
Tyr	Asp	Gly	Glu	Glu	Asp	Phe	Glu	Asn	Ser	Glu	Thr	Thr	Glu	Phe	Ser	
				245				250						255		
ggt	gaa	gaa	cca	agt	tat	gag	gga	tca	gaa	acc	agc	ctt	tca	ttg	gag	816
Gly	Glu	Glu	Pro	Ser	Tyr	Glu	Gly	Ser	Glu	Thr	Ser	Leu	Ser	Leu	Glu	
			260				265						270			
gag	gaa	cag	gag	aaa	agt	ata	gaa	ggc	tgg	tct	cga	act	cat	ggg	ctt	864
Glu	Glu	Gln	Glu	Lys	Ser	Ile	Glu	Gly	Trp	Ser	Arg	Thr	His	Gly	Leu	
		275					280					285				

WO 01/90156

PCT/US01/17158

aag cga tcc tcc cac gtt ggc ctc cca aag tgc tgg gat tac agg cgt 912
 Lys Arg Ser Ser His Val Gly Leu Pro Lys Cys Trp Asp Tyr Arg Arg
 290 295 300

gag cca ccc tgc ctg gcc tgaaaattct gcctcaaaca tctcaaacat 960
 Glu Pro Pro Cys Leu Ala
 305 310

ccattttatat tttgtacaag aaagtaaata aaatTTTTTct ttttaacatt aaaaaaaaaa 1020
 aaaaaaaaaa aatctaga 1038

<210> 12

<211> 310

<212> PRT

<213> Homo sapien

<400> 12

Met	Ala	Thr	Glu	Ser	Thr	Pro	Ser	Glu	Ile	Ile	Glu	Arg	Glu	Arg	Lys
1				5					10					15	
Lys	Leu	Leu	Glu	Ile	Leu	Gln	His	Asp	Pro	Asp	Ser	Ile	Leu	Asp	Thr
			20					25					30		
Leu	Thr	Ser	Arg	Arg	Leu	Ile	Ser	Glu	Glu	Glu	Tyr	Glu	Thr	Leu	Glu
			35					40				45			
Asn	Val	Thr	Asp	Leu	Leu	Lys	Lys	Ser	Arg	Lys	Leu	Leu	Ile	Leu	Val
	50					55					60				
Gln	Lys	Lys	Gly	Glu	Ala	Thr	Cys	Gln	His	Phe	Leu	Lys	Cys	Leu	Phe
65					70					75					80
Ser	Thr	Phe	Pro	Gln	Ser	Ala	Ala	Ile	Cys	Gly	Leu	Arg	His	Glu	Val
				85					90					95	
Leu	Lys	His	Glu	Asn	Thr	Val	Pro	Pro	Gln	Ser	Met	Gly	Ala	Ser	Ser
			100					105					110		
Asn	Ser	Glu	Asp	Ala	Phe	Ser	Pro	Gly	Ile	Lys	Gln	Pro	Glu	Ala	Pro
		115					120					125			
Glu	Ile	Thr	Val	Phe	Phe	Ser	Glu	Lys	Glu	His	Leu	Asp	Leu	Glu	Thr
	130					135					140				
Ser	Glu	Phe	Phe	Arg	Asp	Lys	Lys	Thr	Ser	Tyr	Arg	Glu	Thr	Ala	Leu
145					150					155					160
Ser	Ala	Arg	Lys	Asn	Glu	Lys	Glu	Tyr	Asp	Thr	Pro	Glu	Val	Thr	Leu
				165					170					175	
Ser	Tyr	Ser	Val	Glu	Lys	Val	Gly	Cys	Glu	Val	Pro	Ala	Thr	Ile	Thr
			180					185					190		
Tyr	Ile	Lys	Asp	Gly	Gln	Arg	Tyr	Glu	Glu	Leu	Asp	Asp	Ser	Leu	Tyr
		195					200					205			
Leu	Gly	Lys	Glu	Glu	Tyr	Leu	Gly	Ser	Val	Asp	Thr	Pro	Glu	Asp	Ala
	210					215					220				
Glu	Ala	Thr	Val	Glu	Glu	Glu	Val	Tyr	Asp	Asp	Pro	Glu	His	Val	Gly
225					230					235					240
Tyr	Asp	Gly	Glu	Glu	Asp	Phe	Glu	Asn	Ser	Glu	Thr	Thr	Glu	Phe	Ser
				245					250					255	
Gly	Glu	Glu	Pro	Ser	Tyr	Glu	Gly	Ser	Glu	Thr	Ser	Leu	Ser	Leu	Glu
			260					265					270		
Glu	Glu	Gln	Glu	Lys	Ser	Ile	Glu	Gly	Trp	Ser	Arg	Thr	His	Gly	Leu
		275					280					285			
Lys	Arg	Ser	Ser	His	Val	Gly	Leu	Pro	Lys	Cys	Trp	Asp	Tyr	Arg	Arg
	290					295					300				

WO 01/90156

PCT/US01/17158

Glu Pro Pro Cys Leu Ala
305 310

<210> 13

<400> 13
000

<210> 14

<400> 14
000

<210> 15

<400> 15
000

<210> 16

<400> 16
000

<210> 17

<400> 17
000

<210> 18

<400> 18
000

<210> 19

<400> 19
000

<210> 20

<400> 20
000

<210> 21

<400> 21
000

<210> 22

<400> 22
000

<210> 23

WO 01/90156

PCT/US01/17158

<400> 23
000

<210> 24

<400> 24
000

<210> 25

<400> 25
000

<210> 26

<400> 26
000

<210> 27

<400> 27
000

<210> 28

<400> 28
000

<210> 29

<400> 29
000

<210> 30

<400> 30
000

<210> 31

<400> 31
000

<210> 32

<400> 32
000

<210> 33

<400> 33
000

<210> 34

WO 01/90156

PCT/US01/17158

<400> 34
000

<210> 35

<400> 35
000

<210> 36

<400> 36
000

<210> 37

<400> 37
000

<210> 38

<400> 38
000

<210> 39

<400> 39
000

<210> 40

<400> 40
000

<210> 41

<400> 41
000

<210> 42

<400> 42
000

<210> 43

<400> 43
000

<210> 44

<400> 44
000

<210> 45

WO 01/90156

PCT/US01/17158

<400> 45
000

<210> 46

<400> 46
000

<210> 47

<400> 47
000

<210> 48

<400> 48
000

<210> 49

<400> 49
000

<210> 50

<400> 50
000

<210> 51

<400> 51
000

<210> 52

<400> 52
000

<210> 53

<400> 53
000

<210> 54

<400> 54
000

<210> 55

<400> 55
000

<210> 56

WO 01/90156

PCT/US01/17158

<400> 56
000

<210> 57

<400> 57
000

<210> 58

<400> 58
000

<210> 59

<400> 59
000

<210> 60

<400> 60
000

<210> 61

<400> 61
000

<210> 62

<400> 62
000

<210> 63

<400> 63
000

<210> 64

<400> 64
000

<210> 65

<400> 65
000

<210> 66

<400> 66
000

<210> 67

WO 01/90156

PCT/US01/17158

<400> 67
000

<210> 68

<400> 68
000

<210> 69

<400> 69
000

<210> 70

<400> 70
000

<210> 71

<400> 71
000

<210> 72

<400> 72
000

<210> 73

<400> 73
000

<210> 74

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 74

tacttacttt gtcccttca

19

<210> 75

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 75

tatttgtccc catctcgtc

19

WO 01/90156

PCT/US01/17158

<210> 76
<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer

<400> 76
cggaattcat ggctaccgag agtactcc

28

<210> 77
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer

<400> 77
gtaaaacgac ggccagt

17

<210> 78
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer

<400> 78
gcagaagcca ctgtggaaga ggaggtt

27

<210> 79
<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer

<400> 79
atacgactca ctatagggcg aattggcc

28

<210> 80

<220>
<223> Primer

<400> 80
000

<210> 81

WO 01/90156

PCT/US01/17158

<220>

<223> Primer

<400> 81

000

<210> 82

<211> 3030

<212> DNA

<213> Homo sapien

<220>

<221> CDS

<222> (1) ... (1680)

<400> 82

tgt gaa atg tgc tcg cag gag gct ttt cag gca cag agg agc cag ctg	48
Cys Glu Met Cys Ser Gln Glu Ala Phe Gln Ala Gln Arg Ser Gln Leu	
1 5 10 15	
gtc gag ctg ctg gtc tca ggg tcc ctg gaa ggc ttc gag agt gtc ctg	96
Val Glu Leu Leu Val Ser Gly Ser Leu Glu Gly Phe Glu Ser Val Leu	
20 25 30	
gac tgg ctg ctg tcc tgg gag gtc ctc tcc tgg gag gac tac gag ggc	144
Asp Trp Leu Leu Ser Trp Glu Val Leu Ser Trp Glu Asp Tyr Glu Gly	
35 40 45	
ttc cac ctc ctg ggc cag cct ctc tcc cac ttg gcc agg cgc ctt ctg	192
Phe His Leu Leu Gly Gln Pro Leu Ser His Leu Ala Arg Arg Leu Leu	
50 55 60	
gac acc gtc tgg aat aag ggt act tgg gcc tgt cag aag ctc atc gcg	240
Asp Thr Val Trp Asn Lys Gly Thr Trp Ala Cys Gln Lys Leu Ile Ala	
65 70 75 80	
gct gcc caa gaa gcc cag gcc gac agc cag tcc ccc aag ctg cat ggc	288
Ala Ala Gln Glu Ala Gln Ala Asp Ser Gln Ser Pro Lys Leu His Gly	
85 90 95	
tgc tgg gac ccc cac tcg ctc cac cca gcc cga gac ctg cag agt cac	336
Cys Trp Asp Pro His Ser Leu His Pro Ala Arg Asp Leu Gln Ser His	
100 105 110	
cgg cca gcc att gtc agg agg ctc cac agc cat gtg gag aac atg ctg	384
Arg Pro Ala Ile Val Arg Arg Leu His Ser His Val Glu Asn Met Leu	
115 120 125	
gac ctg gca tgg gag cgg ggt ttc gtc agc cag tat gaa tgt gat gaa	432
Asp Leu Ala Trp Glu Arg Gly Phe Val Ser Gln Tyr Glu Cys Asp Glu	
130 135 140	
atc agg ttg ccg atc ttc aca ccg tcc cag agg gca aga agg ctg ctt	480
Ile Arg Leu Pro Ile Phe Thr Pro Ser Gln Arg Ala Arg Arg Leu Leu	
145 150 155 160	

gat	ctt	gcc	acg	gtg	aaa	gcg	aat	gga	ttg	gct	gcc	ttc	ctt	cta	caa	528
Asp	Leu	Ala	Thr	Val	Lys	Ala	Asn	Gly	Leu	Ala	Ala	Phe	Leu	Leu	Gln	
				165					170					175		
cat	gtt	cag	gaa	tta	cca	gtc	cca	ttg	gcc	ctg	cct	ttg	gaa	gct	gcc	576
His	Val	Gln	Glu	Leu	Pro	Val	Pro	Leu	Ala	Leu	Pro	Leu	Glu	Ala	Ala	
			180					185					190			
aca	tgc	aag	aag	tat	atg	gcc	aag	ctg	agg	acc	acg	gtg	tct	gct	cag	624
Thr	Cys	Lys	Lys	Tyr	Met	Ala	Lys	Leu	Arg	Thr	Thr	Val	Ser	Ala	Gln	
		195					200					205				
tct	cgc	ttc	ctc	agt	acc	tat	gat	gga	gca	gag	acg	ctc	tgc	ctg	gag	672
Ser	Arg	Phe	Leu	Ser	Thr	Tyr	Asp	Gly	Ala	Glu	Thr	Leu	Cys	Leu	Glu	
	210					215					220					
gac	ata	tac	aca	gag	aat	gtc	ctg	gag	gtc	tgg	gca	gat	gtg	ggc	atg	720
Asp	Ile	Tyr	Thr	Glu	Asn	Val	Leu	Glu	Val	Trp	Ala	Asp	Val	Gly	Met	
225					230					235					240	
gct	gga	ccc	ccg	cag	aag	agc	cca	gcc	acc	ctg	ggc	ctg	gag	gag	ctc	768
Ala	Gly	Pro	Pro	Gln	Lys	Ser	Pro	Ala	Thr	Leu	Gly	Leu	Glu	Glu	Leu	
				245					250					255		
ttc	agc	acc	cct	ggc	cac	ctc	aat	gac	gat	gcg	gac	act	gtg	ctg	gtg	816
Phe	Ser	Thr	Pro	Gly	His	Leu	Asn	Asp	Asp	Ala	Asp	Thr	Val	Leu	Val	
			260					265					270			
gtg	ggt	gag	gcg	ggc	agt	ggc	aag	agc	acg	ctc	ctg	cag	cgg	ctg	cac	864
Val	Gly	Glu	Ala	Gly	Ser	Gly	Lys	Ser	Thr	Leu	Leu	Gln	Arg	Leu	His	
		275					280					285				
ttg	ctg	tgg	gct	gca	ggg	caa	gac	ttc	cag	gaa	ttt	ctc	ttt	gtc	ttc	912
Leu	Leu	Trp	Ala	Ala	Gly	Gln	Asp	Phe	Gln	Glu	Phe	Leu	Phe	Val	Phe	
	290					295					300					
cca	ttc	agc	tgc	cgg	cag	ctg	cag	tgc	atg	gcc	aaa	cca	ctc	tct	gtg	960
Pro	Phe	Ser	Cys	Arg	Gln	Leu	Gln	Cys	Met	Ala	Lys	Pro	Leu	Ser	Val	
305					310					315					320	
cgg	act	cta	ctc	ttt	gag	cac	tgc	tgt	tgg	cct	gat	gtt	ggt	caa	gaa	1008
Arg	Thr	Leu	Leu	Phe	Glu	His	Cys	Cys	Trp	Pro	Asp	Val	Gly	Gln	Glu	
				325					330					335		
gac	atc	ttc	cag	tta	ctc	ctt	gac	cac	cct	gac	cgt	gtc	ctg	tta	acc	1056
Asp	Ile	Phe	Gln	Leu	Leu	Leu	Asp	His	Pro	Asp	Arg	Val	Leu	Leu	Thr	
			340					345					350			
ttt	gat	ggc	ttt	gac	gag	ttc	aag	ttc	agg	ttc	acg	gat	cgt	gaa	cgc	1104
Phe	Asp	Gly	Phe	Asp	Glu	Phe	Lys	Phe	Arg	Phe	Thr	Asp	Arg	Glu	Arg	
		355					360					365				
cac	tgc	tcc	ccg	acc	gac	ccc	acc	tct	gtc	cag	acc	ctg	ctc	ttc	aac	1152
His	Cys	Ser	Pro	Thr	Asp	Pro	Thr	Ser	Val	Gln	Thr	Leu	Leu	Phe	Asn	

370	375	380	
ctt ctg cag ggc aac ctg ctg aag aat gcc cgc aag gtg gtg acc agc			1200
Leu Leu Gln Gly Asn Leu Leu Lys Asn Ala Arg Lys Val Val Thr Ser			
385	390	395	400
cgt ccg gcc gct gtg tcg gcg ttc ctc agg aag tac atc cgc acc gag			1248
Arg Pro Ala Ala Val Ser Ala Phe Leu Arg Lys Tyr Ile Arg Thr Glu			
	405	410	415
ttc aac ctc aag ggc ttc tct gaa cag ggc atc gag ctg tac ctg agg			1296
Phe Asn Leu Lys Gly Phe Ser Glu Gln Gly Ile Glu Leu Tyr Leu Arg			
	420	425	430
aag cgc cat cat gag ccc ggg gtg gcg gac cgc ctc atc cgc ctg ctc			1344
Lys Arg His His Glu Pro Gly Val Ala Asp Arg Leu Ile Arg Leu Leu			
	435	440	445
caa gag acc tca gcc ctg cac ggt ttg tgc cac ctg cct gtc ttc tca			1392
Gln Glu Thr Ser Ala Leu His Gly Leu Cys His Leu Pro Val Phe Ser			
	450	455	460
tgg atg gtg tcc aaa tgc cac cag gaa ctg ttg ctg cag gag ggg ggg			1440
Trp Met Val Ser Lys Cys His Gln Glu Leu Leu Leu Gln Glu Gly Gly			
	465	470	480
tcc cca aag acc act aca gat atg tac ctg ctg att ctg cag cat ttt			1488
Ser Pro Lys Thr Thr Thr Asp Met Tyr Leu Leu Ile Leu Gln His Phe			
	485	490	495
ctg ctg cat gcc acc ccc cca gac tca gct tcc caa ggt ctg gga ccc			1536
Leu Leu His Ala Thr Pro Pro Asp Ser Ala Ser Gln Gly Leu Gly Pro			
	500	505	510
agt ctt ctt cgg ggc cgc ctc ccc acc ctc ctg cac ctg ggc aga ctg			1584
Ser Leu Leu Arg Gly Arg Leu Pro Thr Leu Leu His Leu Gly Arg Leu			
	515	520	525
gct ctg tgg ggc ctg ggc atg tgc tgc tac gtg ttc tca gcc cag cag			1632
Ala Leu Trp Gly Leu Gly Met Cys Cys Tyr Val Phe Ser Ala Gln Gln			
	530	535	540
ctc cag gca gca cag gtc agc cct gat gac att tct ctt ggc ttc ctg			1680
Leu Gln Ala Ala Gln Val Ser Pro Asp Asp Ile Ser Leu Gly Phe Leu			
	545	550	555
gtgcgtgccca aagggtgtcgt gccagggagt acggcgcccc tggaattcct tcacatcact			1740
ttccagtgtct tcttttgccgc gttctacctg gcactcagtgt ctgatgtgcc accagctttg			1800
ctcagacacc tcttcaattg tggcaggcca ggcaactcac caatggccag gctcctgccc			1860
acgatgtgca tccaggcctc ggagggaaag gacagcagcg tggcagcttt gctgcagaag			1920
gccgagccgc acaaccttca gatcacagca gccttccttg cagggtgtgt gtcccgggag			1980
cactggggcc tgctggctga gtgccagaca tctgagaagg cctgtctccg gcgccaggcc			2040
tgtgcccgt ggtgtctggc ccgcagcctc cgcaagcact tccactccat cccgccagct			2100
gcaccgggtg aggccaaagag cgtgcatgcc atgcccgggt tcatctggct catccggagc			2160
ctgtacgaga tgcaggagga gcggctggct cggaaggctg cacgtggcct gaatgttggg			2220

```

cacctcaagt tgacattttg cagtgtgggc cccactgagt gtgctgccct ggcctttgtg 2280
ctgcagcacc tccggcggcc cgtggccctg cagctggact acaactctgt gggtgacatt 2340
ggcgtggagc agctgctgcc ttgccttggt gtctgcaagg ctctgtattt gcgcgataac 2400
aatatctcag accgaggcat ctgcaagctc attgaatgtg ctcttcactg cgagcaattg 2460
cagaagttag cgctggggaa taactacatc actgccgcgg gagcccaagt gctggccgag 2520
gggctccgag gcaacacctc cttgcagttc ctgggattct ggggcaacag agtgggtgac 2580
gagggggccc aggccctggc tgaagccttg ggtgatcacc agagcttgag gtggctcagc 2640
ctggtgggga acaacattgg cagtgtgggt gcccaagcct tggcactgat gctggcaaag 2700
aacgtcatgc tagaagaact ctgcctggag gagaaccatc tccaggatga aggtgtatgt 2760
tctctcgcag aaggactgaa gaaaaattca agtttgaaaa tcctgaacat aaaaattcat 2820
gcttcgggat tcaacaaact cttggaaagc attttctgca tcctcctggg tgtggaagca 2880
tttttcctgc agaaagtgtg caagattctt gaagaaatgg tagtcagttg gctagaggtc 2940
aggttgtcca ataactgcat cacctaccta ggggcagaag ccctcctgca ggcccttgaa 3000
aggaatgaca ccacctgga agtctggtaa                                3030

```

<210> 83

<211> 560

<212> PRT

<213> Homo sapien

<400> 83

```

Cys Glu Met Cys Ser Gln Glu Ala Phe Gln Ala Gln Arg Ser Gln Leu
 1          5          10          15
Val Glu Leu Leu Val Ser Gly Ser Leu Glu Gly Phe Glu Ser Val Leu
          20          25          30
Asp Trp Leu Leu Ser Trp Glu Val Leu Ser Trp Glu Asp Tyr Glu Gly
          35          40          45
Phe His Leu Leu Gly Gln Pro Leu Ser His Leu Ala Arg Arg Leu Leu
          50          55          60
Asp Thr Val Trp Asn Lys Gly Thr Trp Ala Cys Gln Lys Leu Ile Ala
65          70          75          80
Ala Ala Gln Glu Ala Gln Ala Asp Ser Gln Ser Pro Lys Leu His Gly
          85          90          95
Cys Trp Asp Pro His Ser Leu His Pro Ala Arg Asp Leu Gln Ser His
          100          105          110
Arg Pro Ala Ile Val Arg Arg Leu His Ser His Val Glu Asn Met Leu
          115          120          125
Asp Leu Ala Trp Glu Arg Gly Phe Val Ser Gln Tyr Glu Cys Asp Glu
          130          135          140
Ile Arg Leu Pro Ile Phe Thr Pro Ser Gln Arg Ala Arg Arg Leu Leu
          145          150          155          160
Asp Leu Ala Thr Val Lys Ala Asn Gly Leu Ala Ala Phe Leu Leu Gln
          165          170          175
His Val Gln Glu Leu Pro Val Pro Leu Ala Leu Pro Leu Glu Ala Ala
          180          185          190
Thr Cys Lys Lys Tyr Met Ala Lys Leu Arg Thr Thr Val Ser Ala Gln
          195          200          205
Ser Arg Phe Leu Ser Thr Tyr Asp Gly Ala Glu Thr Leu Cys Leu Glu
          210          215          220
Asp Ile Tyr Thr Glu Asn Val Leu Glu Val Trp Ala Asp Val Gly Met
          225          230          235          240
Ala Gly Pro Pro Gln Lys Ser Pro Ala Thr Leu Gly Leu Glu Glu Leu
          245          250          255
Phe Ser Thr Pro Gly His Leu Asn Asp Asp Ala Asp Thr Val Leu Val
          260          265          270

```

WO 01/90156

PCT/US01/17158

Val Gly Glu Ala Gly Ser Gly Lys Ser Thr Leu Leu Gln Arg Leu His
 275 280 285
 Leu Leu Trp Ala Ala Gly Gln Asp Phe Gln Glu Phe Leu Phe Val Phe
 290 295 300
 Pro Phe Ser Cys Arg Gln Leu Gln Cys Met Ala Lys Pro Leu Ser Val
 305 310 315 320
 Arg Thr Leu Leu Phe Glu His Cys Cys Trp Pro Asp Val Gly Gln Glu
 325 330 335
 Asp Ile Phe Gln Leu Leu Leu Asp His Pro Asp Arg Val Leu Leu Thr
 340 345 350
 Phe Asp Gly Phe Asp Glu Phe Lys Phe Arg Phe Thr Asp Arg Glu Arg
 355 360 365
 His Cys Ser Pro Thr Asp Pro Thr Ser Val Gln Thr Leu Leu Phe Asn
 370 375 380
 Leu Leu Gln Gly Asn Leu Leu Lys Asn Ala Arg Lys Val Val Thr Ser
 385 390 395 400
 Arg Pro Ala Ala Val Ser Ala Phe Leu Arg Lys Tyr Ile Arg Thr Glu
 405 410 415
 Phe Asn Leu Lys Gly Phe Ser Glu Gln Gly Ile Glu Leu Tyr Leu Arg
 420 425 430
 Lys Arg His His Glu Pro Gly Val Ala Asp Arg Leu Ile Arg Leu Leu
 435 440 445
 Gln Glu Thr Ser Ala Leu His Gly Leu Cys His Leu Pro Val Phe Ser
 450 455 460
 Trp Met Val Ser Lys Cys His Gln Glu Leu Leu Leu Gln Glu Gly Gly
 465 470 475 480
 Ser Pro Lys Thr Thr Thr Asp Met Tyr Leu Leu Ile Leu Gln His Phe
 485 490 495
 Leu Leu His Ala Thr Pro Pro Asp Ser Ala Ser Gln Gly Leu Gly Pro
 500 505 510
 Ser Leu Leu Arg Gly Arg Leu Pro Thr Leu Leu His Leu Gly Arg Leu
 515 520 525
 Ala Leu Trp Gly Leu Gly Met Cys Cys Tyr Val Phe Ser Ala Gln Gln
 530 535 540
 Leu Gln Ala Ala Gln Val Ser Pro Asp Asp Ile Ser Leu Gly Phe Leu
 545 550 555 560

<210> 84

<211> 1107

<212> DNA

<213> Homo sapien

<400> 84

attctttttt taactttttac ttattcatta ggatgatttc ataatatatt tcctgggttta 60
 gaggaacag gaacaatggc taccgagagt actccctcag agatcataga aagagaaaga 120
 aaaaagttgc ttgaaatcct tcaacatgat cctgattcta tcttagacac gttaacttct 180
 cggaggctga tttctgagga agagtatgag actctggaga atgttacaga tctcctgaag 240
 aaaagtcgga agctgttaat tttggtacag aaaaaggagg aggcgacctg tcagcatttt 300
 ctcaagtgtt tathtagtac ttttccacag tcagctgcca tttgcggctt aaggcatgaa 360
 gttttaaaac atgagaatac agtacctcct caatctatgg gggcaagcag taattcagaa 420
 gatgcttttt ctcttggaat aaaacagcct gaagcccctg agatcacagt gttcttcagt 480
 gagaaggaac acttggattt ggaaacctct gagtttttca gggacaagaa aactagttat 540
 agggaaacag ctttgtctgc caggaagaat gagaaggaat atgacacacc agaagtcaca 600
 ttatcatatt cagttgagaa agttggatgt gaagttccag caactattac atatataaaa 660

WO 01/90156

PCT/US01/17158

```

gatggacaga gatatgagga gctagatgat tctttatact taggaaaaga ggaatatcta 720
ggatctgttg acacccctga agatgcagaa gccactgtgg aagaggaggt ttatgatgac 780
ccagagcacg ttggatatga tggatgaagag gacttcgaga attcagaaac cacagagttc 840
tctggtgaag aaccaagtta tgagggatca gaaaccagcc tttcattgga ggaggaacag 900
gagaaaagta tagaaggctg gtctcgaact catgggctta agcgatcctc ccacgttggc 960
ctcccaaagt gctgggatta caggcgtgag ccaccctgcc tggcctgaaa attctgcctc 1020
aaacatctca aacatccatt tatattttgt acaagaaagt aaataaaatt tttcttttta 1080
acattaaaaa aaaaaaaaaa aaaaaaa 1107

```

<210> 85

<211> 510

<212> DNA

<213> Homo sapien

<220>

<221> CDS

<222> (15) ... (305)

<400> 85

```

aggagagaaa agcc atg gcc gac aag gtc ctg aag gag aag aga aag ctg 50
                Met Ala Asp Lys Val Leu Lys Glu Lys Arg Lys Leu
                1                5                10

ttt atc cat tcc atg ggt gaa ggt aca ata aat ggc tta ctg gat gaa 98
Phe Ile His Ser Met Gly Glu Gly Thr Ile Asn Gly Leu Leu Asp Glu
                15                20                25

tta tta cag aca agg gtg ctg aac cag gaa gag atg gag aaa gta aaa 146
Leu Leu Gln Thr Arg Val Leu Asn Gln Glu Glu Met Glu Lys Val Lys
                30                35                40

cgt gaa aat gct aca gtt atg gat aag acc cga gct ttg att gac tcc 194
Arg Glu Asn Ala Thr Val Met Asp Lys Thr Arg Ala Leu Ile Asp Ser
                45                50                55                60

gtt att ccg aaa ggg gca cag gca tgc caa att tgc atc aca tac att 242
Val Ile Pro Lys Gly Ala Gln Ala Cys Gln Ile Cys Ile Thr Tyr Ile
                65                70                75

tgt gaa gaa gac agt tac ctg gca gag acg ctg gga ctc tca gca ggt 290
Cys Glu Glu Asp Ser Tyr Leu Ala Glu Thr Leu Gly Leu Ser Ala Gly
                80                85                90

ccg ata cct gga aat tagcttagct tagtacacaa gactcccaat tactattttc 345
Pro Ile Pro Gly Asn
                95

ttccttccca gctcttcagg cagtgcagga caaccagct atgccacat gctcaagccc 405
agaaggcaga atcaagcttt gctttctaga agacgctcaa aggatatgga aacaaaagtt 465
gcagaggtgc catgttcaga atacaataat aaagtggagt aaaga 510

```

<210> 86

<211> 97

<212> PRT

<213> Homo sapien

WO 01/90156

PCT/US01/17158

<400> 86

Met	Ala	Asp	Lys	Val	Leu	Lys	Glu	Lys	Arg	Lys	Leu	Phe	Ile	His	Ser
1				5					10					15	
Met	Gly	Glu	Gly	Thr	Ile	Asn	Gly	Leu	Leu	Asp	Glu	Leu	Leu	Gln	Thr
			20					25					30		
Arg	Val	Leu	Asn	Gln	Glu	Glu	Met	Glu	Lys	Val	Lys	Arg	Glu	Asn	Ala
			35				40					45			
Thr	Val	Met	Asp	Lys	Thr	Arg	Ala	Leu	Ile	Asp	Ser	Val	Ile	Pro	Lys
		50				55					60				
Gly	Ala	Gln	Ala	Cys	Gln	Ile	Cys	Ile	Thr	Tyr	Ile	Cys	Glu	Glu	Asp
65					70					75				80	
Ser	Tyr	Leu	Ala	Glu	Thr	Leu	Gly	Leu	Ser	Ala	Gly	Pro	Ile	Pro	Gly
				85					90					95	

Asn

<210> 87

<211> 97

<212> PRT

<213> Homo sapien

<400> 87

Met	Ala	Asp	Lys	Val	Leu	Lys	Glu	Lys	Arg	Lys	Leu	Phe	Ile	Arg	Ser
1				5					10					15	
Met	Gly	Glu	Gly	Thr	Ile	Asn	Gly	Leu	Leu	Asp	Glu	Leu	Leu	Gln	Thr
			20					25					30		
Arg	Val	Leu	Asn	Lys	Glu	Glu	Met	Glu	Lys	Val	Lys	Arg	Glu	Asn	Ala
			35				40					45			
Thr	Val	Met	Asp	Lys	Thr	Arg	Ala	Leu	Ile	Asp	Ser	Val	Ile	Pro	Lys
		50				55					60				
Gly	Ala	Gln	Ala	Cys	Gln	Ile	Cys	Ile	Thr	Tyr	Ile	Cys	Glu	Glu	Asp
65					70					75				80	
Ser	Tyr	Leu	Ala	Gly	Thr	Leu	Gly	Leu	Ser	Ala	Asp	Gln	Thr	Ser	Gly
				85					90					95	

Asn

<210> 88

<400> 88

000

<210> 89

<211> 321

<212> DNA

<213> Homo sapien

<220>

<221> CDS

<222> (1)...(318)

<400> 89

WO 01/90156

PCT/US01/17158

atg atc ctc ctg aag aag aga cgg ctg ctt atc aat tca ttg ggt gaa 48
 Met Ile Leu Leu Lys Lys Arg Arg Leu Leu Ile Asn Ser Leu Gly Glu
 1 5 10 15

 ggt aca ata aat ggc tta ctg gat gaa tta ttg gag aca aat gtg ctg 96
 Gly Thr Ile Asn Gly Leu Leu Asp Glu Leu Leu Glu Thr Asn Val Leu
 20 25 30

 agc cag gaa gac aca gag ata gta aaa tgt gaa aat gtt aca gtt atc 144
 Ser Gln Glu Asp Thr Glu Ile Val Lys Cys Glu Asn Val Thr Val Ile
 35 40 45

 gat aag gcc cga gat ttg ctt gac tct gtt att cgg aaa ggg gca ggg 192
 Asp Lys Ala Arg Asp Leu Leu Asp Ser Val Ile Arg Lys Gly Ala Gly
 50 55 60

 gca tgt gaa att tgc atc aca tac att tgt gaa gaa gac agg tac ctg 240
 Ala Cys Glu Ile Cys Ile Thr Tyr Ile Cys Glu Glu Asp Arg Tyr Leu
 65 70 75 80

 gca ggg acg ctg gga ctc tca gca gga aat gac tac aga gct gga ggc 288
 Ala Gly Thr Leu Gly Leu Ser Ala Gly Asn Asp Tyr Arg Ala Gly Gly
 85 90 95

 att tgc tca ccg ccc aga gca caa gac ctc tga 321
 Ile Cys Ser Pro Pro Arg Ala Gln Asp Leu
 100 105

<210> 90

<211> 106

<212> PRT

<213> Homo sapien

<400> 90

Met Ile Leu Leu Lys Lys Arg Arg Leu Leu Ile Asn Ser Leu Gly Glu
 1 5 10 15
 Gly Thr Ile Asn Gly Leu Leu Asp Glu Leu Leu Glu Thr Asn Val Leu
 20 25 30
 Ser Gln Glu Asp Thr Glu Ile Val Lys Cys Glu Asn Val Thr Val Ile
 35 40 45
 Asp Lys Ala Arg Asp Leu Leu Asp Ser Val Ile Arg Lys Gly Ala Gly
 50 55 60
 Ala Cys Glu Ile Cys Ile Thr Tyr Ile Cys Glu Glu Asp Arg Tyr Leu
 65 70 75 80
 Ala Gly Thr Leu Gly Leu Ser Ala Gly Asn Asp Tyr Arg Ala Gly Gly
 85 90 95
 Ile Cys Ser Pro Pro Arg Ala Gln Asp Leu
 100 105

<210> 91

<211> 108

<212> PRT

<213> Homo sapien

WO 01/90156

PCT/US01/17158

<400> 91

```

Met Ala Asp Lys Val Leu Leu Glu Lys Arg Lys Leu Leu Ile Asn Ser
 1           5           10           15
Leu Gly Glu Gly Thr Ile Asn Gly Leu Leu Asp Glu Leu Leu Glu Thr
           20           25           30
Asn Val Leu Ser Gln Glu Asp Glu Ile Val Lys Arg Glu Asn Ala Thr
           35           40           45
Val Ile Asp Lys Ala Arg Ala Leu Leu Asp Ser Val Ile Arg Lys Gly
           50           55           60
Ala Gly Ala Cys Glu Ile Cys Ile Thr Tyr Ile Cys Glu Glu Asp Ser
65           70           75           80
Tyr Leu Ala Gly Thr Leu Gly Leu Ser Ala Gly Asn Ala Val Gln Ala
           85           90           95
Gly Gly Ala Cys Ser Thr Ser Ser Gly Gln Asp Leu
           100          105

```

<210> 92

<400> 92

000

<210> 93

<400> 93

000

<210> 94

<400> 94

000

<210> 95

<400> 95

000

<210> 96

<211> 3396

<212> DNA

<213> Homo sapien

<220>

<221> CDS

<222> (277) ... (3348)

<400> 96

```

cgccccgggca ggtgtttata ctccggaggg tgtccccgtg cgtcatcggt ggagtggacc 60
aaaactggtg atctgtttgc cctgtgtgac cttgcccaga accctgctga ctgagagAAC 120
acatctgctg gaagtcctct gggattcaag gtacagggaa tgaagagtag ttttacagaa 180
aaaagaggac aatattggga tcacctttga cctttccatt tggaaataat attttctatt 240
gtgttataga aaggtgggaa gctttcatcc agaaca atg aat ttc ata aag gac 294
                               Met Asn Phe Ile Lys Asp
                               1           5

```

aat agc cga gcc ctt att caa aga atg gga atg act gtt ata aag caa	342
Asn Ser Arg Ala Leu Ile Gln Arg Met Gly Met Thr Val Ile Lys Gln	
10 15 20	
atc aca gat gac cta ttt gta tgg aat gtt ctg aat cgc gaa gaa gta	390
Ile Thr Asp Asp Leu Phe Val Trp Asn Val Leu Asn Arg Glu Glu Val	
25 30 35	
aac atc att tgc tgc gag aag gtg gag cag gat gct gct aga ggg atc	438
Asn Ile Ile Cys Cys Glu Lys Val Glu Gln Asp Ala Ala Arg Gly Ile	
40 45 50	
att cac atg att ttg aaa aag ggt tca gag tcc tgt aac ctc ttt ctt	486
Ile His Met Ile Leu Lys Lys Gly Ser Glu Ser Cys Asn Leu Phe Leu	
55 60 65 70	
aaa tcc ctt aag gag tgg aac tat cct cta ttt cag gac ttg aat gga	534
Lys Ser Leu Lys Glu Trp Asn Tyr Pro Leu Phe Gln Asp Leu Asn Gly	
75 80 85	
caa agt ctt ttt cat cag aca tca gaa gga gac ttg gac gat ttg gct	582
Gln Ser Leu Phe His Gln Thr Ser Glu Gly Asp Leu Asp Asp Leu Ala	
90 95 100	
cag gat tta aag gac ttg tac cat acc cca tct ttt ctg aac ttt tat	630
Gln Asp Leu Lys Asp Leu Tyr His Thr Pro Ser Phe Leu Asn Phe Tyr	
105 110 115	
ccc ctt ggt gaa gat att gac att att ttt aac ttg aaa agc acc ttc	678
Pro Leu Gly Glu Asp Ile Asp Ile Ile Phe Asn Leu Lys Ser Thr Phe	
120 125 130	
aca gaa cct atc ctg tgg agg aag gac caa cac cat cac cgc gtg gag	726
Thr Glu Pro Ile Leu Trp Arg Lys Asp Gln His His His Arg Val Glu	
135 140 145 150	
cag ctg acc ctg aat ggc ctc ctg cag gct ctt cag agc ccc tgc atc	774
Gln Leu Thr Leu Asn Gly Leu Leu Gln Ala Leu Gln Ser Pro Cys Ile	
155 160 165	
att gaa ggg gaa tct ggc aaa ggc aag tcc act ctg ctg cag cgc att	822
Ile Glu Gly Glu Ser Gly Lys Gly Lys Ser Thr Leu Leu Gln Arg Ile	
170 175 180	
gcc atg ctc tgg ggc tcc gga aag tgc aag gct ctg acc aag ttc aaa	870
Ala Met Leu Trp Gly Ser Gly Lys Cys Lys Ala Leu Thr Lys Phe Lys	
185 190 195	
ttc gtc ttc ttc ctc cgt ctc agc agg gcc cag ggt gga ctt ttt gaa	918
Phe Val Phe Phe Leu Arg Leu Ser Arg Ala Gln Gly Gly Leu Phe Glu	
200 205 210	
acc ctc tgt gat caa ctc ctg gat ata cct ggc aca atc agg aag cag	966
Thr Leu Cys Asp Gln Leu Leu Asp Ile Pro Gly Thr Ile Arg Lys Gln	

WO 01/90156

PCT/US01/17158

215		220		225		230	
aca ttc atg gcc atg ctg ctg aag ctg cgg cag agg gtt ctt ttc ctt	1014						
Thr Phe Met Ala Met Leu Leu Lys Leu Arg Gln Arg Val Leu Phe Leu							
		235		240		245	
ctt gat ggc tac aat gaa ttc aag ccc cag aac tgc cca gaa atc gaa	1062						
Leu Asp Gly Tyr Asn Glu Phe Lys Pro Gln Asn Cys Pro Glu Ile Glu							
		250		255		260	
gcc ctg ata aag gaa aac cac cgc ttc aag aac atg gtc atc gtc acc	1110						
Ala Leu Ile Lys Glu Asn His Arg Phe Lys Asn Met Val Ile Val Thr							
		265		270		275	
act acc act gag tgc ctg agg cac ata cgg cag ttt ggt gcc ctg act	1158						
Thr Thr Thr Glu Cys Leu Arg His Ile Arg Gln Phe Gly Ala Leu Thr							
		280		285		290	
gct gag gtg ggg gat atg aca gaa gac agc gcc cag gct ctc atc cga	1206						
Ala Glu Val Gly Asp Met Thr Glu Asp Ser Ala Gln Ala Leu Ile Arg							
		295		300		305	
gaa gtg ctg atc aag gag ctt gct gaa ggc ttg ttg ctc caa att cag	1254						
Glu Val Leu Ile Lys Glu Leu Ala Glu Gly Leu Leu Leu Gln Ile Gln							
		315		320		325	
aaa tcc agg tgc ttg agg aat ctc atg aag acc cct ctc ttt gtg gtc	1302						
Lys Ser Arg Cys Leu Arg Asn Leu Met Lys Thr Pro Leu Phe Val Val							
		330		335		340	
atc act tgt gca atc cag atg ggt gaa agt gag ttc cac tct cac aca	1350						
Ile Thr Cys Ala Ile Gln Met Gly Glu Ser Glu Phe His Ser His Thr							
		345		350		355	
caa aca acg ctg ttc cat acc ttc tat gat ctg ttg ata cag aaa aac	1398						
Gln Thr Thr Leu Phe His Thr Phe Tyr Asp Leu Leu Ile Gln Lys Asn							
		360		365		370	
aaa cac aaa cat aaa ggt gtg gct gca agt gac ttc att cgg agc ctg	1446						
Lys His Lys His Lys Gly Val Ala Ala Ser Asp Phe Ile Arg Ser Leu							
		375		380		385	
gac cac cgt gga gac cta gct ctg gag ggt gtg ttc tcc cac aag ttt	1494						
Asp His Arg Gly Asp Leu Ala Leu Glu Gly Val Phe Ser His Lys Phe							
		395		400		405	
gat ttc gaa ctg cag gat gtg tcc agc gtg aat gag gat gtc ctg ctg	1542						
Asp Phe Glu Leu Gln Asp Val Ser Ser Val Asn Glu Asp Val Leu Leu							
		410		415		420	
aca act ggg ctc ctc tgt aaa tat aca gct caa agg ttc aag cca aag	1590						
Thr Thr Gly Leu Leu Cys Lys Tyr Thr Ala Gln Arg Phe Lys Pro Lys							
		425		430		435	
tat aaa ttc ttt cac aag tca ttc cag gag tac aca gca gga cga aga	1638						

Tyr	Lys	Phe	Phe	His	Lys	Ser	Phe	Gln	Glu	Tyr	Thr	Ala	Gly	Arg	Arg	
440						445					450					
ctc	agc	agt	tta	ttg	acg	tct	cat	gag	cca	gag	gag	gtg	acc	aag	ggg	1686
Leu	Ser	Ser	Leu	Leu	Thr	Ser	His	Glu	Pro	Glu	Glu	Val	Thr	Lys	Gly	
455					460					465					470	
aat	ggt	tac	ttg	cag	aaa	atg	gtt	tcc	att	tcg	gac	att	aca	tcc	act	1734
Asn	Gly	Tyr	Leu	Gln	Lys	Met	Val	Ser	Ile	Ser	Asp	Ile	Thr	Ser	Thr	
				475				480						485		
tat	agc	agc	ctg	ctc	cgg	tac	acc	tgt	ggg	tca	tct	gtg	gaa	gcc	acc	1782
Tyr	Ser	Ser	Leu	Leu	Arg	Tyr	Thr	Cys	Gly	Ser	Ser	Val	Glu	Ala	Thr	
			490					495					500			
agg	gct	gtt	atg	aag	cac	ctc	gca	gca	gtg	tat	caa	cac	ggc	tgc	ctt	1830
Arg	Ala	Val	Met	Lys	His	Leu	Ala	Ala	Val	Tyr	Gln	His	Gly	Cys	Leu	
		505					510					515				
ctc	gga	ctt	tcc	atc	gcc	aag	agg	cct	ctc	tgg	aga	cag	gaa	tct	ttg	1878
Leu	Gly	Leu	Ser	Ile	Ala	Lys	Arg	Pro	Leu	Trp	Arg	Gln	Glu	Ser	Leu	
	520					525					530					
caa	agt	gtg	aaa	aac	acc	act	gag	caa	gaa	att	ctg	aaa	gcc	ata	aac	1926
Gln	Ser	Val	Lys	Asn	Thr	Thr	Glu	Gln	Glu	Ile	Leu	Lys	Ala	Ile	Asn	
535					540					545					550	
atc	aat	tcc	ttt	gta	gag	tgt	ggc	atc	cat	tta	tat	caa	gag	agt	aca	1974
Ile	Asn	Ser	Phe	Val	Glu	Cys	Gly	Ile	His	Leu	Tyr	Gln	Glu	Ser	Thr	
				555				560						565		
tcc	aaa	tca	gcc	ctg	agc	caa	gaa	ttt	gaa	gct	ttc	ttt	caa	ggt	aaa	2022
Ser	Lys	Ser	Ala	Leu	Ser	Gln	Glu	Phe	Glu	Ala	Phe	Phe	Gln	Gly	Lys	
			570				575						580			
agc	tta	tat	atc	aac	tca	ggg	aac	atc	ccc	gat	tac	tta	ttt	gac	ttc	2070
Ser	Leu	Tyr	Ile	Asn	Ser	Gly	Asn	Ile	Pro	Asp	Tyr	Leu	Phe	Asp	Phe	
		585					590					595				
ttt	gaa	cat	ttg	ccc	aat	tgt	gca	agt	gcc	ctg	gac	ttc	att	aaa	ctg	2118
Phe	Glu	His	Leu	Pro	Asn	Cys	Ala	Ser	Ala	Leu	Asp	Phe	Ile	Lys	Leu	
	600					605					610					
gac	ttt	tat	ggg	gga	gct	atg	gct	tca	tgg	gaa	aag	gct	gca	gaa	gac	2166
Asp	Phe	Tyr	Gly	Gly	Ala	Met	Ala	Ser	Trp	Glu	Lys	Ala	Ala	Glu	Asp	
615					620					625					630	
aca	ggt	gga	atc	cac	atg	gaa	gag	gcc	cca	gaa	acc	tac	att	ccc	agc	2214
Thr	Gly	Gly	Ile	His	Met	Glu	Glu	Ala	Pro	Glu	Thr	Tyr	Ile	Pro	Ser	
				635				640						645		
agg	gct	gta	tct	ttg	ttc	ttc	aac	tgg	aag	cag	gaa	ttc	agg	act	ctg	2262
Arg	Ala	Val	Ser	Leu	Phe	Phe	Asn	Trp	Lys	Gln	Glu	Phe	Arg	Thr	Leu	
			650					655					660			

WO 01/90156

PCT/US01/17158

gag gtc aca ctc cgg gat ttc agc aag ttg aat aag caa gat atc aga	2310
Glu Val Thr Leu Arg Asp Phe Ser Lys Leu Asn Lys Gln Asp Ile Arg	
665 670 675	
tat ctg ggg aaa ata ttc agc tct gcc aca agc ctc agg ctg caa ata	2358
Tyr Leu Gly Lys Ile Phe Ser Ser Ala Thr Ser Leu Arg Leu Gln Ile	
680 685 690	
aag aga tgt gct ggt gtg gct gga agc ctc agt ttg gtc ctc agc acc	2406
Lys Arg Cys Ala Gly Val Ala Gly Ser Leu Ser Leu Val Leu Ser Thr	
695 700 705 710	
tgt aag aac att tat tct ctc atg gtg gaa gcc agt ccc ctc acc ata	2454
Cys Lys Asn Ile Tyr Ser Leu Met Val Glu Ala Ser Pro Leu Thr Ile	
715 720 725	
gaa gat gag agg cac atc aca tct gta aca aac ctg aaa acc ttg agt	2502
Glu Asp Glu Arg His Ile Thr Ser Val Thr Asn Leu Lys Thr Leu Ser	
730 735 740	
att cat gac cta cag aat caa cgg ctg ccg ggt ggt ctg act gac agc	2550
Ile His Asp Leu Gln Asn Gln Arg Leu Pro Gly Gly Leu Thr Asp Ser	
745 750 755	
ttg ggt aac ttg aag aac ctt aca aag ctc ata atg gat aac ata aag	2598
Leu Gly Asn Leu Lys Asn Leu Thr Lys Leu Ile Met Asp Asn Ile Lys	
760 765 770	
atg aat gaa gaa gat gct ata aaa cta gct gaa ggc ctg aaa aac ctg	2646
Met Asn Glu Glu Asp Ala Ile Lys Leu Ala Glu Gly Leu Lys Asn Leu	
775 780 785 790	
aag aag atg tgt tta ttt cat ttg acc cac ttg tct gac att gga gag	2694
Lys Lys Met Cys Leu Phe His Leu Thr His Leu Ser Asp Ile Gly Glu	
795 800 805	
gga atg gat tac ata gtc aag tct ctg tca agt gaa ccc tgt gac ctt	2742
Gly Met Asp Tyr Ile Val Lys Ser Leu Ser Ser Glu Pro Cys Asp Leu	
810 815 820	
gaa gaa att caa tta gtc tcc tgc tgc ttg tct gca aat gca gtg aaa	2790
Glu Glu Ile Gln Leu Val Ser Cys Cys Leu Ser Ala Asn Ala Val Lys	
825 830 835	
atc cta gct cag aat ctt cac aat ttg gtc aaa ctg agc att ctt gat	2838
Ile Leu Ala Gln Asn Leu His Asn Leu Val Lys Leu Ser Ile Leu Asp	
840 845 850	
tta tca gaa aat tac ctg gaa aaa gat gga aat gaa gct ctt cat gaa	2886
Leu Ser Glu Asn Tyr Leu Glu Lys Asp Gly Asn Glu Ala Leu His Glu	
855 860 865 870	
ctg atc gac agg atg aac gtg cta gaa cag ctc acc gca ctg atg ctg	2934
Leu Ile Asp Arg Met Asn Val Leu Glu Gln Leu Thr Ala Leu Met Leu	
875 880 885	

WO 01/90156

PCT/US01/17158

ccc tgg ggc tgt gac gtg caa ggc agc ctg agc agc ctg ttg aaa cat 2982
 Pro Trp Gly Cys Asp Val Gln Gly Ser Leu Ser Ser Leu Leu Lys His
 890 895 900

ttg gag gag gtc cca caa ctc gtc aag ctt ggg ttg aaa aac tgg aga 3030
 Leu Glu Glu Val Pro Gln Leu Val Lys Leu Gly Leu Lys Asn Trp Arg
 905 910 915

ctc aca gat aca gag att aga att tta ggt gca ttt ttt gga aag aac 3078
 Leu Thr Asp Thr Glu Ile Arg Ile Leu Gly Ala Phe Phe Gly Lys Asn
 920 925 930

cct ctg aaa aac ttc cag cag ttg aat ttg gcg gga aat cgt gtg agc 3126
 Pro Leu Lys Asn Phe Gln Gln Leu Asn Leu Ala Gly Asn Arg Val Ser
 935 940 945 950

agt gat gga tgg ctt gcc ttc atg ggt gta ttt gag aat ctt aag caa 3174
 Ser Asp Gly Trp Leu Ala Phe Met Gly Val Phe Glu Asn Leu Lys Gln
 955 960 965

tta gtg ttt ttt gac ttt agt act aaa gaa ttt cta cct gat cca gca 3222
 Leu Val Phe Phe Asp Phe Ser Thr Lys Glu Phe Leu Pro Asp Pro Ala
 970 975 980

tta gtc aga aaa ctt agc caa gtg tta tcc aag tta act ttt ctg caa 3270
 Leu Val Arg Lys Leu Ser Gln Val Leu Ser Lys Leu Thr Phe Leu Gln
 985 990 995

gaa gct agg ctt gtt ggg tgg caa ttt gat gat gat gat ctc agt gtt 3318
 Glu Ala Arg Leu Val Gly Trp Gln Phe Asp Asp Asp Asp Leu Ser Val
 1000 1005 1010

att aca ggt gct ttt aaa cta gta act gct taaataaagt gtactcgaag 3368
 Ile Thr Gly Ala Phe Lys Leu Val Thr Ala
 1015 1020

ccaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 3396

<210> 97

<211> 1024

<212> PRT

<213> Homo sapien

<400> 97

Met Asn Phe Ile Lys Asp Asn Ser Arg Ala Leu Ile Gln Arg Met Gly
 1 5 10 15
 Met Thr Val Ile Lys Gln Ile Thr Asp Asp Leu Phe Val Trp Asn Val
 20 25 30
 Leu Asn Arg Glu Glu Val Asn Ile Ile Cys Cys Glu Lys Val Glu Gln
 35 40 45
 Asp Ala Ala Arg Gly Ile Ile His Met Ile Leu Lys Lys Gly Ser Glu
 50 55 60
 Ser Cys Asn Leu Phe Leu Lys Ser Leu Lys Glu Trp Asn Tyr Pro Leu
 65 70 75 80

Phe	Gln	Asp	Leu	Asn	Gly	Gln	Ser	Leu	Phe	His	Gln	Thr	Ser	Glu	Gly			
				85					90					95				
Asp	Leu	Asp	Asp	Leu	Ala	Gln	Asp	Leu	Lys	Asp	Leu	Tyr	His	Thr	Pro			
			100					105					110					
Ser	Phe	Leu	Asn	Phe	Tyr	Pro	Leu	Gly	Glu	Asp	Ile	Asp	Ile	Ile	Phe			
			115				120					125						
Asn	Leu	Lys	Ser	Thr	Phe	Thr	Glu	Pro	Ile	Leu	Trp	Arg	Lys	Asp	Gln			
			130				135					140						
His	His	His	Arg	Val	Glu	Gln	Leu	Thr	Leu	Asn	Gly	Leu	Leu	Gln	Ala			
145					150					155					160			
Leu	Gln	Ser	Pro	Cys	Ile	Ile	Glu	Gly	Glu	Ser	Gly	Lys	Gly	Lys	Ser			
				165				170						175				
Thr	Leu	Leu	Gln	Arg	Ile	Ala	Met	Leu	Trp	Gly	Ser	Gly	Lys	Cys	Lys			
			180					185					190					
Ala	Leu	Thr	Lys	Phe	Lys	Phe	Val	Phe	Phe	Leu	Arg	Leu	Ser	Arg	Ala			
			195				200					205						
Gln	Gly	Gly	Leu	Phe	Glu	Thr	Leu	Cys	Asp	Gln	Leu	Leu	Asp	Ile	Pro			
			210				215					220						
Gly	Thr	Ile	Arg	Lys	Gln	Thr	Phe	Met	Ala	Met	Leu	Leu	Lys	Leu	Arg			
225					230					235					240			
Gln	Arg	Val	Leu	Phe	Leu	Leu	Asp	Gly	Tyr	Asn	Glu	Phe	Lys	Pro	Gln			
				245					250					255				
Asn	Cys	Pro	Glu	Ile	Glu	Ala	Leu	Ile	Lys	Glu	Asn	His	Arg	Phe	Lys			
			260					265					270					
Asn	Met	Val	Ile	Val	Thr	Thr	Thr	Thr	Glu	Cys	Leu	Arg	His	Ile	Arg			
			275				280						285					
Gln	Phe	Gly	Ala	Leu	Thr	Ala	Glu	Val	Gly	Asp	Met	Thr	Glu	Asp	Ser			
			290			295					300							
Ala	Gln	Ala	Leu	Ile	Arg	Glu	Val	Leu	Ile	Lys	Glu	Leu	Ala	Glu	Gly			
305					310					315					320			
Leu	Leu	Leu	Gln	Ile	Gln	Lys	Ser	Arg	Cys	Leu	Arg	Asn	Leu	Met	Lys			
				325					330					335				
Thr	Pro	Leu	Phe	Val	Val	Ile	Thr	Cys	Ala	Ile	Gln	Met	Gly	Glu	Ser			
			340					345					350					
Glu	Phe	His	Ser	His	Thr	Gln	Thr	Thr	Leu	Phe	His	Thr	Phe	Tyr	Asp			
			355				360					365						
Leu	Leu	Ile	Gln	Lys	Asn	Lys	His	Lys	His	Lys	Gly	Val	Ala	Ala	Ser			
			370			375					380							
Asp	Phe	Ile	Arg	Ser	Leu	Asp	His	Arg	Gly	Asp	Leu	Ala	Leu	Glu	Gly			
385					390					395					400			
Val	Phe	Ser	His	Lys	Phe	Asp	Phe	Glu	Leu	Gln	Asp	Val	Ser	Ser	Val			
				405				410						415				
Asn	Glu	Asp	Val	Leu	Leu	Thr	Thr	Gly	Leu	Leu	Cys	Lys	Tyr	Thr	Ala			
			420					425					430					
Gln	Arg	Phe	Lys	Pro	Lys	Tyr	Lys	Phe	Phe	His	Lys	Ser	Phe	Gln	Glu			
			435				440					445						
Tyr	Thr	Ala	Gly	Arg	Arg	Leu	Ser	Ser	Leu	Leu	Thr	Ser	His	Glu	Pro			
			450			455					460							
Glu	Glu	Val	Thr	Lys	Gly	Asn	Gly	Tyr	Leu	Gln	Lys	Met	Val	Ser	Ile			
465					470					475					480			
Ser	Asp	Ile	Thr	Ser	Thr	Tyr	Ser	Ser	Leu	Leu	Arg	Tyr	Thr	Cys	Gly			
				485				490					495					
Ser	Ser	Val	Glu	Ala	Thr	Arg	Ala	Val	Met	Lys	His	Leu	Ala	Ala	Val			
			500					505					510					
Tyr	Gln	His	Gly	Cys	Leu	Leu	Gly	Leu	Ser	Ile	Ala	Lys	Arg	Pro	Leu			

		515					520					525					
Trp	Arg	Gln	Glu	Ser	Leu	Gln	Ser	Val	Lys	Asn	Thr	Thr	Glu	Gln	Glu		
	530						535					540					
Ile	Leu	Lys	Ala	Ile	Asn	Ile	Asn	Ser	Phe	Val	Glu	Cys	Gly	Ile	His		
545					550					555					560		
Leu	Tyr	Gln	Glu	Ser	Thr	Ser	Lys	Ser	Ala	Leu	Ser	Gln	Glu	Phe	Glu		
				565					570					575			
Ala	Phe	Phe	Gln	Gly	Lys	Ser	Leu	Tyr	Ile	Asn	Ser	Gly	Asn	Ile	Pro		
			580					585					590				
Asp	Tyr	Leu	Phe	Asp	Phe	Phe	Glu	His	Leu	Pro	Asn	Cys	Ala	Ser	Ala		
	595						600					605					
Leu	Asp	Phe	Ile	Lys	Leu	Asp	Phe	Tyr	Gly	Gly	Ala	Met	Ala	Ser	Trp		
	610						615					620					
Glu	Lys	Ala	Ala	Glu	Asp	Thr	Gly	Gly	Ile	His	Met	Glu	Glu	Ala	Pro		
625					630										640		
Glu	Thr	Tyr	Ile	Pro	Ser	Arg	Ala	Val	Ser	Leu	Phe	Phe	Asn	Trp	Lys		
				645					650					655			
Gln	Glu	Phe	Arg	Thr	Leu	Glu	Val	Thr	Leu	Arg	Asp	Phe	Ser	Lys	Leu		
			660					665					670				
Asn	Lys	Gln	Asp	Ile	Arg	Tyr	Leu	Gly	Lys	Ile	Phe	Ser	Ser	Ala	Thr		
	675						680					685					
Ser	Leu	Arg	Leu	Gln	Ile	Lys	Arg	Cys	Ala	Gly	Val	Ala	Gly	Ser	Leu		
	690						695				700						
Ser	Leu	Val	Leu	Ser	Thr	Cys	Lys	Asn	Ile	Tyr	Ser	Leu	Met	Val	Glu		
705					710					715					720		
Ala	Ser	Pro	Leu	Thr	Ile	Glu	Asp	Glu	Arg	His	Ile	Thr	Ser	Val	Thr		
				725					730					735			
Asn	Leu	Lys	Thr	Leu	Ser	Ile	His	Asp	Leu	Gln	Asn	Gln	Arg	Leu	Pro		
			740					745					750				
Gly	Gly	Leu	Thr	Asp	Ser	Leu	Gly	Asn	Leu	Lys	Asn	Leu	Thr	Lys	Leu		
		755					760					765					
Ile	Met	Asp	Asn	Ile	Lys	Met	Asn	Glu	Glu	Asp	Ala	Ile	Lys	Leu	Ala		
	770					775					780						
Glu	Gly	Leu	Lys	Asn	Leu	Lys	Lys	Met	Cys	Leu	Phe	His	Leu	Thr	His		
785					790					795					800		
Leu	Ser	Asp	Ile	Gly	Glu	Gly	Met	Asp	Tyr	Ile	Val	Lys	Ser	Leu	Ser		
			805						810					815			
Ser	Glu	Pro	Cys	Asp	Leu	Glu	Glu	Ile	Gln	Leu	Val	Ser	Cys	Cys	Leu		
			820					825					830				
Ser	Ala	Asn	Ala	Val	Lys	Ile	Leu	Ala	Gln	Asn	Leu	His	Asn	Leu	Val		
		835					840					845					
Lys	Leu	Ser	Ile	Leu	Asp	Leu	Ser	Glu	Asn	Tyr	Leu	Glu	Lys	Asp	Gly		
	850					855					860						
Asn	Glu	Ala	Leu	His	Glu	Leu	Ile	Asp	Arg	Met	Asn	Val	Leu	Glu	Gln		
865					870					875					880		
Leu	Thr	Ala	Leu	Met	Leu	Pro	Trp	Gly	Cys	Asp	Val	Gln	Gly	Ser	Leu		
				885					890					895			
Ser	Ser	Leu	Leu	Lys	His	Leu	Glu	Glu	Val	Pro	Gln	Leu	Val	Lys	Leu		
			900					905					910				
Gly	Leu	Lys	Asn	Trp	Arg	Leu	Thr	Asp	Thr	Glu	Ile	Arg	Ile	Leu	Gly		
		915					920					925					
Ala	Phe	Phe	Gly	Lys	Asn	Pro	Leu	Lys	Asn	Phe	Gln	Gln	Leu	Asn	Leu		
	930					935					940						
Ala	Gly	Asn	Arg	Val	Ser	Ser	Asp	Gly	Trp	Leu	Ala	Phe	Met	Gly	Val		
945					950					955					960		

<400> 98																	
cgcccggggca	ggtgtttata	ctccggaggg	tgtccccgtg	cgtcatcggt	ggagtggacc	60											
aaaactggtg	atctgtttgc	cctgtgtgac	cttgcccaga	accctgctga	ctgagagaac	120											
acatctgctg	gaagtcctct	gggattcaag	gtacagggaa	tgaagagtag	ttttacagaa	180											
aaaagaggac	aatattggga	tcacctttga	cctttccatt	tggaaataat	attttctatt	240											
gtgttataga	aaggtgggaa	gctttcatcc	agaaca	atg	aat	ttc	ata	aag	gac	294							
				Met	Asn	Phe	Ile	Lys	Asp								
				1				5									
aat	agc	cga	gcc	ctt	att	caa	aga	atg	gga	atg	act	gtt	ata	aag	caa	342	
Asn	Ser	Arg	Ala	Leu	Ile	Gln	Arg	Met	Gly	Met	Thr	Val	Ile	Lys	Gln		
			10					15					20				
atc	aca	gat	gac	cta	ttt	gta	tgg	aat	gtt	ctg	aat	cgc	gaa	gaa	gta	390	
Ile	Thr	Asp	Asp	Leu	Phe	Val	Trp	Asn	Val	Leu	Asn	Arg	Glu	Glu	Val		
			25				30					35					
aac	atc	att	tgc	tgc	gag	aag	gtg	gag	cag	gat	gct	gct	aga	ggg	atc	438	
Asn	Ile	Ile	Cys	Cys	Glu	Lys	Val	Glu	Gln	Asp	Ala	Ala	Arg	Gly	Ile		
			40				45				50						
att	cac	atg	att	ttg	aaa	aag	ggg	tca	gag	tcc	tgt	aac	ctc	ttt	ctt	486	
Ile	His	Met	Ile	Leu	Lys	Lys	Gly	Ser	Glu	Ser	Cys	Asn	Leu	Phe	Leu		
	55				60					65					70		
aaa	tcc	ctt	aag	gag	tgg	aac	tat	cct	cta	ttt	cag	gac	ttg	aat	gga	534	
Lys	Ser	Leu	Lys	Glu	Trp	Asn	Tyr	Pro	Leu	Phe	Gln	Asp	Leu	Asn	Gly		
				75					80					85			
caa	agt	ggg	ctg	act	gac	agc	ttg	ggg	aac	ttg	aag	aac	ctt	aca	aag	582	
Gln	Ser	Gly	Leu	Thr	Asp	Ser	Leu	Gly	Asn	Leu	Lys	Asn	Leu	Thr	Lys		
			90					95					100				
ctc	ata	atg	gat	aac	ata	aag	atg	aat	gaa	gaa	gat	gct	ata	aaa	cta	630	
Leu	Ile	Met	Asp	Asn	Ile	Lys	Met	Asn	Glu	Glu	Asp	Ala	Ile	Lys	Leu		
			105				110					115					

gct gaa ggc ctg aaa aac ctg aag aag atg tgt tta ttt cat ttg acc	678
Ala Glu Gly Leu Lys Asn Leu Lys Lys Met Cys Leu Phe His Leu Thr	
120 125 130	
cac ttg tct gac att gga gag gga atg gat tac ata gtc aag tct ctg	726
His Leu Ser Asp Ile Gly Glu Gly Met Asp Tyr Ile Val Lys Ser Leu	
135 140 145 150	
tca agt gaa ccc tgt gac ctt gaa gaa att caa tta gtc tcc tgc tgc	774
Ser Ser Glu Pro Cys Asp Leu Glu Glu Ile Gln Leu Val Ser Cys Cys	
155 160 165	
ttg tct gca aat gca gtg aaa atc cta gct cag aat ctt cac aat ttg	822
Leu Ser Ala Asn Ala Val Lys Ile Leu Ala Gln Asn Leu His Asn Leu	
170 175 180	
gtc aaa ctg agc att ctt gat tta tca gaa aat tac ctg gaa aaa gat	870
Val Lys Leu Ser Ile Leu Asp Leu Ser Glu Asn Tyr Leu Glu Lys Asp	
185 190 195	
gga aat gaa gct ctt cat gaa ctg atc gac agg atg aac gtg cta gaa	918
Gly Asn Glu Ala Leu His Glu Leu Ile Asp Arg Met Asn Val Leu Glu	
200 205 210	
cag ctc acc gca ctg atg ctg ccc tgg ggc tgt gac gtg caa ggc agc	966
Gln Leu Thr Ala Leu Met Leu Pro Trp Gly Cys Asp Val Gln Gly Ser	
215 220 225 230	
ctg agc agc ctg ttg aaa cat ttg gag gag gtc cca caa ctc gtc aag	1014
Leu Ser Ser Leu Leu Lys His Leu Glu Glu Val Pro Gln Leu Val Lys	
235 240 245	
ctt ggg ttg aaa aac tgg aga ctc aca gat aca gag att aga att tta	1062
Leu Gly Leu Lys Asn Trp Arg Leu Thr Asp Thr Glu Ile Arg Ile Leu	
250 255 260	
ggt gca ttt ttt gga aag aac cct ctg aaa aac ttc cag cag ttg aat	1110
Gly Ala Phe Phe Gly Lys Asn Pro Leu Lys Asn Phe Gln Gln Leu Asn	
265 270 275	
ttg gcg gga aat cgt gtg agc agt gat gga tgg ctt gcc ttc atg ggt	1158
Leu Ala Gly Asn Arg Val Ser Ser Asp Gly Trp Leu Ala Phe Met Gly	
280 285 290	
gta ttt gag aat ctt aag caa tta gtg ttt ttt gac ttt agt act aaa	1206
Val Phe Glu Asn Leu Lys Gln Leu Val Phe Phe Asp Phe Ser Thr Lys	
295 300 305 310	
gaa ttt cta cct gat cca gca tta gtc aga aaa ctt agc caa gtg tta	1254
Glu Phe Leu Pro Asp Pro Ala Leu Val Arg Lys Leu Ser Gln Val Leu	
315 320 325	
tcc aag tta act ttt ctg caa gaa gct agg ctt gtt ggg tgg caa ttt	1302
Ser Lys Leu Thr Phe Leu Gln Glu Ala Arg Leu Val Gly Trp Gln Phe	

WO 01/90156

PCT/US01/17158

330 335 340
 gat gat gat gat ctc agt gtt att aca ggt gct ttt aaa cta gta act 1350
 Asp Asp Asp Asp Leu Ser Val Ile Thr Gly Ala Phe Lys Leu Val Thr
 345 350 355
 gct taaataaagt gtactcgaag caaaaaaaaaa aaaaaaaaaa aa 1395
 Ala

<210> 99
 <211> 359
 <212> PRT
 <213> Homo sapien

<400> 99
 Met Asn Phe Ile Lys Asp Asn Ser Arg Ala Leu Ile Gln Arg Met Gly
 1 5 10 15
 Met Thr Val Ile Lys Gln Ile Thr Asp Asp Leu Phe Val Trp Asn Val
 20 25 30
 Leu Asn Arg Glu Glu Val Asn Ile Ile Cys Cys Glu Lys Val Glu Gln
 35 40 45
 Asp Ala Ala Arg Gly Ile Ile His Met Ile Leu Lys Lys Gly Ser Glu
 50 55 60
 Ser Cys Asn Leu Phe Leu Lys Ser Leu Lys Glu Trp Asn Tyr Pro Leu
 65 70 75 80
 Phe Gln Asp Leu Asn Gly Gln Ser Gly Leu Thr Asp Ser Leu Gly Asn
 85 90 95
 Leu Lys Asn Leu Thr Lys Leu Ile Met Asp Asn Ile Lys Met Asn Glu
 100 105 110
 Glu Asp Ala Ile Lys Leu Ala Glu Gly Leu Lys Asn Leu Lys Lys Met
 115 120 125
 Cys Leu Phe His Leu Thr His Leu Ser Asp Ile Gly Glu Gly Met Asp
 130 135 140
 Tyr Ile Val Lys Ser Leu Ser Ser Glu Pro Cys Asp Leu Glu Glu Ile
 145 150 155 160
 Gln Leu Val Ser Cys Cys Leu Ser Ala Asn Ala Val Lys Ile Leu Ala
 165 170 175
 Gln Asn Leu His Asn Leu Val Lys Leu Ser Ile Leu Asp Leu Ser Glu
 180 185 190
 Asn Tyr Leu Glu Lys Asp Gly Asn Glu Ala Leu His Glu Leu Ile Asp
 195 200 205
 Arg Met Asn Val Leu Glu Gln Leu Thr Ala Leu Met Leu Pro Trp Gly
 210 215 220
 Cys Asp Val Gln Gly Ser Leu Ser Ser Leu Leu Lys His Leu Glu Glu
 225 230 235 240
 Val Pro Gln Leu Val Lys Leu Gly Leu Lys Asn Trp Arg Leu Thr Asp
 245 250 255
 Thr Glu Ile Arg Ile Leu Gly Ala Phe Phe Gly Lys Asn Pro Leu Lys
 260 265 270
 Asn Phe Gln Gln Leu Asn Leu Ala Gly Asn Arg Val Ser Ser Asp Gly
 275 280 285
 Trp Leu Ala Phe Met Gly Val Phe Glu Asn Leu Lys Gln Leu Val Phe
 290 295 300

WO 01/90156

PCT/US01/17158

Phe Asp Phe Ser Thr Lys Glu Phe Leu Pro Asp Pro Ala Leu Val Arg
 305 310 315 320
 Lys Leu Ser Gln Val Leu Ser Lys Leu Thr Phe Leu Gln Glu Ala Arg
 325 330 335
 Leu Val Gly Trp Gln Phe Asp Asp Asp Asp Leu Ser Val Ile Thr Gly
 340 345 350
 Ala Phe Lys Leu Val Thr Ala
 355

<210> 100

<211> 578

<212> DNA

<213> Homo sapien

<220>

<221> CDS

<222> (277)...(552)

<400> 100

cgcccgggca ggtgtttata ctccggaggg tgtccccgtg cgtcatcggg ggagtggacc 60
 aaaactgggtg atctgtttgc cctgtgtgac cttgccccaga accctgctga ctgagagAAC 120
 acatctgctg gaagtcctct gggattcaag gtacagggaa tgaagagtag ttttacagaa 180
 aaaagaggac aatattggga tcacctttga cctttccatt tggaaataat attttctatt 240
 gtgttataga aaggtgggaa gctttcatcc agaaca atg aat ttc ata aag gac 294
 Met Asn Phe Ile Lys Asp
 1 5

aat agc cga gcc ctt att caa aga atg gga atg act gtt ata aag caa 342
 Asn Ser Arg Ala Leu Ile Gln Arg Met Gly Met Thr Val Ile Lys Gln
 10 15 20

atc aca gat gac cta ttt gta tgg aat gtt ctg aat cgc gaa gaa gta 390
 Ile Thr Asp Asp Leu Phe Val Trp Asn Val Leu Asn Arg Glu Glu Val
 25 30 35

aac atc att tgc tgc gag aag gtg gag cag gat gct gct aga ggg atc 438
 Asn Ile Ile Cys Cys Glu Lys Val Glu Gln Asp Ala Ala Arg Gly Ile
 40 45 50

att cac atg att ttg aaa aag ggt tca gag tcc tgt aac ctc ttt ctt 486
 Ile His Met Ile Leu Lys Lys Gly Ser Glu Ser Cys Asn Leu Phe Leu
 55 60 65 70

aaa tcc ctt aag gag tgg aac tat cct cta ttt cag gac ttg aat gga 534
 Lys Ser Leu Lys Glu Trp Asn Tyr Pro Leu Phe Gln Asp Leu Asn Gly
 75 80 85

caa agt ctt tta aca gct tagaaagtac agtagacata ctgggg 578
 Gln Ser Leu Leu Thr Ala
 90

<210> 101

<211> 92

WO 01/90156

PCT/US01/17158

<212> PRT

<213> Homo sapien

<400> 101

Met	Asn	Phe	Ile	Lys	Asp	Asn	Ser	Arg	Ala	Leu	Ile	Gln	Arg	Met	Gly
1				5					10					15	
Met	Thr	Val	Ile	Lys	Gln	Ile	Thr	Asp	Asp	Leu	Phe	Val	Trp	Asn	Val
			20					25					30		
Leu	Asn	Arg	Glu	Glu	Val	Asn	Ile	Ile	Cys	Cys	Glu	Lys	Val	Glu	Gln
		35					40					45			
Asp	Ala	Ala	Arg	Gly	Ile	Ile	His	Met	Ile	Leu	Lys	Lys	Gly	Ser	Glu
	50					55					60				
Ser	Cys	Asn	Leu	Phe	Leu	Lys	Ser	Leu	Lys	Glu	Trp	Asn	Tyr	Pro	Leu
65					70					75					80
Phe	Gln	Asp	Leu	Asn	Gly	Gln	Ser	Leu	Leu	Thr	Ala				
				85					90						

<210> 102

<211> 768

<212> DNA

<213> Homo sapien

<220>

<221> CDS

<222> (277)...(744)

<400> 102

cgcccgggca	ggtgtttata	ctccggaggg	tgtccccgtg	cgatcatcggt	ggagtggacc	60
aaaactggtg	atctgtttgc	cctgtgtgac	cttgcccaga	accctgctga	ctgagagaac	120
acatctgctg	gaagtcctct	gggattcaag	gtacagggaa	tgaagagtag	ttttacagaa	180
aaaagaggac	aatattggga	tcacctttga	cctttccatt	tggaaataat	attttctatt	240
gtgttataga	aaggtgggaa	gctttcatcc	agaaca	atg	aat ttc ata aag gac	294
				Met	Asn Phe Ile Lys Asp	
				1	5	
aat agc cga gcc ctt att caa aga atg gga atg act gtt ata aag caa	342					
Asn Ser Arg Ala Leu Ile Gln Arg Met Gly Met Thr Val Ile Lys Gln						
	10 15 20					
atc aca gat gac cta ttt gta tgg aat gtt ctg aat cgc gaa gaa gta	390					
Ile Thr Asp Asp Leu Phe Val Trp Asn Val Leu Asn Arg Glu Glu Val						
	25 30 35					
aac atc att tgc tgc gag aag gtg gag cag gat gct gct aga ggg atc	438					
Asn Ile Ile Cys Cys Glu Lys Val Glu Gln Asp Ala Ala Arg Gly Ile						
	40 45 50					
att cac atg att ttg aaa aag ggt tca gag tcc tgt aac ctc ttt ctt	486					
Ile His Met Ile Leu Lys Lys Gly Ser Glu Ser Cys Asn Leu Phe Leu						
	55 60 65 70					
aaa tcc ctt aag gag tgg aac tat cct cta ttt cag gac ttg aat gga	534					
Lys Ser Leu Lys Glu Trp Asn Tyr Pro Leu Phe Gln Asp Leu Asn Gly						
	75 80 85					

WO 01/90156

PCT/US01/17158

caa agt ctt ttt cat cag aca tca gaa gga gac ttg gac gat ttg gct 582
 Gln Ser Leu Phe His Gln Thr Ser Glu Gly Asp Leu Asp Asp Leu Ala
 90 95 100

cag gat tta aag gac ttg tac cat acc cca tct ttt ctg aac ttt tat 630
 Gln Asp Leu Lys Asp Leu Tyr His Thr Pro Ser Phe Leu Asn Phe Tyr
 105 110 115

ccc ctt ggt gaa gat att gac att att ttt aac ttg aaa agc acc ttc 678
 Pro Leu Gly Glu Asp Ile Asp Ile Ile Phe Asn Leu Lys Ser Thr Phe
 120 125 130

aca gaa cct gtc ctg tgg agg aag gac caa cac cat cac cgc gtg gag 726
 Thr Glu Pro Val Leu Trp Arg Lys Asp Gln His His His Arg Val Glu
 135 140 145 150

cag ctg acc cta gtt tta tagcatcttc tacctgcccg ggcg 768
 Gln Leu Thr Leu Val Leu
 155

<210> 103

<211> 156

<212> PRT

<213> Homo sapien

<400> 103

Met Asn Phe Ile Lys Asp Asn Ser Arg Ala Leu Ile Gln Arg Met Gly
 1 5 10 15
 Met Thr Val Ile Lys Gln Ile Thr Asp Asp Leu Phe Val Trp Asn Val
 20 25 30
 Leu Asn Arg Glu Glu Val Asn Ile Ile Cys Cys Glu Lys Val Glu Gln
 35 40 45
 Asp Ala Ala Arg Gly Ile Ile His Met Ile Leu Lys Lys Gly Ser Glu
 50 55 60
 Ser Cys Asn Leu Phe Leu Lys Ser Leu Lys Glu Trp Asn Tyr Pro Leu
 65 70 75 80
 Phe Gln Asp Leu Asn Gly Gln Ser Leu Phe His Gln Thr Ser Glu Gly
 85 90 95
 Asp Leu Asp Asp Leu Ala Gln Asp Leu Lys Asp Leu Tyr His Thr Pro
 100 105 110
 Ser Phe Leu Asn Phe Tyr Pro Leu Gly Glu Asp Ile Asp Ile Ile Phe
 115 120 125
 Asn Leu Lys Ser Thr Phe Thr Glu Pro Val Leu Trp Arg Lys Asp Gln
 130 135 140
 His His His Arg Val Glu Gln Leu Thr Leu Val Leu
 145 150 155

<210> 104

<211> 24

<212> DNA

<213> Artificial Sequence

WO 01/90156

PCT/US01/17158

<220>

<223> Primer

<400> 104

aagaagagac ggctgcttat caat

24

<210> 105

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 105

ccacagcagg cctcgaagat gatc

24

<210> 106

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 106

atgatcctcc tgaagaagag

20

<210> 107

<211> 1009

<212> PRT

<213> Homo sapien

<400> 107

Cys	Glu	Met	Cys	Ser	Gln	Glu	Ala	Phe	Gln	Ala	Gln	Arg	Ser	Gln	Leu
1			5					10					15		
Val	Glu	Leu	Leu	Val	Ser	Gly	Ser	Leu	Glu	Gly	Phe	Glu	Ser	Val	Leu
		20					25					30			
Asp	Trp	Leu	Leu	Ser	Trp	Glu	Val	Leu	Ser	Trp	Glu	Asp	Tyr	Glu	Gly
	35					40					45				
Phe	His	Leu	Leu	Gly	Gln	Pro	Leu	Ser	His	Leu	Ala	Arg	Arg	Leu	Leu
	50				55					60					
Asp	Thr	Val	Trp	Asn	Lys	Gly	Thr	Trp	Ala	Cys	Gln	Lys	Leu	Ile	Ala
65				70					75				80		
Ala	Ala	Gln	Glu	Ala	Gln	Ala	Asp	Ser	Gln	Ser	Pro	Lys	Leu	His	Gly
		85						90				95			
Cys	Trp	Asp	Pro	His	Ser	Leu	His	Pro	Ala	Arg	Asp	Leu	Gln	Ser	His
		100						105				110			
Arg	Pro	Ala	Ile	Val	Arg	Arg	Leu	His	Ser	His	Val	Glu	Asn	Met	Leu
	115					120						125			
Asp	Leu	Ala	Trp	Glu	Arg	Gly	Phe	Val	Ser	Gln	Tyr	Glu	Cys	Asp	Glu
	130					135					140				
Ile	Arg	Leu	Pro	Ile	Phe	Thr	Pro	Ser	Gln	Arg	Ala	Arg	Arg	Leu	Leu
145				150					155					160	
Asp	Leu	Ala	Thr	Val	Lys	Ala	Asn	Gly	Leu	Ala	Ala	Phe	Leu	Leu	Gln

WO 01/90156

PCT/US01/17158

				165					170				175			
His	Val	Gln	Glu	Leu	Pro	Val	Pro	Leu	Ala	Leu	Pro	Leu	Glu	Ala	Ala	
			180						185				190			
Thr	Cys	Lys	Lys	Tyr	Met	Ala	Lys	Leu	Arg	Thr	Thr	Val	Ser	Ala	Gln	
		195						200				205				
Ser	Arg	Phe	Leu	Ser	Thr	Tyr	Asp	Gly	Ala	Glu	Thr	Leu	Cys	Leu	Glu	
	210					215					220					
Asp	Ile	Tyr	Thr	Glu	Asn	Val	Leu	Glu	Val	Trp	Ala	Asp	Val	Gly	Met	
225					230					235					240	
Ala	Gly	Pro	Pro	Gln	Lys	Ser	Pro	Ala	Thr	Leu	Gly	Leu	Glu	Glu	Leu	
				245					250						255	
Phe	Ser	Thr	Pro	Gly	His	Leu	Asn	Asp	Asp	Ala	Asp	Thr	Val	Leu	Val	
			260					265					270			
Val	Gly	Glu	Ala	Gly	Ser	Gly	Lys	Ser	Thr	Leu	Leu	Gln	Arg	Leu	His	
	275						280					285				
Leu	Leu	Trp	Ala	Ala	Gly	Gln	Asp	Phe	Gln	Glu	Phe	Leu	Phe	Val	Phe	
	290					295					300					
Pro	Phe	Ser	Cys	Arg	Gln	Leu	Gln	Cys	Met	Ala	Lys	Pro	Leu	Ser	Val	
305					310					315					320	
Arg	Thr	Leu	Leu	Phe	Glu	His	Cys	Cys	Trp	Pro	Asp	Val	Gly	Gln	Glu	
				325					330					335		
Asp	Ile	Phe	Gln	Leu	Leu	Leu	Asp	His	Pro	Asp	Arg	Val	Leu	Leu	Thr	
			340					345					350			
Phe	Asp	Gly	Phe	Asp	Glu	Phe	Lys	Phe	Arg	Phe	Thr	Asp	Arg	Glu	Arg	
	355						360					365				
His	Cys	Ser	Pro	Thr	Asp	Pro	Thr	Ser	Val	Gln	Thr	Leu	Leu	Phe	Asn	
	370					375					380					
Leu	Leu	Gln	Gly	Asn	Leu	Leu	Lys	Asn	Ala	Arg	Lys	Val	Val	Thr	Ser	
385					390					395					400	
Arg	Pro	Ala	Ala	Val	Ser	Ala	Phe	Leu	Arg	Lys	Tyr	Ile	Arg	Thr	Glu	
				405					410					415		
Phe	Asn	Leu	Lys	Gly	Phe	Ser	Glu	Gln	Gly	Ile	Glu	Leu	Tyr	Leu	Arg	
			420					425				430				
Lys	Arg	His	His	Glu	Pro	Gly	Val	Ala	Asp	Arg	Leu	Ile	Arg	Leu	Leu	
	435						440					445				
Gln	Glu	Thr	Ser	Ala	Leu	His	Gly	Leu	Cys	His	Leu	Pro	Val	Phe	Ser	
	450					455					460					
Trp	Met	Val	Ser	Lys	Cys	His	Gln	Glu	Leu	Leu	Leu	Gln	Glu	Gly	Gly	
465					470					475					480	
Ser	Pro	Lys	Thr	Thr	Thr	Asp	Met	Tyr	Leu	Leu	Ile	Leu	Gln	His	Phe	
				485					490					495		
Leu	Leu	His	Ala	Thr	Pro	Pro	Asp	Ser	Ala	Ser	Gln	Gly	Leu	Gly	Pro	
			500					505					510			
Ser	Leu	Leu	Arg	Gly	Arg	Leu	Pro	Thr	Leu	Leu	His	Leu	Gly	Arg	Leu	
	515						520					525				
Ala	Leu	Trp	Gly	Leu	Gly	Met	Cys	Cys	Tyr	Val	Phe	Ser	Ala	Gln	Gln	
	530					535					540					
Leu	Gln	Ala	Ala	Gln	Val	Ser	Pro	Asp	Asp	Ile	Ser	Leu	Gly	Phe	Leu	
545					550					555					560	
Val	Arg	Ala	Lys	Gly	Val	Val	Pro	Gly	Ser	Thr	Ala	Pro	Leu	Glu	Phe	
				565					570					575		
Leu	His	Ile	Thr	Phe	Gln	Cys	Phe	Phe	Ala	Ala	Phe	Tyr	Leu	Ala	Leu	
			580					585					590			
Ser	Ala	Asp	Val	Pro	Pro	Ala	Leu	Leu	Arg	His	Leu	Phe	Asn	Cys	Gly	
	595						600					605				

Arg	Pro	Gly	Asn	Ser	Pro	Met	Ala	Arg	Leu	Leu	Pro	Thr	Met	Cys	Ile
610						615					620				
Gln	Ala	Ser	Glu	Gly	Lys	Asp	Ser	Ser	Val	Ala	Ala	Leu	Leu	Gln	Lys
625					630					635					640
Ala	Glu	Pro	His	Asn	Leu	Gln	Ile	Thr	Ala	Ala	Phe	Leu	Ala	Gly	Leu
				645					650					655	
Leu	Ser	Arg	Glu	His	Trp	Gly	Leu	Leu	Ala	Glu	Cys	Gln	Thr	Ser	Glu
			660					665					670		
Lys	Ala	Leu	Leu	Arg	Arg	Gln	Ala	Cys	Ala	Arg	Trp	Cys	Leu	Ala	Arg
		675					680					685			
Ser	Leu	Arg	Lys	His	Phe	His	Ser	Ile	Pro	Pro	Ala	Ala	Pro	Gly	Glu
690						695					700				
Ala	Lys	Ser	Val	His	Ala	Met	Pro	Gly	Phe	Ile	Trp	Leu	Ile	Arg	Ser
705					710					715					720
Leu	Tyr	Glu	Met	Gln	Glu	Glu	Arg	Leu	Ala	Arg	Lys	Ala	Ala	Arg	Gly
				725					730					735	
Leu	Asn	Val	Gly	His	Leu	Lys	Leu	Thr	Phe	Cys	Ser	Val	Gly	Pro	Thr
			740					745					750		
Glu	Cys	Ala	Ala	Leu	Ala	Phe	Val	Leu	Gln	His	Leu	Arg	Arg	Pro	Val
		755					760					765			
Ala	Leu	Gln	Leu	Asp	Tyr	Asn	Ser	Val	Gly	Asp	Ile	Gly	Val	Glu	Gln
770						775					780				
Leu	Leu	Pro	Cys	Leu	Gly	Val	Cys	Lys	Ala	Leu	Tyr	Leu	Arg	Asp	Asn
785					790					795					800
Asn	Ile	Ser	Asp	Arg	Gly	Ile	Cys	Lys	Leu	Ile	Glu	Cys	Ala	Leu	His
				805					810					815	
Cys	Glu	Gln	Leu	Gln	Lys	Leu	Ala	Leu	Gly	Asn	Asn	Tyr	Ile	Thr	Ala
			820					825					830		
Ala	Gly	Ala	Gln	Val	Leu	Ala	Glu	Gly	Leu	Arg	Gly	Asn	Thr	Ser	Leu
		835					840					845			
Gln	Phe	Leu	Gly	Phe	Trp	Gly	Asn	Arg	Val	Gly	Asp	Glu	Gly	Ala	Gln
850						855					860				
Ala	Leu	Ala	Glu	Ala	Leu	Gly	Asp	His	Gln	Ser	Leu	Arg	Trp	Leu	Ser
865					870					875					880
Leu	Val	Gly	Asn	Asn	Ile	Gly	Ser	Val	Gly	Ala	Gln	Ala	Leu	Ala	Leu
				885					890					895	
Met	Leu	Ala	Lys	Asn	Val	Met	Leu	Glu	Glu	Leu	Cys	Leu	Glu	Glu	Asn
			900					905					910		
His	Leu	Gln	Asp	Glu	Gly	Val	Cys	Ser	Leu	Ala	Glu	Gly	Leu	Lys	Lys
		915					920					925			
Asn	Ser	Ser	Leu	Lys	Ile	Leu	Asn	Ile	Lys	Ile	His	Ala	Ser	Gly	Phe
930						935					940				
Asn	Lys	Leu	Leu	Glu	Ser	Ile	Phe	Cys	Ile	Leu	Leu	Val	Val	Glu	Ala
945					950					955					960
Phe	Phe	Leu	Gln	Lys	Val	Val	Lys	Ile	Leu	Glu	Glu	Met	Val	Val	Ser
				965					970					975	
Trp	Leu	Glu	Val	Arg	Leu	Ser	Asn	Asn	Cys	Ile	Thr	Tyr	Leu	Gly	Ala
			980					985					990		
Glu	Ala	Leu	Leu	Gln	Ala	Leu	Glu	Arg	Asn	Asp	Thr	Ile	Leu	Glu	Val
		995					1000					1005			
Trp															

<210> 108

WO 01/90156

PCT/US01/17158

<400> 108
000

<210> 109

<400> 109
000

<210> 110

<400> 110
000

<210> 111

<400> 111
000

<210> 112

<220>
<221> VARIANT
<222> (1)...(87)
<223> Xaa = Any Amino Acid

<400> 112
000

<210> 113

<400> 113
000

<210> 114

<400> 114
000

<210> 115

<400> 115
000

<210> 116

<400> 116
000

<210> 117

<400> 117
000

<210> 118

WO 01/90156

PCT/US01/17158

<400> 118
000

<210> 119

<400> 119
000

<210> 120

<400> 120
000

<210> 121

<400> 121
000

<210> 122

<400> 122
000

<210> 123

<400> 123
000

<210> 124

<400> 124
000

<210> 125

<400> 125
000

<210> 126

<400> 126
000

<210> 127

<400> 127
000

<210> 128

<400> 128
000

<210> 129

WO 01/90156

PCT/US01/17158

<400> 129
000

<210> 130

<400> 130
000

<210> 131

<400> 131
000

<210> 132

<400> 132
000

<210> 133

<400> 133
000

<210> 134

<400> 134
000

<210> 135

<400> 135
000

<210> 136

<400> 136
000

<210> 137

<400> 137
000

<210> 138

<400> 138
000

<210> 139

<400> 139
000

<210> 140

WO 01/90156

PCT/US01/17158

<400> 140
000

<210> 141

<400> 141
000

<210> 142

<400> 142
000

<210> 143

<400> 143
000

<210> 144

<400> 144
000

<210> 145

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 145

ccagaattca tggccgacaa ggtcctgaag

30

<210> 146

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 146

ccactcgagc taatttccag gtatcggacc

30

<210> 147

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 147

gaagacagtt acctggcaga 20

<210> 148
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> primer

<400> 148
 ttgtattctg aacatggcac c 21

<210> 149
 <211> 36
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> primer

<400> 149
 gatcatcatc caggccgccc gtggtgacag ccctgg 36

<210> 150
 <211> 36
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> primer

<400> 150
 ccagggtgt caccacgggc ggcttgatg atgatc 36

<210> 151
 <211> 26
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> primer

<400> 151
 cggaattcat ggccgacaag gtcctg 26

<210> 152
 <211> 38
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> primer

<400> 152

cgctcgagtt agtcttgcatt attaaggtaa tttccaga 38

<210> 153
 <211> 23
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> primer

<400> 153
 catgtgaatg atccctctag cag 23

<210> 154
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> primer

<400> 154
 gggctcggct atcgtgctct a 21

<210> 155
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> primer

<400> 155
 acgatagccg agcccttatt c 21

<210> 156
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> primer

<400> 156
 gtatggaatg ttctgaatcg c 21

<210> 157
 <211> 33
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> primer

<400> 157

WO 01/90156

PCT/US01/17158

cccgatcca tgaatttcac aaaggacaat agc 33

<210> 158

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 158

cccttcgaac aagtcctgaa atagaggata 30

<210> 159

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 159

ggtggagcag gatgctgcta gagg 24

<210> 160

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 160

cacagtgggc caggctccga atgaagtca 29

<210> 161

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 161

catcatttgc tgcgagaagg tggag 25

<210> 162

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 162

WO 01/90156

PCT/US01/17158

ttaacttgga taacacttgg ctaag

25

<210> 163

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 163

gtaaacatca ttgctgcga gaa

23

<210> 164

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 164

cccgggcagg tagaagatgc tat

23

<210> 165

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 165

aatttcataa aggacaatag ccgag

25

<210> 166

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 166

tgtctactgt actttctaag ctggt

25

<210> 167

<211> 225

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (1)...(225)

WO 01/90156

PCT/US01/17158

<400> 167

gag agt act ccc tca gag atc ata gaa aga gaa aga aaa aag ttg ctt 48
 Glu Ser Thr Pro Ser Glu Ile Ile Glu Arg Glu Arg Lys Lys Leu Leu
 1 5 10 15

gaa atc ctt caa cat gat cct gat tct atc tta gac acg tta act tct 96
 Glu Ile Leu Gln His Asp Pro Asp Ser Ile Leu Asp Thr Leu Thr Ser
 20 25 30

cgg agg ctg att tct gag gaa gag tat gag act ctg gag aat gtt aca 144
 Arg Arg Leu Ile Ser Glu Glu Glu Tyr Glu Thr Leu Glu Asn Val Thr
 35 40 45

gat ctc ctg aag aaa agt cgg aag ctg tta att ttg gta cag aaa aag 192
 Asp Leu Leu Lys Lys Ser Arg Lys Leu Leu Ile Leu Val Gln Lys Lys
 50 55 60

gga gag gcg acc tgt cag cat ttt ctc aag tgt 225
 Gly Glu Ala Thr Cys Gln His Phe Leu Lys Cys
 65 70 75

<210> 168

<211> 75

<212> PRT

<213> Homo sapiens

<400> 168

Glu Ser Thr Pro Ser Glu Ile Ile Glu Arg Glu Arg Lys Lys Leu Leu
 1 5 10 15
 Glu Ile Leu Gln His Asp Pro Asp Ser Ile Leu Asp Thr Leu Thr Ser
 20 25 30
 Arg Arg Leu Ile Ser Glu Glu Glu Tyr Glu Thr Leu Glu Asn Val Thr
 35 40 45
 Asp Leu Leu Lys Lys Ser Arg Lys Leu Leu Ile Leu Val Gln Lys Lys
 50 55 60
 Gly Glu Ala Thr Cys Gln His Phe Leu Lys Cys
 65 70 75

<210> 169

<211> 228

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (1)...(228)

<400> 169

atg tgc tcg cag gag gct ttt cag gca cag agg agc cag ctg gtc gag 48
 Met Cys Ser Gln Glu Ala Phe Gln Ala Gln Arg Ser Gln Leu Val Glu
 1 5 10 15

ctg ctg gtc tca ggg tcc ctg gaa ggc ttc gag agt gtc ctg gac tgg 96

WO 01/90156

PCT/US01/17158

Leu Leu Val Ser Gly Ser Leu Glu Gly Phe Glu Ser Val Leu Asp Trp
 20 25 30

 ctg ctg tcc tgg gag gtc ctc tcc tgg gag gac tac gag ggc ttc cac 144
 Leu Leu Ser Trp Glu Val Leu Ser Trp Glu Asp Tyr Glu Gly Phe His
 35 40 45

 ctc ctg ggc cag cct ctc tcc cac ttg gcc agg cgc ctt ctg gac acc 192
 Leu Leu Gly Gln Pro Leu Ser His Leu Ala Arg Arg Leu Leu Asp Thr
 50 55 60

 gtc tgg aat aag ggt act tgg gcc tgt cag aag ctc 228
 Val Trp Asn Lys Gly Thr Trp Ala Cys Gln Lys Leu
 65 70 75

<210> 170
 <211> 76
 <212> PRT
 <213> Homo sapiens

<400> 170
 Met Cys Ser Gln Glu Ala Phe Gln Ala Gln Arg Ser Gln Leu Val Glu
 1 5 10 15
 Leu Leu Val Ser Gly Ser Leu Glu Gly Phe Glu Ser Val Leu Asp Trp
 20 25 30
 Leu Leu Ser Trp Glu Val Leu Ser Trp Glu Asp Tyr Glu Gly Phe His
 35 40 45
 Leu Leu Gly Gln Pro Leu Ser His Leu Ala Arg Arg Leu Leu Asp Thr
 50 55 60
 Val Trp Asn Lys Gly Thr Trp Ala Cys Gln Lys Leu
 65 70 75

<210> 171
 <211> 243
 <212> DNA
 <213> Homo sapiens

<220>
 <221> CDS
 <222> (1)...(243)

<400> 171
 cca gcc cga gac ctg cag agt cac cgg cca gcc att gtc agg agg ctc 48
 Pro Ala Arg Asp Leu Gln Ser His Arg Pro Ala Ile Val Arg Arg Leu
 1 5 10 15

 cac agc cat gtg gag aac atg ctg gac ctg gca tgg gag cgg ggt ttc 96
 His Ser His Val Glu Asn Met Leu Asp Leu Ala Trp Glu Arg Gly Phe
 20 25 30

 gtc agc cag tat gaa tgt gat gaa atc agg ttg ccg atc ttc aca ccg 144
 Val Ser Gln Tyr Glu Cys Asp Glu Ile Arg Leu Pro Ile Phe Thr Pro
 35 40 45

WO 01/90156

PCT/US01/17158

tcc cag agg gca aga agg ctg ctt gat ctt gcc acg gtg aaa gcg aat 192
 Ser Gln Arg Ala Arg Arg Leu Leu Asp Leu Ala Thr Val Lys Ala Asn
 50 55 60

gga ttg gct gcc ttc ctt cta caa cat gtt cag gaa tta cca gtc cca 240
 Gly Leu Ala Ala Phe Leu Leu Gln His Val Gln Glu Leu Pro Val Pro
 65 70 75 80

ttg 243
 Leu

<210> 172

<211> 81

<212> PRT

<213> Homo sapiens

<400> 172

Pro Ala Arg Asp Leu Gln Ser His Arg Pro Ala Ile Val Arg Arg Leu
 1 5 10 15
 His Ser His Val Glu Asn Met Leu Asp Leu Ala Trp Glu Arg Gly Phe
 20 25 30
 Val Ser Gln Tyr Glu Cys Asp Glu Ile Arg Leu Pro Ile Phe Thr Pro
 35 40 45
 Ser Gln Arg Ala Arg Arg Leu Leu Asp Leu Ala Thr Val Lys Ala Asn
 50 55 60
 Gly Leu Ala Ala Phe Leu Leu Gln His Val Gln Glu Leu Pro Val Pro
 65 70 75 80
 Leu

<210> 173

<211> 888

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (1)...(888)

<400> 173

gac gat gcg gac act gtg ctg gtg gtg ggt gag gcg ggc agt ggc aag 48
 Asp Asp Ala Asp Thr Val Leu Val Val Gly Glu Ala Gly Ser Gly Lys
 1 5 10 15

agc acg ctc ctg cag cgg ctg cac ttg ctg tgg gct gca ggg caa gac 96
 Ser Thr Leu Leu Gln Arg Leu His Leu Leu Trp Ala Ala Gly Gln Asp
 20 25 30

ttc cag gaa ttt ctc ttt gtc ttc cca ttc agc tgc cgg cag ctg cag 144
 Phe Gln Glu Phe Leu Phe Val Phe Pro Phe Ser Cys Arg Gln Leu Gln
 35 40 45

tgc atg gcc aaa cca ctc tct gtg cgg act cta ctc ttt gag cac tgc	192
Cys Met Ala Lys Pro Leu Ser Val Arg Thr Leu Leu Phe Glu His Cys	
50 55 60	
tgt tgg cct gat gtt ggt caa gaa gac atc ttc cag tta ctc ctt gac	240
Cys Trp Pro Asp Val Gly Gln Glu Asp Ile Phe Gln Leu Leu Leu Asp	
65 70 75 80	
cac cct gac cgt gtc ctg tta acc ttt gat ggc ttt gac gag ttc aag	288
His Pro Asp Arg Val Leu Leu Thr Phe Asp Gly Phe Asp Glu Phe Lys	
85 90 95	
ttc agg ttc acg gat cgt gaa cgc cac tgc tcc ccg acc gac ccc acc	336
Phe Arg Phe Thr Asp Arg Glu Arg His Cys Ser Pro Thr Asp Pro Thr	
100 105 110	
tct gtc cag acc ctg ctc ttc aac ctt ctg cag ggc aac ctg ctg aag	384
Ser Val Gln Thr Leu Leu Phe Asn Leu Leu Gln Gly Asn Leu Leu Lys	
115 120 125	
aat gcc cgc aag gtg gtg acc agc cgt ccg gcc gct gtg tcg gcg ttc	432
Asn Ala Arg Lys Val Val Thr Ser Arg Pro Ala Ala Val Ser Ala Phe	
130 135 140	
ctc agg aag tac atc cgc acc gag ttc aac ctc aag ggc ttc tct gaa	480
Leu Arg Lys Tyr Ile Arg Thr Glu Phe Asn Leu Lys Gly Phe Ser Glu	
145 150 155 160	
cag ggc atc gag ctg tac ctg agg aag cgc cat cat gag ccc ggg gtg	528
Gln Gly Ile Glu Leu Tyr Leu Arg Lys Arg His His Glu Pro Gly Val	
165 170 175	
gcg gac cgc ctc atc cgc ctg ctc caa gag acc tca gcc ctg cac ggt	576
Ala Asp Arg Leu Ile Arg Leu Leu Gln Glu Thr Ser Ala Leu His Gly	
180 185 190	
ttg tgc cac ctg cct gtc ttc tca tgg atg gtg tcc aaa tgc cac cag	624
Leu Cys His Leu Pro Val Phe Ser Trp Met Val Ser Lys Cys His Gln	
195 200 205	
gaa ctg ttg ctg cag gag ggg ggg tcc cca aag acc act aca gat atg	672
Glu Leu Leu Leu Gln Glu Gly Gly Ser Pro Lys Thr Thr Thr Asp Met	
210 215 220	
tac ctg ctg att ctg cag cat ttt ctg ctg cat gcc acc ccc cca gac	720
Tyr Leu Leu Ile Leu Gln His Phe Leu Leu His Ala Thr Pro Pro Asp	
225 230 235 240	
tca gct tcc caa ggt ctg gga ccc agt ctt ctt cgg ggc cgc ctc ccc	768
Ser Ala Ser Gln Gly Leu Gly Pro Ser Leu Leu Arg Gly Arg Leu Pro	
245 250 255	
acc ctc ctg cac ctg ggc aga ctg gct ctg tgg ggc ctg ggc atg tgc	816
Thr Leu Leu His Leu Gly Arg Leu Ala Leu Trp Gly Leu Gly Met Cys	

WO 01/90156

PCT/US01/17158

260	265	270	
tgc tac gtg ttc tca gcc cag cag ctc cag gca gca cag gtc agc cct			864
Cys Tyr Val Phe Ser Ala Gln Gln Leu Gln Ala Ala Gln Val Ser Pro			
275	280	285	

gat gac att tct ctt ggc ttc ctg	888
Asp Asp Ile Ser Leu Gly Phe Leu	
290	295

<210> 174

<211> 296

<212> PRT

<213> Homo sapiens

<400> 174

Asp Asp Ala Asp Thr Val Leu Val Val Gly Glu Ala Gly Ser Gly Lys	
1 5 10 15	
Ser Thr Leu Leu Gln Arg Leu His Leu Leu Trp Ala Ala Gly Gln Asp	
20 25 30	
Phe Gln Glu Phe Leu Phe Val Phe Pro Phe Ser Cys Arg Gln Leu Gln	
35 40 45	
Cys Met Ala Lys Pro Leu Ser Val Arg Thr Leu Leu Phe Glu His Cys	
50 55 60	
Cys Trp Pro Asp Val Gly Gln Glu Asp Ile Phe Gln Leu Leu Leu Asp	
65 70 75 80	
His Pro Asp Arg Val Leu Leu Thr Phe Asp Gly Phe Asp Glu Phe Lys	
85 90 95	
Phe Arg Phe Thr Asp Arg Glu Arg His Cys Ser Pro Thr Asp Pro Thr	
100 105 110	
Ser Val Gln Thr Leu Leu Phe Asn Leu Leu Gln Gly Asn Leu Leu Lys	
115 120 125	
Asn Ala Arg Lys Val Val Thr Ser Arg Pro Ala Ala Val Ser Ala Phe	
130 135 140	
Leu Arg Lys Tyr Ile Arg Thr Glu Phe Asn Leu Lys Gly Phe Ser Glu	
145 150 155 160	
Gln Gly Ile Glu Leu Tyr Leu Arg Lys Arg His His Glu Pro Gly Val	
165 170 175	
Ala Asp Arg Leu Ile Arg Leu Leu Gln Glu Thr Ser Ala Leu His Gly	
180 185 190	
Leu Cys His Leu Pro Val Phe Ser Trp Met Val Ser Lys Cys His Gln	
195 200 205	
Glu Leu Leu Leu Gln Glu Gly Gly Ser Pro Lys Thr Thr Thr Asp Met	
210 215 220	
Tyr Leu Leu Ile Leu Gln His Phe Leu Leu His Ala Thr Pro Pro Asp	
225 230 235 240	
Ser Ala Ser Gln Gly Leu Gly Pro Ser Leu Leu Arg Gly Arg Leu Pro	
245 250 255	
Thr Leu Leu His Leu Gly Arg Leu Ala Leu Trp Gly Leu Gly Met Cys	
260 265 270	
Cys Tyr Val Phe Ser Ala Gln Gln Leu Gln Ala Ala Gln Val Ser Pro	
275 280 285	
Asp Asp Ile Ser Leu Gly Phe Leu	
290 295	

WO 01/90156

PCT/US01/17158

<210> 175
 <211> 1209
 <212> DNA
 <213> Homo sapiens

<220>
 <221> CDS
 <222> (1)...(1209)

<400> 175
 gag ccc ggg gtg gcg gac cgc ctc atc cgc ctg ctc caa gag acc tca 48
 Glu Pro Gly Val Ala Asp Arg Leu Ile Arg Leu Leu Gln Glu Thr Ser
 1 5 10 15
 gcc ctg cac ggt ttg tgc cac ctg cct gtc ttc tca tgg atg gtg tcc 96
 Ala Leu His Gly Leu Cys His Leu Pro Val Phe Ser Trp Met Val Ser
 20 25 30
 aaa tgc cac cag gaa ctg ttg ctg cag gag ggg ggg tcc cca aag acc 144
 Lys Cys His Gln Glu Leu Leu Leu Gln Glu Gly Gly Ser Pro Lys Thr
 35 40 45
 act aca gat atg tac ctg ctg att ctg cag cat ttt ctg ctg cat gcc 192
 Thr Thr Asp Met Tyr Leu Leu Ile Leu Gln His Phe Leu Leu His Ala
 50 55 60
 acc ccc cca gac tca gct tcc caa ggt ctg gga ccc agt ctt ctt cgg 240
 Thr Pro Pro Asp Ser Ala Ser Gln Gly Leu Gly Pro Ser Leu Leu Arg
 65 70 75 80
 ggc cgc ctc ccc acc ctc ctg cac ctg ggc aga ctg gct ctg tgg ggc 288
 Gly Arg Leu Pro Thr Leu Leu His Leu Gly Arg Leu Ala Leu Trp Gly
 85 90 95
 ctg ggc atg tgc tgc tac gtg ttc tca gcc cag cag ctc cag gca gca 336
 Leu Gly Met Cys Cys Tyr Val Phe Ser Ala Gln Gln Leu Gln Ala Ala
 100 105 110
 cag gtc agc cct gat gac att tct ctt ggc ttc ctg gtg cgt gcc aaa 384
 Gln Val Ser Pro Asp Asp Ile Ser Leu Gly Phe Leu Val Arg Ala Lys
 115 120 125
 ggt gtc gtg cca ggg agt acg gcg ccc ctg gaa ttc ctt cac atc act 432
 Gly Val Val Pro Gly Ser Thr Ala Pro Leu Glu Phe Leu His Ile Thr
 130 135 140
 ttc cag tgc ttc ttt gcc gcg ttc tac ctg gca ctc agt gct gat gtg 480
 Phe Gln Cys Phe Phe Ala Ala Phe Tyr Leu Ala Leu Ser Ala Asp Val
 145 150 155 160
 cca cca gct ttg ctc aga cac ctc ttc aat tgt ggc agg cca ggc aac 528
 Pro Pro Ala Leu Leu Arg His Leu Phe Asn Cys Gly Arg Pro Gly Asn
 165 170 175

tca cca atg gcc agg ctc ctg ccc acg atg tgc atc cag gcc tcg gag	576
Ser Pro Met Ala Arg Leu Leu Pro Thr Met Cys Ile Gln Ala Ser Glu	
180 185 190	
gga aag gac agc agc gtg gca gct ttg ctg cag aag gcc gag ccg cac	624
Gly Lys Asp Ser Ser Val Ala Ala Leu Leu Gln Lys Ala Glu Pro His	
195 200 205	
aac ctt cag atc aca gca gcc ttc ctg gca ggg ctg ttg tcc cgg gag	672
Asn Leu Gln Ile Thr Ala Ala Phe Leu Ala Gly Leu Leu Ser Arg Glu	
210 215 220	
cac tgg ggc ctg ctg gct gag tgc cag aca tct gag aag gcc ctg ctc	720
His Trp Gly Leu Leu Ala Glu Cys Gln Thr Ser Glu Lys Ala Leu Leu	
225 230 235 240	
cgg cgc cag gcc tgt gcc cgc tgg tgt ctg gcc cgc agc ctc cgc aag	768
Arg Arg Gln Ala Cys Ala Arg Trp Cys Leu Ala Arg Ser Leu Arg Lys	
245 250 255	
cac ttc cac tcc atc ccg cca gct gca ccg ggt gag gcc aag agc gtg	816
His Phe His Ser Ile Pro Pro Ala Ala Pro Gly Glu Ala Lys Ser Val	
260 265 270	
cat gcc atg ccc ggg ttc atc tgg ctc atc cgg agc ctg tac gag atg	864
His Ala Met Pro Gly Phe Ile Trp Leu Ile Arg Ser Leu Tyr Glu Met	
275 280 285	
cag gag gag cgg ctg gct cgg aag gct gca cgt ggc ctg aat gtt ggg	912
Gln Glu Glu Arg Leu Ala Arg Lys Ala Ala Arg Gly Leu Asn Val Gly	
290 295 300	
cac ctc aag ttg aca ttt tgc agt gtg ggc ccc act gag tgt gct gcc	960
His Leu Lys Leu Thr Phe Cys Ser Val Gly Pro Thr Glu Cys Ala Ala	
305 310 315 320	
ctg gcc ttt gtg ctg cag cac ctc cgg cgg ccc gtg gcc ctg cag ctg	1008
Leu Ala Phe Val Leu Gln His Leu Arg Arg Pro Val Ala Leu Gln Leu	
325 330 335	
gac tac aac tct gtg ggt gac att ggc gtg gag cag ctg ctg cct tgc	1056
Asp Tyr Asn Ser Val Gly Asp Ile Gly Val Glu Gln Leu Leu Pro Cys	
340 345 350	
ctt ggt gtc tgc aag gct ctg tat ttg cgc gat aac aat atc tca gac	1104
Leu Gly Val Cys Lys Ala Leu Tyr Leu Arg Asp Asn Asn Ile Ser Asp	
355 360 365	
cga ggc atc tgc aag ctc att gaa tgt gct ctt cac tgc gag caa ttg	1152
Arg Gly Ile Cys Lys Leu Ile Glu Cys Ala Leu His Cys Glu Gln Leu	
370 375 380	
cag aag tta gcg ctg ggg aat aac tac atc act gcc gcg gga gcc caa	1200
Gln Lys Leu Ala Leu Gly Asn Asn Tyr Ile Thr Ala Ala Gly Ala Gln	

WO 01/90156

PCT/US01/17158

385

390

395

400

gtg ctg gcc
Val Leu Ala

1209

<210> 176

<211> 403

<212> PRT

<213> Homo sapiens

<400> 176

Glu	Pro	Gly	Val	Ala	Asp	Arg	Leu	Ile	Arg	Leu	Leu	Gln	Glu	Thr	Ser
1				5					10					15	
Ala	Leu	His	Gly	Leu	Cys	His	Leu	Pro	Val	Phe	Ser	Trp	Met	Val	Ser
			20					25					30		
Lys	Cys	His	Gln	Glu	Leu	Leu	Leu	Gln	Glu	Gly	Gly	Ser	Pro	Lys	Thr
		35					40					45			
Thr	Thr	Asp	Met	Tyr	Leu	Leu	Ile	Leu	Gln	His	Phe	Leu	Leu	His	Ala
	50					55					60				
Thr	Pro	Pro	Asp	Ser	Ala	Ser	Gln	Gly	Leu	Gly	Pro	Ser	Leu	Leu	Arg
65					70					75					80
Gly	Arg	Leu	Pro	Thr	Leu	Leu	His	Leu	Gly	Arg	Leu	Ala	Leu	Trp	Gly
				85					90					95	
Leu	Gly	Met	Cys	Cys	Tyr	Val	Phe	Ser	Ala	Gln	Gln	Leu	Gln	Ala	Ala
			100					105					110		
Gln	Val	Ser	Pro	Asp	Asp	Ile	Ser	Leu	Gly	Phe	Leu	Val	Arg	Ala	Lys
		115					120						125		
Gly	Val	Val	Pro	Gly	Ser	Thr	Ala	Pro	Leu	Glu	Phe	Leu	His	Ile	Thr
	130					135					140				
Phe	Gln	Cys	Phe	Phe	Ala	Ala	Phe	Tyr	Leu	Ala	Leu	Ser	Ala	Asp	Val
145					150					155					160
Pro	Pro	Ala	Leu	Leu	Arg	His	Leu	Phe	Asn	Cys	Gly	Arg	Pro	Gly	Asn
				165					170					175	
Ser	Pro	Met	Ala	Arg	Leu	Leu	Pro	Thr	Met	Cys	Ile	Gln	Ala	Ser	Glu
			180					185					190		
Gly	Lys	Asp	Ser	Ser	Val	Ala	Ala	Leu	Leu	Gln	Lys	Ala	Glu	Pro	His
		195				200						205			
Asn	Leu	Gln	Ile	Thr	Ala	Ala	Phe	Leu	Ala	Gly	Leu	Leu	Ser	Arg	Glu
	210					215					220				
His	Trp	Gly	Leu	Leu	Ala	Glu	Cys	Gln	Thr	Ser	Glu	Lys	Ala	Leu	Leu
225					230					235					240
Arg	Arg	Gln	Ala	Cys	Ala	Arg	Trp	Cys	Leu	Ala	Arg	Ser	Leu	Arg	Lys
				245					250					255	
His	Phe	His	Ser	Ile	Pro	Pro	Ala	Ala	Pro	Gly	Glu	Ala	Lys	Ser	Val
			260					265					270		
His	Ala	Met	Pro	Gly	Phe	Ile	Trp	Leu	Ile	Arg	Ser	Leu	Tyr	Glu	Met
		275					280					285			
Gln	Glu	Glu	Arg	Leu	Ala	Arg	Lys	Ala	Ala	Arg	Gly	Leu	Asn	Val	Gly
	290					295					300				
His	Leu	Lys	Leu	Thr	Phe	Cys	Ser	Val	Gly	Pro	Thr	Glu	Cys	Ala	Ala
305					310					315					320
Leu	Ala	Phe	Val	Leu	Gln	His	Leu	Arg	Arg	Pro	Val	Ala	Leu	Gln	Leu
				325					330					335	

WO 01/90156

PCT/US01/17158

Asp Tyr Asn Ser Val Gly Asp Ile Gly Val Glu Gln Leu Leu Pro Cys
 340 345 350
 Leu Gly Val Cys Lys Ala Leu Tyr Leu Arg Asp Asn Asn Ile Ser Asp
 355 360 365
 Arg Gly Ile Cys Lys Leu Ile Glu Cys Ala Leu His Cys Glu Gln Leu
 370 375 380
 Gln Lys Leu Ala Leu Gly Asn Asn Tyr Ile Thr Ala Ala Gly Ala Gln
 385 390 395 400
 Val Leu Ala

<210> 177
 <211> 261
 <212> DNA
 <213> Homo sapiens

<220>
 <221> CDS
 <222> (1)...(261)

<400> 177
 atg aat ttc ata aag gac aat agc cga gcc ctt att caa aga atg gga 48
 Met Asn Phe Ile Lys Asp Asn Ser Arg Ala Leu Ile Gln Arg Met Gly
 1 5 10 15

 atg act gtt ata aag caa atc aca gat gac cta ttt gta tgg aat gtt 96
 Met Thr Val Ile Lys Gln Ile Thr Asp Asp Leu Phe Val Trp Asn Val
 20 25 30

 ctg aat cgc gaa gaa gta aac atc att tgc tgc gag aag gtg gag cag 144
 Leu Asn Arg Glu Glu Val Asn Ile Ile Cys Cys Glu Lys Val Glu Gln
 35 40 45

 gat gct gct aga ggg atc att cac atg att ttg aaa aag ggt tca gag 192
 Asp Ala Ala Arg Gly Ile Ile His Met Ile Leu Lys Lys Gly Ser Glu
 50 55 60

 tcc tgt aac ctc ttt ctt aaa tcc ctt aag gag tgg aac tat cct cta 240
 Ser Cys Asn Leu Phe Leu Lys Ser Leu Lys Glu Trp Asn Tyr Pro Leu
 65 70 75 80

 ttt cag gac ttg aat gga caa 261
 Phe Gln Asp Leu Asn Gly Gln
 85

<210> 178
 <211> 87
 <212> PRT
 <213> Homo sapiens

<400> 178
 Met Asn Phe Ile Lys Asp Asn Ser Arg Ala Leu Ile Gln Arg Met Gly
 1 5 10 15

WO 01/90156

PCT/US01/17158

```

Met Thr Val Ile Lys Gln Ile Thr Asp Asp Leu Phe Val Trp Asn Val
      20              25              30
Leu Asn Arg Glu Glu Val Asn Ile Ile Cys Cys Glu Lys Val Glu Gln
      35              40              45
Asp Ala Ala Arg Gly Ile Ile His Met Ile Leu Lys Lys Gly Ser Glu
      50              55              60
Ser Cys Asn Leu Phe Leu Lys Ser Leu Lys Glu Trp Asn Tyr Pro Leu
65              70              75              80
Phe Gln Asp Leu Asn Gly Gln
      85

```

<210> 179

<211> 891

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (1) ... (891)

<400> 179

```

ctt cag agc ccc tgc atc att gaa ggg gaa tct ggc aaa ggc aag tcc 48
Leu Gln Ser Pro Cys Ile Ile Glu Gly Glu Ser Gly Lys Gly Lys Ser
 1              5              10              15

act ctg ctg cag cgc att gcc atg ctc tgg ggc tcc gga aag tgc aag 96
Thr Leu Leu Gln Arg Ile Ala Met Leu Trp Gly Ser Gly Lys Cys Lys
      20              25              30

gct ctg acc aag ttc aaa ttc gtc ttc ttc ctc cgt ctc agc agg gcc 144
Ala Leu Thr Lys Phe Lys Phe Val Phe Phe Leu Arg Leu Ser Arg Ala
      35              40              45

cag ggt gga ctt ttt gaa acc ctc tgt gat caa ctc ctg gat ata cct 192
Gln Gly Gly Leu Phe Glu Thr Leu Cys Asp Gln Leu Leu Asp Ile Pro
      50              55              60

ggc aca atc agg aag cag aca ttc atg gcc atg ctg ctg aag ctg cgg 240
Gly Thr Ile Arg Lys Gln Thr Phe Met Ala Met Leu Leu Lys Leu Arg
65              70              75              80

cag agg gtt ctt ttc ctt ctt gat ggc tac aat gaa ttc aag ccc cag 288
Gln Arg Val Leu Phe Leu Leu Asp Gly Tyr Asn Glu Phe Lys Pro Gln
      85              90              95

aac tgc cca gaa atc gaa gcc ctg ata aag gaa aac cac cgc ttc aag 336
Asn Cys Pro Glu Ile Glu Ala Leu Ile Lys Glu Asn His Arg Phe Lys
      100              105              110

aac atg gtc atc gtc acc act acc act gag tgc ctg agg cac ata cgg 384
Asn Met Val Ile Val Thr Thr Thr Thr Glu Cys Leu Arg His Ile Arg
      115              120              125

cag ttt ggt gcc ctg act gct gag gtg ggg gat atg aca gaa gac agc 432

```

Gln	Phe	Gly	Ala	Leu	Thr	Ala	Glu	Val	Gly	Asp	Met	Thr	Glu	Asp	Ser		
130						135					140						
gcc	cag	gct	ctc	atc	cga	gaa	gtg	ctg	atc	aag	gag	ctt	gct	gaa	ggc	480	
Ala	Gln	Ala	Leu	Ile	Arg	Glu	Val	Leu	Ile	Lys	Glu	Leu	Ala	Glu	Gly		
145					150					155					160		
ttg	ttg	ctc	caa	att	cag	aaa	tcc	agg	tgc	ttg	agg	aat	ctc	atg	aag	528	
Leu	Leu	Leu	Gln	Ile	Gln	Lys	Ser	Arg	Cys	Leu	Arg	Asn	Leu	Met	Lys		
				165					170					175			
acc	cct	ctc	ttt	gtg	gtc	atc	act	tgt	gca	atc	cag	atg	ggc	gaa	agt	576	
Thr	Pro	Leu	Phe	Val	Val	Ile	Thr	Cys	Ala	Ile	Gln	Met	Gly	Glu	Ser		
			180					185					190				
gag	ttc	cac	tct	cac	aca	caa	aca	acg	ctg	ttc	cat	acc	ttc	tat	gat	624	
Glu	Phe	His	Ser	His	Thr	Gln	Thr	Thr	Leu	Phe	His	Thr	Phe	Tyr	Asp		
		195					200					205					
ctg	ttg	ata	cag	aaa	aac	aaa	cac	aaa	cat	aaa	ggc	gtg	gct	gca	agt	672	
Leu	Leu	Ile	Gln	Lys	Asn	Lys	His	Lys	His	Lys	Gly	Val	Ala	Ala	Ser		
	210					215					220						
gac	ttc	att	cgg	agc	ctg	gac	cac	cgt	gga	gac	cta	gct	ctg	gag	ggc	720	
Asp	Phe	Ile	Arg	Ser	Leu	Asp	His	Arg	Gly	Asp	Leu	Ala	Leu	Glu	Gly		
225					230					235					240		
gtg	ttc	tcc	cac	aag	ttt	gat	ttc	gaa	ctg	cag	gat	gtg	tcc	agc	gtg	768	
Val	Phe	Ser	His	Lys	Phe	Asp	Phe	Glu	Leu	Gln	Asp	Val	Ser	Ser	Val		
				245					250					255			
aat	gag	gat	gtc	ctg	ctg	aca	act	ggg	ctc	ctc	tgt	aaa	tat	aca	gct	816	
Asn	Glu	Asp	Val	Leu	Leu	Thr	Thr	Gly	Leu	Leu	Cys	Lys	Tyr	Thr	Ala		
			260					265					270				
caa	agg	ttc	aag	cca	aag	tat	aaa	ttc	ttt	cac	aag	tca	ttc	cag	gag	864	
Gln	Arg	Phe	Lys	Pro	Lys	Tyr	Lys	Phe	Phe	His	Lys	Ser	Phe	Gln	Glu		
		275					280					285					
tac	aca	gca	gga	cga	aga	ctc	agc	agt								891	
Tyr	Thr	Ala	Gly	Arg	Arg	Leu	Ser	Ser									
	290					295											

<210> 180

<211> 297

<212> PRT

<213> Homo sapiens

<400> 180

Leu	Gln	Ser	Pro	Cys	Ile	Ile	Glu	Gly	Glu	Ser	Gly	Lys	Gly	Lys	Ser		
1				5					10					15			
Thr	Leu	Leu	Gln	Arg	Ile	Ala	Met	Leu	Trp	Gly	Ser	Gly	Lys	Cys	Lys		
			20					25					30				
Ala	Leu	Thr	Lys	Phe	Lys	Phe	Val	Phe	Phe	Leu	Arg	Leu	Ser	Arg	Ala		

<400> 181																
ggt	aac	ttg	aag	aac	ctt	aca	aag	ctc	ata	atg	gat	aac	ata	aag	atg	48
Gly	Asn	Leu	Lys	Asn	Leu	Thr	Lys	Leu	Ile	Met	Asp	Asn	Ile	Lys	Met	
1				5					10					15		
aat	gaa	gaa	gat	gct	ata	aaa	cta	gct	gaa	ggc	ctg	aaa	aac	ctg	aag	96
Asn	Glu	Glu	Asp	Ala	Ile	Lys	Leu	Ala	Glu	Gly	Leu	Lys	Asn	Leu	Lys	
			20					25					30			
aag	atg	tgt	tta	ttt	cat	ttg	acc	cac	ttg	tct	gac	att	gga	gag	gga	144
Lys	Met	Cys	Leu	Phe	His	Leu	Thr	His	Leu	Ser	Asp	Ile	Gly	Glu	Gly	

35	40	45	
atg gat tac ata gtc aag tct ctg tca agt gaa ccc tgt gac ctt gaa			192
Met Asp Tyr Ile Val Lys Ser Leu Ser Ser Glu Pro Cys Asp Leu Glu			
50	55	60	
gaa att caa tta gtc tcc tgc tgc ttg tct gca aat gca gtg aaa atc			240
Glu Ile Gln Leu Val Ser Cys Cys Leu Ser Ala Asn Ala Val Lys Ile			
65	70	75	80
cta gct cag aat ctt cac aat ttg gtc aaa ctg agc att ctt gat tta			288
Leu Ala Gln Asn Leu His Asn Leu Val Lys Leu Ser Ile Leu Asp Leu			
	85	90	95
tca gaa aat tac ctg gaa aaa gat gga aat gaa gct ctt cat gaa ctg			336
Ser Glu Asn Tyr Leu Glu Lys Asp Gly Asn Glu Ala Leu His Glu Leu			
	100	105	110
atc gac agg atg aac gtg cta gaa cag ctc acc gca ctg atg ctg ccc			384
Ile Asp Arg Met Asn Val Leu Glu Gln Leu Thr Ala Leu Met Leu Pro			
	115	120	125
tgg ggc tgt gac gtg caa ggc agc ctg agc agc ctg ttg aaa cat ttg			432
Trp Gly Cys Asp Val Gln Gly Ser Leu Ser Ser Leu Leu Lys His Leu			
	130	135	140
gag gag gtc cca caa ctc gtc aag ctt ggg ttg aaa aac tgg aga ctc			480
Glu Glu Val Pro Gln Leu Val Lys Leu Gly Leu Lys Asn Trp Arg Leu			
	145	150	155
aca gat aca gag att aga att tta ggt gca ttt ttt gga aag aac cct			528
Thr Asp Thr Glu Ile Arg Ile Leu Gly Ala Phe Phe Gly Lys Asn Pro			
	165	170	175
ctg aaa aac ttc cag cag ttg aat ttg gcg gga aat cgt gtg agc agt			576
Leu Lys Asn Phe Gln Gln Leu Asn Leu Ala Gly Asn Arg Val Ser Ser			
	180	185	190
gat gga tgg ctt gcc ttc atg ggt gta ttt gag aat ctt aag			618
Asp Gly Trp Leu Ala Phe Met Gly Val Phe Glu Asn Leu Lys			
	195	200	205

<210> 182

<211> 206

<212> PRT

<213> Homo sapiens

<400> 182

Gly Asn Leu Lys Asn Leu Thr Lys Leu Ile Met Asp Asn Ile Lys Met	
1 5 10 15	
Asn Glu Glu Asp Ala Ile Lys Leu Ala Glu Gly Leu Lys Asn Leu Lys	
20 25 30	
Lys Met Cys Leu Phe His Leu Thr His Leu Ser Asp Ile Gly Glu Gly	

```
<210> 184
<211> 55
<212> PRT
<213> Homo sapiens
```

WO 01/90156

PCT/US01/17158

<400> 184

Thr	Tyr	Ile	Pro	Ser	Arg	Ala	Val	Ser	Leu	Phe	Phe	Asn	Trp	Lys	Gln
1				5					10					15	
Glu	Phe	Arg	Thr	Leu	Glu	Val	Thr	Leu	Arg	Asp	Phe	Ser	Lys	Leu	Asn
			20					25					30		
Lys	Gln	Asp	Ile	Arg	Tyr	Leu	Gly	Lys	Ile	Phe	Ser	Ser	Ala	Thr	Ser
		35					40					45			
Leu	Arg	Leu	Gln	Ile	Lys	Arg									
	50					55									

<210> 185

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 185

gaaatgtgct cgcaggagg

19

<210> 186

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 186

gatgagcttc tgacaggccc

20

<210> 187

<211> 3063

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (1)...(2385)

<221> CDS

<222> (2389)...(2928)

<400> 187

tgt	gaa	atg	tgc	tcg	cag	gag	gct	ttt	cag	gca	cag	agg	agc	cag	ctg	48
Cys	Glu	Met	Cys	Ser	Gln	Glu	Ala	Phe	Gln	Ala	Gln	Arg	Ser	Gln	Leu	
1				5					10					15		

gtc	gag	ctg	ctg	gtc	tca	ggg	tcc	ctg	gaa	ggc	ttc	gag	agt	gtc	ctg	96
Val	Glu	Leu	Leu	Val	Ser	Gly	Ser	Leu	Glu	Gly	Phe	Glu	Ser	Val	Leu	
			20					25					30			

gac	tgg	ctg	ctg	tcc	tgg	gag	gtc	ctc	tcc	tgg	gag	gac	tac	gag	ggc	144
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

Asp	Trp	Leu	Leu	Ser	Trp	Glu	Val	Leu	Ser	Trp	Glu	Asp	Tyr	Glu	Gly	
		35					40					45				
ttc	cac	ctc	ctg	ggc	cag	cct	ctc	tcc	cac	ttg	gcc	agg	cgc	ctt	ctg	192
Phe	His	Leu	Leu	Gly	Gln	Pro	Leu	Ser	His	Leu	Ala	Arg	Arg	Leu	Leu	
		50				55					60					
gac	acc	gtc	tgg	aat	aag	ggc	act	tgg	gcc	tgt	cag	aag	ctc	atc	gcg	240
Asp	Thr	Val	Trp	Asn	Lys	Gly	Thr	Trp	Ala	Cys	Gln	Lys	Leu	Ile	Ala	
		65			70					75					80	
gct	gcc	caa	gaa	gcc	cag	gcc	gac	agc	cag	tcc	ccc	aag	ctg	cat	ggc	288
Ala	Ala	Gln	Glu	Ala	Gln	Ala	Asp	Ser	Gln	Ser	Pro	Lys	Leu	His	Gly	
				85				90						95		
tgc	tgg	gac	ccc	cac	tcg	ctc	cac	cca	gcc	cga	gac	ctg	cag	agt	cac	336
Cys	Trp	Asp	Pro	His	Ser	Leu	His	Pro	Ala	Arg	Asp	Leu	Gln	Ser	His	
			100					105					110			
cgg	cca	gcc	att	gtc	agg	agg	ctc	cac	agc	cat	gtg	gag	aac	atg	ctg	384
Arg	Pro	Ala	Ile	Val	Arg	Arg	Leu	His	Ser	His	Val	Glu	Asn	Met	Leu	
		115					120					125				
gac	ctg	gca	tgg	gag	cgg	ggc	ttc	gtc	agc	cag	tat	gaa	tgt	gat	gaa	432
Asp	Leu	Ala	Trp	Glu	Arg	Gly	Phe	Val	Ser	Gln	Tyr	Glu	Cys	Asp	Glu	
	130					135					140					
atc	agg	ttg	ccg	atc	ttc	aca	ccg	tcc	cag	agg	gca	aga	agg	ctg	ctt	480
Ile	Arg	Leu	Pro	Ile	Phe	Thr	Pro	Ser	Gln	Arg	Ala	Arg	Arg	Leu	Leu	
	145				150				155						160	
gat	ctt	gcc	acg	gtg	aaa	gcg	aat	gga	ttg	gct	gcc	ttc	ctt	cta	caa	528
Asp	Leu	Ala	Thr	Val	Lys	Ala	Asn	Gly	Leu	Ala	Ala	Phe	Leu	Leu	Gln	
				165				170						175		
cat	gtt	cag	gaa	tta	cca	gtc	cca	ttg	gcc	ctg	cct	ttg	gaa	gct	gcc	576
His	Val	Gln	Glu	Leu	Pro	Val	Pro	Leu	Ala	Leu	Pro	Leu	Glu	Ala	Ala	
			180					185					190			
aca	tgc	aag	aag	tat	atg	gcc	aag	ctg	agg	acc	acg	gtg	tct	gct	cag	624
Thr	Cys	Lys	Lys	Tyr	Met	Ala	Lys	Leu	Arg	Thr	Thr	Val	Ser	Ala	Gln	
		195					200					205				
tct	cgc	ttc	ctc	agt	acc	tat	gat	gga	gca	gag	acg	ctc	tgc	ctg	gag	672
Ser	Arg	Phe	Leu	Ser	Thr	Tyr	Asp	Gly	Ala	Glu	Thr	Leu	Cys	Leu	Glu	
	210					215					220					
gac	ata	tac	aca	gag	aat	gtc	ctg	gag	gtc	tgg	gca	gat	gtg	ggc	atg	720
Asp	Ile	Tyr	Thr	Glu	Asn	Val	Leu	Glu	Val	Trp	Ala	Asp	Val	Gly	Met	
	225				230					235					240	
gct	gga	ccc	ccg	cag	aag	agc	cca	gcc	acc	ctg	ggc	ctg	gag	gag	ctc	768
Ala	Gly	Pro	Pro	Gln	Lys	Ser	Pro	Ala	Thr	Leu	Gly	Leu	Glu	Glu	Leu	
				245				250						255		

WO 01/90156

PCT/US01/17158

ttc agc acc cct ggc cac ctc aat gac gat gcg gac act gtg ctg gtg	816
Phe Ser Thr Pro Gly His Leu Asn Asp Asp Ala Asp Thr Val Leu Val	
260 265 270	
gtg ggt gag gcg ggc agt ggc aag agc acg ctc ctg cag cgg ctg cac	864
Val Gly Glu Ala Gly Ser Gly Lys Ser Thr Leu Leu Gln Arg Leu His	
275 280 285	
ttg ctg tgg gct gca ggg caa gac ttc cag gaa ttt ctc ttt gtc ttc	912
Leu Leu Trp Ala Ala Gly Gln Asp Phe Gln Glu Phe Leu Phe Val Phe	
290 295 300	
cca ttc agc tgc cgg cag ctg cag tgc atg gcc aaa cca ctc tct gtg	960
Pro Phe Ser Cys Arg Gln Leu Gln Cys Met Ala Lys Pro Leu Ser Val	
305 310 315 320	
cgg act cta ctc ttt gag cac tgc tgt tgg cct gat gtt ggt caa gaa	1008
Arg Thr Leu Leu Phe Glu His Cys Cys Trp Pro Asp Val Gly Gln Glu	
325 330 335	
gac atc ttc cag tta ctc ctt gac cac cct gac cgt gtc ctg tta acc	1056
Asp Ile Phe Gln Leu Leu Leu Asp His Pro Asp Arg Val Leu Leu Thr	
340 345 350	
ttt gat ggc ttt gac gag ttc aag ttc agg ttc acg gat cgt gaa cgc	1104
Phe Asp Gly Phe Asp Glu Phe Lys Phe Arg Phe Thr Asp Arg Glu Arg	
355 360 365	
cac tgc tcc ccg acc gac ccc acc tct gtc cag acc ctg ctc ttc aac	1152
His Cys Ser Pro Thr Asp Pro Thr Ser Val Gln Thr Leu Leu Phe Asn	
370 375 380	
ctt ctg cag ggc aac ctg ctg aag aat gcc cgc aag gtg gtg acc agc	1200
Leu Leu Gln Gly Asn Leu Leu Lys Asn Ala Arg Lys Val Val Thr Ser	
385 390 395 400	
cgt ccg gcc gct gtg tcg gcg ttc ctc agg aag tac atc cgc acc gag	1248
Arg Pro Ala Ala Val Ser Ala Phe Leu Arg Lys Tyr Ile Arg Thr Glu	
405 410 415	
ttc aac ctc aag ggc ttc tct gaa cag ggc atc gag ctg tac ctg agg	1296
Phe Asn Leu Lys Gly Phe Ser Glu Gln Gly Ile Glu Leu Tyr Leu Arg	
420 425 430	
aag cgc cat cat gag ccc ggg gtg gcg gac cgc ctc atc cgc ctg ctc	1344
Lys Arg His His Glu Pro Gly Val Ala Asp Arg Leu Ile Arg Leu Leu	
435 440 445	
caa gag acc tca gcc ctg cac ggt ttg tgc cac ctg cct gtc ttc tca	1392
Gln Glu Thr Ser Ala Leu His Gly Leu Cys His Leu Pro Val Phe Ser	
450 455 460	
tgg atg gtg tcc aaa tgc cac cag gaa ctg ttg ctg cag gag ggg ggg	1440
Trp Met Val Ser Lys Cys His Gln Glu Leu Leu Leu Gln Glu Gly Gly	
465 470 475 480	

tcc cca aag acc act aca gat atg tac ctg ctg att ctg cag cat ttt	1488
Ser Pro Lys Thr Thr Thr Asp Met Tyr Leu Leu Ile Leu Gln His Phe	
485 490 495	
ctg ctg cat gcc acc ccc cca gac tca gct tcc caa ggt ctg gga ccc	1536
Leu Leu His Ala Thr Pro Pro Asp Ser Ala Ser Gln Gly Leu Gly Pro	
500 505 510	
agt ctt ctt cgg ggc cgc ctc ccc acc ctc ctg cac ctg ggc aga ctg	1584
Ser Leu Leu Arg Gly Arg Leu Pro Thr Leu Leu His Leu Gly Arg Leu	
515 520 525	
gct ctg tgg ggc ctg ggc atg tgc tgc tac gtg ttc tca gcc cag cag	1632
Ala Leu Trp Gly Leu Gly Met Cys Cys Tyr Val Phe Ser Ala Gln Gln	
530 535 540	
ctc cag gca gca cag gtc agc cct gat gac att tct ctt ggc ttc ctg	1680
Leu Gln Ala Ala Gln Val Ser Pro Asp Asp Ile Ser Leu Gly Phe Leu	
545 550 555 560	
gtg cgt gcc aaa ggt gtc gtg cca ggg agt acg gcg ccc ctg gaa ttc	1728
Val Arg Ala Lys Gly Val Val Pro Gly Ser Thr Ala Pro Leu Glu Phe	
565 570 575	
ctt cac atc act ttc cag tgc ttc ttt gcc gcg ttc tac ctg gca ctc	1776
Leu His Ile Thr Phe Gln Cys Phe Phe Ala Ala Phe Tyr Leu Ala Leu	
580 585 590	
agt gct gat gtg cca cca gct ttg ctc aga cac ctc ttc aat tgt ggc	1824
Ser Ala Asp Val Pro Pro Ala Leu Leu Arg His Leu Phe Asn Cys Gly	
595 600 605	
agg cca ggc aac tca cca atg gcc agg ctc ctg ccc acg atg tgc atc	1872
Arg Pro Gly Asn Ser Pro Met Ala Arg Leu Leu Pro Thr Met Cys Ile	
610 615 620	
cag gcc tcg gag gga aag gac agc agc gtg gca gct ttg ctg cag aag	1920
Gln Ala Ser Glu Gly Lys Asp Ser Ser Val Ala Ala Leu Leu Gln Lys	
625 630 635 640	
gcc gag ccg cac aac ctt cag atc aca gca gcc ttc ctg gca ggg ctg	1968
Ala Glu Pro His Asn Leu Gln Ile Thr Ala Ala Phe Leu Ala Gly Leu	
645 650 655	
ttg tcc cgg gag cac tgg ggc ctg ctg gct gag tgc cag aca tct gag	2016
Leu Ser Arg Glu His Trp Gly Leu Leu Ala Glu Cys Gln Thr Ser Glu	
660 665 670	
aag gcc ctg ctc cgg cgc cag gcc tgt gcc cgc tgg tgt ctg gcc cgc	2064
Lys Ala Leu Leu Arg Arg Gln Ala Cys Ala Arg Trp Cys Leu Ala Arg	
675 680 685	
agc ctc cgc aag cac ttc cac tcc atc ccg cca gct gca ccg ggt gag	2112
Ser Leu Arg Lys His Phe His Ser Ile Pro Pro Ala Ala Pro Gly Glu	

690	695	700	
gcc aag agc gtg cat	gcc atg ccc ggg ttc atc	tgg ctc atc cgg agc	2160
Ala Lys Ser Val His	Ala Met Pro Gly Phe Ile	Trp Leu Ile Arg Ser	
705	710	715 720	
ctg tac gag atg cag	gag gag cgg ctg gct cgg	aag gct gca cgt ggc	2208
Leu Tyr Glu Met Gln	Glu Glu Arg Leu Ala Arg	Lys Ala Ala Arg Gly	
	725	730 735	
ctg aat gtt ggg cac ctc	aag ttg aca ttt tgc agt	gtg ggc ccc act	2256
Leu Asn Val Gly His	Leu Lys Leu Thr Phe Cys	Ser Val Gly Pro Thr	
	740	745 750	
gag tgt gct gcc ctg	gcc ttt gtg ctg cag cac	ctc cgg cgg ccc gtg	2304
Glu Cys Ala Ala Leu	Ala Phe Val Leu Gln His	Leu Arg Arg Pro Val	
	755	760 765	
gcc ctg cag ctg gac	tac aac tct gtg ggt gac	att ggc gtg gag cag	2352
Ala Leu Gln Leu Asp	Tyr Asn Ser Val Gly Asp	Ile Gly Val Glu Gln	
	770	775 780	
ctg ctg cct tgc ctt	ggg gtc tgc aag gct ctg	taa ttc tgg ggc aac	2400
Leu Leu Pro Cys Leu	Gly Val Cys Lys Ala Leu	Phe Trp Gly Asn	
	785	790 795	
aga gtg ggt gac gag	ggg gcc cag gcc ctg	gct gaa gcc ttg ggt gat	2448
Arg Val Gly Asp Glu	Gly Ala Gln Ala Leu Ala	Glu Ala Leu Gly Asp	
	800	805 810 815	
cac cag agc ttg agg	tgg ctc agc ctg gtg	ggg aac aac att ggc agt	2496
His Gln Ser Leu Arg	Trp Leu Ser Leu Val Gly	Asn Asn Ile Gly Ser	
	820	825 830	
gtg ggt gcc caa gcc	ttg gca ctg atg ctg	gca aag aac gtc atg cta	2544
Val Gly Ala Gln Ala	Leu Ala Leu Met Leu Ala	Lys Asn Val Met Leu	
	835	840 845	
gaa gaa ctc tgc ctg	gag gag aac cat ctc	cag gat gaa ggt gta tgt	2592
Glu Glu Leu Cys Leu	Glu Glu Asn His Leu Gln	Asp Glu Gly Val Cys	
	850	855 860	
tct ctc gca gaa gga	ctg aag aaa aat tca	agt ttg aaa atc ctg aac	2640
Ser Leu Ala Glu Gly	Leu Lys Lys Asn Ser Ser	Leu Lys Ile Leu Asn	
	865	870 875	
ata aaa att cat gct	tgc gga ttc aac aaa	ctc ttg gaa agc att ttc	2688
Ile Lys Ile His Ala	Ser Gly Phe Asn Lys Leu	Leu Glu Ser Ile Phe	
	880	885 890 895	
tgc atc ctc ctg gtt	gtg gaa gca ttt ttc	ctg cag aaa gtt gtc aag	2736
Cys Ile Leu Leu Val	Val Glu Ala Phe Phe	Leu Gln Lys Val Val Lys	
	900	905 910	
att ctt gaa gaa atg	gta gtc agt tgg cta	gag gtc agg ttg tcc aat	2784

WO 01/90156

PCT/US01/17158

Ile Leu Glu Glu Met Val Val Ser Trp Leu Glu Val Arg Leu Ser Asn
 915 920 925

aac tgc atc acc tac cta ggg gca gaa gcc ctc ctg cag gcc ctt gaa 2832
 Asn Cys Ile Thr Tyr Leu Gly Ala Glu Ala Leu Leu Gln Ala Leu Glu
 930 935 940

agg aat gac acc atc ctg gaa gtc tgg ctc cga ggg aac act ttc tct 2880
 Arg Asn Asp Thr Ile Leu Glu Val Trp Leu Arg Gly Asn Thr Phe Ser
 945 950 955

cta gag gag gtt gac aag ctc ggc tgc agg gac acc aga ctc ttg ctt 2928
 Leu Glu Glu Val Asp Lys Leu Gly Cys Arg Asp Thr Arg Leu Leu Leu
 960 965 970 975

tgaagtctcc gggaggatgt tcgtctcagt ttgtttgtga gcaggctgtg agtttggggcc 2988
 ccagaggctg ggtgacatgt gttggcagcc tcttcaaaat gagccctgtc ctgcctaagg 3048
 ctgaacttgt tttct 3063

<210> 188

<211> 795

<212> PRT

<213> Homo sapiens

<400> 188

Cys Glu Met Cys Ser Gln Glu Ala Phe Gln Ala Gln Arg Ser Gln Leu
 1 5 10 15
 Val Glu Leu Leu Val Ser Gly Ser Leu Glu Gly Phe Glu Ser Val Leu
 20 25 30
 Asp Trp Leu Leu Ser Trp Glu Val Leu Ser Trp Glu Asp Tyr Glu Gly
 35 40 45
 Phe His Leu Leu Gly Gln Pro Leu Ser His Leu Ala Arg Arg Leu Leu
 50 55 60
 Asp Thr Val Trp Asn Lys Gly Thr Trp Ala Cys Gln Lys Leu Ile Ala
 65 70 75 80
 Ala Ala Gln Glu Ala Gln Ala Asp Ser Gln Ser Pro Lys Leu His Gly
 85 90 95
 Cys Trp Asp Pro His Ser Leu His Pro Ala Arg Asp Leu Gln Ser His
 100 105 110
 Arg Pro Ala Ile Val Arg Arg Leu His Ser His Val Glu Asn Met Leu
 115 120 125
 Asp Leu Ala Trp Glu Arg Gly Phe Val Ser Gln Tyr Glu Cys Asp Glu
 130 135 140
 Ile Arg Leu Pro Ile Phe Thr Pro Ser Gln Arg Ala Arg Arg Leu Leu
 145 150 155 160
 Asp Leu Ala Thr Val Lys Ala Asn Gly Leu Ala Ala Phe Leu Leu Gln
 165 170 175
 His Val Gln Glu Leu Pro Val Pro Leu Ala Leu Pro Leu Glu Ala Ala
 180 185 190
 Thr Cys Lys Lys Tyr Met Ala Lys Leu Arg Thr Thr Val Ser Ala Gln
 195 200 205
 Ser Arg Phe Leu Ser Thr Tyr Asp Gly Ala Glu Thr Leu Cys Leu Glu
 210 215 220
 Asp Ile Tyr Thr Glu Asn Val Leu Glu Val Trp Ala Asp Val Gly Met
 225 230 235 240

Ala	Gly	Pro	Pro	Gln	Lys	Ser	Pro	Ala	Thr	Leu	Gly	Leu	Glu	Glu	Leu	
				245					250					255		
Phe	Ser	Thr	Pro	Gly	His	Leu	Asn	Asp	Asp	Ala	Asp	Thr	Val	Leu	Val	
			260					265					270			
Val	Gly	Glu	Ala	Gly	Ser	Gly	Lys	Ser	Thr	Leu	Leu	Gln	Arg	Leu	His	
		275					280					285				
Leu	Leu	Trp	Ala	Ala	Gly	Gln	Asp	Phe	Gln	Glu	Phe	Leu	Phe	Val	Phe	
		290				295					300					
Pro	Phe	Ser	Cys	Arg	Gln	Leu	Gln	Cys	Met	Ala	Lys	Pro	Leu	Ser	Val	
305					310					315					320	
Arg	Thr	Leu	Leu	Phe	Glu	His	Cys	Cys	Trp	Pro	Asp	Val	Gly	Gln	Glu	
				325					330					335		
Asp	Ile	Phe	Gln	Leu	Leu	Leu	Asp	His	Pro	Asp	Arg	Val	Leu	Leu	Thr	
			340					345					350			
Phe	Asp	Gly	Phe	Asp	Glu	Phe	Lys	Phe	Arg	Phe	Thr	Asp	Arg	Glu	Arg	
		355					360					365				
His	Cys	Ser	Pro	Thr	Asp	Pro	Thr	Ser	Val	Gln	Thr	Leu	Leu	Phe	Asn	
						375					380					
Leu	Leu	Gln	Gly	Asn	Leu	Leu	Lys	Asn	Ala	Arg	Lys	Val	Val	Thr	Ser	
385					390					395					400	
Arg	Pro	Ala	Ala	Val	Ser	Ala	Phe	Leu	Arg	Lys	Tyr	Ile	Arg	Thr	Glu	
				405					410					415		
Phe	Asn	Leu	Lys	Gly	Phe	Ser	Glu	Gln	Gly	Ile	Glu	Leu	Tyr	Leu	Arg	
			420					425					430			
Lys	Arg	His	His	Glu	Pro	Gly	Val	Ala	Asp	Arg	Leu	Ile	Arg	Leu	Leu	
		435					440					445				
Gln	Glu	Thr	Ser	Ala	Leu	His	Gly	Leu	Cys	His	Leu	Pro	Val	Phe	Ser	
	450					455					460					
Trp	Met	Val	Ser	Lys	Cys	His	Gln	Glu	Leu	Leu	Leu	Gln	Glu	Gly	Gly	
465					470					475					480	
Ser	Pro	Lys	Thr	Thr	Thr	Asp	Met	Tyr	Leu	Leu	Ile	Leu	Gln	His	Phe	
				485					490					495		
Leu	Leu	His	Ala	Thr	Pro	Pro	Asp	Ser	Ala	Ser	Gln	Gly	Leu	Gly	Pro	
			500					505					510			
Ser	Leu	Leu	Arg	Gly	Arg	Leu	Pro	Thr	Leu	Leu	His	Leu	Gly	Arg	Leu	
		515					520					525				
Ala	Leu	Trp	Gly	Leu	Gly	Met	Cys	Cys	Tyr	Val	Phe	Ser	Ala	Gln	Gln	
		530				535					540					
Leu	Gln	Ala	Ala	Gln	Val	Ser	Pro	Asp	Asp	Ile	Ser	Leu	Gly	Phe	Leu	
545					550					555					560	
Val	Arg	Ala	Lys	Gly	Val	Val	Pro	Gly	Ser	Thr	Ala	Pro	Leu	Glu	Phe	
				565					570					575		
Leu	His	Ile	Thr	Phe	Gln	Cys	Phe	Phe	Ala	Ala	Phe	Tyr	Leu	Ala	Leu	
			580					585					590			
Ser	Ala	Asp	Val	Pro	Pro	Ala	Leu	Leu	Arg	His	Leu	Phe	Asn	Cys	Gly	
		595					600					605				
Arg	Pro	Gly	Asn	Ser	Pro	Met	Ala	Arg	Leu	Leu	Pro	Thr	Met	Cys	Ile	
		610				615					620					
Gln	Ala	Ser	Glu	Gly	Lys	Asp	Ser	Ser	Val	Ala	Ala	Leu	Leu	Gln	Lys	
625					630					635					640	
Ala	Glu	Pro	His	Asn	Leu	Gln	Ile	Thr	Ala	Ala	Phe	Leu	Ala	Gly	Leu	
				645					650					655		
Leu	Ser	Arg	Glu	His	Trp	Gly	Leu	Leu	Ala	Glu	Cys	Gln	Thr	Ser	Glu	
			660				665					670				
Lys	Ala	Leu	Leu	Arg	Arg	Gln	Ala	Cys	Ala	Arg	Trp	Cys	Leu	Ala	Arg	

WO 01/90156

PCT/US01/17158

675	680	685
Ser Leu Arg Lys His Phe His	Ser Ile Pro Pro Ala Ala	Pro Gly Glu
690	695	700
Ala Lys Ser Val His Ala Met	Pro Gly Phe Ile Trp	Leu Ile Arg Ser
705	710	715
Leu Tyr Glu Met Gln Glu Glu	Arg Leu Ala Arg Lys	Ala Ala Arg Gly
725	730	735
Leu Asn Val Gly His Leu Lys	Leu Thr Phe Cys Ser	Val Gly Pro Thr
740	745	750
Glu Cys Ala Ala Leu Ala Phe	Val Leu Gln His Leu	Arg Arg Pro Val
755	760	765
Ala Leu Gln Leu Asp Tyr Asn	Ser Val Gly Asp Ile	Gly Val Glu Gln
770	775	780
Leu Leu Pro Cys Leu Gly Val	Cys Lys Ala Leu	
785	790	795

<210> 189

<211> 180

<212> PRT

<213> Homo sapiens

<400> 189

Phe Trp Gly Asn Arg Val Gly Asp	Glu Gly Ala Gln Ala Leu Ala Glu
1	5 10 15
Ala Leu Gly Asp His Gln Ser Leu Arg	Trp Leu Ser Leu Val Gly Asn
20	25 30
Asn Ile Gly Ser Val Gly Ala Gln Ala	Leu Ala Leu Met Leu Ala Lys
35	40 45
Asn Val Met Leu Glu Glu Leu Cys Leu	Glu Glu Asn His Leu Gln Asp
50	55 60
Glu Gly Val Cys Ser Leu Ala Glu Gly	Leu Lys Lys Asn Ser Ser Leu
65	70 75 80
Lys Ile Leu Asn Ile Lys Ile His Ala	Ser Gly Phe Asn Lys Leu Leu
85	90 95
Glu Ser Ile Phe Cys Ile Leu Leu Val	Val Glu Ala Phe Phe Leu Gln
100	105 110
Lys Val Val Lys Ile Leu Glu Glu Met	Val Val Ser Trp Leu Glu Val
115	120 125
Arg Leu Ser Asn Asn Cys Ile Thr Tyr	Leu Gly Ala Glu Ala Leu Leu
130	135 140
Gln Ala Leu Glu Arg Asn Asp Thr Ile	Leu Glu Val Trp Leu Arg Gly
145	150 155 160
Asn Thr Phe Ser Leu Glu Glu Val Asp	Lys Leu Gly Cys Arg Asp Thr
165	170 175
Arg Leu Leu Leu	
180	

<210> 190

<211> 721

<212> DNA

<213> Mus musculus

<220>

<221> CDS

<222> (193)...(612)

<400> 190

cctgggggttc ctgcacatta ccttccgtgc ttttttgccg ctttctactt ggctgtcagt 60
 gctgacacat cgggtggcctc tctcaagcac cttttcagct gtggccggct gggcagctca 120
 ctgctgggaa ggctgctgcc caacctgtgt atccagggt ccagagtcaa gaagggcagc 180
 gaagcagccc tg ctg cag aag gct gag cca cac aac ctg caa atc aca gca 231
 Leu Gln Lys Ala Glu Pro His Asn Leu Gln Ile Thr Ala
 1 5 10

gcc ttc cta gca ggt ctg ttg tcc cag cag cat cgg gac ctg ttg gct 279
 Ala Phe Leu Ala Gly Leu Leu Ser Gln Gln His Arg Asp Leu Leu Ala
 15 20 25

gca tgc cag gtc tcc gag agg gta ctg ctc cag cgt cag gca cgt gcc 327
 Ala Cys Gln Val Ser Glu Arg Val Leu Leu Gln Arg Gln Ala Arg Ala
 30 35 40 45

cgc tcg tgt ctg gcc cac agc ctc cgc gag cac ttc cat tcc atc ccg 375
 Arg Ser Cys Leu Ala His Ser Leu Arg Glu His Phe His Ser Ile Pro
 50 55 60

cct gcc gtg ccc ggt gag acc aag agc atg cat gct atg ccg ggc ttc 423
 Pro Ala Val Pro Gly Glu Thr Lys Ser Met His Ala Met Pro Gly Phe
 65 70 75

att tgg ctc atc cgt agc ctg tac gag atg cag gag gag cag ttg gcc 471
 Ile Trp Leu Ile Arg Ser Leu Tyr Glu Met Gln Glu Glu Gln Leu Ala
 80 85 90

cag gag gct gtc cgt cgc ttg gac atc ggg cac ctg aag ttg aca ttt 519
 Gln Glu Ala Val Arg Arg Leu Asp Ile Gly His Leu Lys Leu Thr Phe
 95 100 105

tgc aga gtg ggc cct gca gag tgt gct gca ctg gcc ttt gta ctg caa 567
 Cys Arg Val Gly Pro Ala Glu Cys Ala Ala Leu Ala Phe Val Leu Gln
 110 115 120 125

cat ctc cag cgg cct gtg gcc cta cag ctg gat tac aac tct gtg 612
 His Leu Gln Arg Pro Val Ala Leu Gln Leu Asp Tyr Asn Ser Val
 130 135 140

ggagatgttg ggagtgaac agctgcgacc gtgccttttg ggtctgcaca gctctgtagt 672
 gagtgtgaca aggtcttgcc gattgggcct gtggcaaagt ctactgtca 721

<210> 191

<211> 140

<212> PRT

<213> Mus musculus

<400> 191

Leu Gln Lys Ala Glu Pro His Asn Leu Gln Ile Thr Ala Ala Phe Leu
 1 5 10 15
 Ala Gly Leu Leu Ser Gln Gln His Arg Asp Leu Leu Ala Ala Cys Gln

WO 01/90156

PCT/US01/17158

			20					25						30					
Val	Ser	Glu	Arg	Val	Leu	Leu	Gln	Arg	Gln	Ala	Arg	Ala	Arg	Ser	Cys				
		35					40					45							
Leu	Ala	His	Ser	Leu	Arg	Glu	His	Phe	His	Ser	Ile	Pro	Pro	Ala	Val				
	50					55					60								
Pro	Gly	Glu	Thr	Lys	Ser	Met	His	Ala	Met	Pro	Gly	Phe	Ile	Trp	Leu				
65					70					75					80				
Ile	Arg	Ser	Leu	Tyr	Glu	Met	Gln	Glu	Glu	Gln	Leu	Ala	Gln	Glu	Ala				
				85				90						95					
Val	Arg	Arg	Leu	Asp	Ile	Gly	His	Leu	Lys	Leu	Thr	Phe	Cys	Arg	Val				
			100					105					110						
Gly	Pro	Ala	Glu	Cys	Ala	Ala	Leu	Ala	Phe	Val	Leu	Gln	His	Leu	Gln				
		115					120					125							
Arg	Pro	Val	Ala	Leu	Gln	Leu	Asp	Tyr	Asn	Ser	Val								
	130					135					140								

<210> 192

<211> 419

<212> DNA

<213> Mus musculus

<220>

<221> CDS

<222> (1)...(417)

<400> 192

ctg	cag	aag	gct	gag	cca	cac	aac	ctg	cag	atc	aca	gca	gcc	ttc	cta				48
Leu	Gln	Lys	Ala	Glu	Pro	His	Asn	Leu	Gln	Ile	Thr	Ala	Ala	Phe	Leu				
1				5				10						15					
gca	ggt	ctg	ttg	tcc	cag	cag	cat	cgg	gac	ctg	ttg	gct	gca	tgc	cag				96
Ala	Gly	Leu	Leu	Ser	Gln	Gln	His	Arg	Asp	Leu	Leu	Ala	Ala	Cys	Gln				
			20					25					30						
atc	tcc	gag	agg	gtg	ctg	ctc	cag	cgt	cag	gca	cgt	gcc	cgc	tcg	tgt				144
Ile	Ser	Glu	Arg	Val	Leu	Leu	Gln	Arg	Gln	Ala	Arg	Ala	Arg	Ser	Cys				
		35					40					45							
ctg	gcc	cac	agc	ctc	cgc	gag	cac	ttc	cat	tcc	atc	ccg	cct	gcc	gtg				192
Leu	Ala	His	Ser	Leu	Arg	Glu	His	Phe	His	Ser	Ile	Pro	Pro	Ala	Val				
	50					55					60								
ccc	ggt	gag	acc	aag	agc	atg	cat	gct	atg	ccg	ggc	ttt	att	tgg	ctc				240
Pro	Gly	Glu	Thr	Lys	Ser	Met	His	Ala	Met	Pro	Gly	Phe	Ile	Trp	Leu				
65					70					75					80				
atc	cgg	agc	ctg	tac	gag	atg	cag	gag	gag	cag	ttg	gcc	cag	gag	gct				288
Ile	Arg	Ser	Leu	Tyr	Glu	Met	Gln	Glu	Glu	Gln	Leu	Ala	Gln	Glu	Ala				
				85				90						95					
gtc	cgt	cgc	ttg	gac	atc	ggg	cac	ctg	aag	ttg	aca	ttt	tgc	aga	gtg				336
Val	Arg	Arg	Leu	Asp	Ile	Gly	His	Leu	Lys	Leu	Thr	Phe	Cys	Arg	Val				
			100					105					110						

WO 01/90156

PCT/US01/17158

ggc cct gca gag tgt gct gcg ctg gcc ttt gta ctg caa cat ctc cag 384
 Gly Pro Ala Glu Cys Ala Ala Leu Ala Phe Val Leu Gln His Leu Gln
 115 120 125

cgg cct gtg gcc cta cag ctg gat tac aac tct gt 419
 Arg Pro Val Ala Leu Gln Leu Asp Tyr Asn Ser
 130 135

<210> 193
 <211> 139
 <212> PRT
 <213> Mus musculus

<400> 193
 Leu Gln Lys Ala Glu Pro His Asn Leu Gln Ile Thr Ala Ala Phe Leu
 1 5 10 15
 Ala Gly Leu Leu Ser Gln Gln His Arg Asp Leu Leu Ala Ala Cys Gln
 20 25 30
 Ile Ser Glu Arg Val Leu Leu Gln Arg Gln Ala Arg Ala Arg Ser Cys
 35 40 45
 Leu Ala His Ser Leu Arg Glu His Phe His Ser Ile Pro Pro Ala Val
 50 55 60
 Pro Gly Glu Thr Lys Ser Met His Ala Met Pro Gly Phe Ile Trp Leu
 65 70 75 80
 Ile Arg Ser Leu Tyr Glu Met Gln Glu Glu Gln Leu Ala Gln Glu Ala
 85 90 95
 Val Arg Arg Leu Asp Ile Gly His Leu Lys Leu Thr Phe Cys Arg Val
 100 105 110
 Gly Pro Ala Glu Cys Ala Ala Leu Ala Phe Val Leu Gln His Leu Gln
 115 120 125
 Arg Pro Val Ala Leu Gln Leu Asp Tyr Asn Ser
 130 135

<210> 194
 <211> 26
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> primer

<400> 194
 ctgcagaagg ctgagccaca caacct 26

<210> 195
 <211> 30
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> primer

<400> 195

WO 01/90156

PCT/US01/17158

acagagttgt aatccagctg tagggccaca

30

We claim:

1. An isolated nucleic acid molecule
encoding a CARD-containing polypeptide, or a CARD, NB-
ARC, ANGIO-R, LRR or SAM domain therefrom, selected
5 from:

(a) DNA encoding a polypeptide
comprising the amino acid sequence set forth
in SEQ ID NOS: 12, 168, 188, 170, 172, 174,
176, 97, 99, 101, 103, 178, 180, 182, 184, 86
10 and 90; and

(b) DNA that hybridizes to the DNA of
(a) under moderately stringent conditions,
wherein said DNA encodes a biologically
active polypeptide.

15 2. The nucleic acid molecule of claim 1,
wherein the nucleotide sequence of said nucleic acid
molecule comprises any of SEQ ID NOS:11, 167, 187, 169,
171, 173, 175, 96, 98, 100, 102, 177, 179, 181, 183, 85
and 89.

20 3. The nucleic acid molecule of claim 1,
wherein said nucleic acid molecule is cDNA.

4. A vector containing the nucleic acid
molecule of claim 1.

5. Recombinant cells containing the nucleic
25 acid molecule of claim 1.

6. An isolated oligonucleotide comprising
at least 15 contiguous nucleotides of the nucleic acid
molecule of claim 2.

7. An oligonucleotide according to claim 6, wherein said oligonucleotide is labeled with a detectable marker.

8. A kit for detecting the presence of
5 CARD-encoding nucleic acid molecule comprising at least one oligonucleotide according to claim 6.

9. An isolated CARD-containing polypeptide, or a CARD, NB-ARC, ANGIO-R, LRR or SAM domain therefrom, comprising an amino acid sequence at least
10 70% identical to the amino acid sequence set forth in any of SEQ ID NOS:12, 168, 188, 170, 172, 174, 176, 97, 99, 101, 103, 178, 180, 182, 184, 86 and 90.

10. The CARD-containing polypeptide of claim
15 9, wherein said polypeptide is encoded by a nucleotide sequence set forth as any of SEQ ID NOS:11, 167, 187, 169, 171, 173, 175, 96, 98, 100, 102, 177, 179, 181, 183, 85 and 89.

11. A peptide, comprising at least 10
20 contiguous amino acids of the polypeptide of claim 9.

12. A method of producing a CARD-containing polypeptide comprising expressing the cDNA of claim 3 *in vitro* or in a cell under conditions suitable for expression of said polypeptide, wherein said cells are
25 selected from the group consisting of bacteria cells, yeast cells, plant cells, animal cells, mammalian cells and insect cells.

13. An isolated anti-CARD antibody having specific reactivity with the CARD-containing
30 polypeptide of claim 9.

14. The antibody of claim 13, wherein said antibody is a monoclonal antibody.

15. A cell line producing the monoclonal antibody of claim 14.

5 16. The antibody of claim 13, wherein said antibody is a polyclonal antibody.

17. A method for identifying a nucleic acid molecule encoding a CARD-containing polypeptide, said method comprising:

10 contacting a sample containing nucleic acids with an oligonucleotide according to claim 6, wherein said contacting is effected under high stringency hybridization conditions, and identifying a nucleic acid molecule which hybridizes thereto.

15 18. A method for detecting the presence of a CARD-containing polypeptide in a sample, said method comprising contacting a test sample with an antibody according to claim 13, detecting the presence of an antibody:CARD complex, and thereby detecting the
20 presence of a human CARD-containing polypeptide in said test sample.

19. A method of identifying a CARD-associated polypeptide (CAP) comprising the steps of:
 (a) contacting the CARD-containing
25 polypeptide of claim 9 with a candidate CAP;
 (b) detecting association of said CARD-containing polypeptide with said CAP.

20. A method of identifying an effective agent that alters the association of a CARD-containing polypeptide with a CARD-associated polypeptide (CAP), comprising the steps of:

- 5 (a) contacting the CARD-containing polypeptide of claim 9 and said CAP under conditions that allow said CARD-containing polypeptide and said CAP to associate with an agent suspected of being able to alter the
- 10 association of said CARD-containing polypeptide and said CAP; and
- (b) detecting the altered association of said CARD-containing polypeptide and said CAP, wherein said altered association
- 15 identifies an effective agent.

21. A method of identifying an effective agent that alters the association of a CARD-containing polypeptide with a CARD-associated polypeptide (CAP), comprising the steps of:

- 20 (a) contacting the CARD-containing polypeptide of claim 9 and said CAP under conditions that allow said CARD-containing polypeptide and said CAP to associate with an agent suspected of being able to alter the
- 25 association of said CARD-containing polypeptide and said CAP; and
- (b) detecting the altered association of said CARD-containing polypeptide and said CAP, wherein said altered association
- 30 identifies an effective agent, wherein said CAP is a CARD-containing polypeptide according to claim 9.

22. A method of altering the level of a biochemical process modulated by a CARD-containing polypeptide, comprising the steps of:

- 5 (a) introducing the nucleic acid molecule of claim 1 into a cell; and
- (b) expressing said nucleic acid molecule in said cell, whereby the expression of said nucleic acid alters the level of a biochemical process modulated by a CARD-containing polypeptide.
- 10

23. The method of claim 22, wherein said biochemical process modulated by a CARD-containing polypeptide is selected from the group consisting of apoptosis, NF-kB induction, cytokine processing, cJun

15 N-terminal kinase induction, caspase-mediated proteolysis, transcription, inflammation and cell adhesion.

24. A method of altering the level of a biochemical process modulated by a CARD-containing

20 polypeptide, comprising introducing an antisense nucleotide sequence into a cell, wherein said antisense nucleotide sequence specifically hybridizes to a nucleic acid molecule encoding the CARD-containing polypeptide of claim 11, whereby hybridization reduces

25 or inhibits the expression of said CARD-containing polypeptide in said cell.

25. A method of altering the level of a biochemical process modulated by a CARD-containing polypeptide, comprising contacting a sample with an

30 agent that effectively alters the association of the CARD-containing polypeptide of claim 9 with a CARD-associated polypeptide, whereby the level of a

biochemical process modulated by a CARD-containing polypeptide is altered.

26. A method of diagnosing or predicting clinical prognosis of a pathology characterized by an increased or decreased level of a CARD-containing polypeptide in a subject, comprising the steps of:
- (a) obtaining a test sample from the subject;
 - (b) contacting said test sample with an agent that can bind the CARD-containing polypeptide of claim 9 under suitable conditions, which allow specific binding of said agent to said CARD-containing polypeptide; and
 - (c) comparing the amount of said specific binding in said test sample with the amount of specific binding in a reference sample, wherein an increased or decreased amount of said specific binding in said test sample as compared to said reference sample is diagnostic or predictive of clinical prognosis of a pathology.

27. A composition comprising a compound selected from the group consisting of a CARD-containing polypeptide, a functional fragment therefrom, and an anti-CARD antibody; and a pharmaceutically acceptable carrier.

28. A method of treating a pathology characterized by abnormal cell proliferation, abnormal cell death, or inflammation, said method comprising administering to an individual an effective amount of the composition of claim 27.

29. A chimeric polypeptide comprising a domain selected from the group consisting of SEQ ID NOS:168, 170, 172, 174, 176, 178, 180, 182 and 184.

30. A method of identifying an effective agent that modulates an activity of a NB-ARC domain of a CARD-containing polypeptide, comprising the steps of:

(a) contacting a polypeptide comprising an NB-ARC domain set forth as either of SEQ ID NOS:174 or 180 with an agent known or suspected of modulating an activity of an NB-ARC domain; and

(b) measuring the activity of the NB-ARC domain, whereby an increase or decrease of said activity identifies said agent as an agent that modulates the activity of the NB-ARC domain of said CARD-containing polypeptide;

wherein the activity of the NB-ARC domain of said CARD-containing polypeptide is selected from homo-oligomerization, hetero-oligomerization, nucleotide hydrolysis, and nucleotide binding.

1/5




Figure 1A




Figure 1B



Figure 1C

2/5

CLANA	MNFIKDNSRALIQRMGMTVIKQITDDLFVWNVLNREEVNIICCEKVEQDAARGIIHMILKKGSES
CLANB	MNFIKDNSRALIQRMGMTVIKQITDDLFVWNVLNREEVNIICCEKVEQDAARGIIHMILKKGSES
CLANG	MNFIKDNSRALIQRMGMTVIKQITDDLFVWNVLNREEVNIICCEKVEQDAARGIIHMILKKGSES
CLAND	MNFIKDNSRALIQRMGMTVIKQITDDLFVWNVLNREEVNIICCEKVEQDAARGIIHMILKKGSES
CLANA	CNLFKSLKEWNYPLFQDLNGQSLFHQTSEGDLLDLAQDLKDLYHTPSFLNFYPLGEDIDIDIFNL
CLANB	CNLFKSLKEWNYPLFQDLNGQ-----
CLANG	CNLFKSLKEWNYPLFQDLNGQSLFHQTSEGDLLDLAQDLKDLYHTPSFLNFYPLGEDIDIDIFNL
CLAND	CNLFKSLKEWNYPLFQDLNGQSLTA
CLANA	KSTFTPEPLWRKDQHHRVEQLTLNGLLQALQSPCIEGESGKGKSTLLQRIAMLWGSGKCKALT
CLANB	-----
CLANG	KSTFTPEPLWRKDQHHRVEQLTLVL
CLANA	KFKFVFFLRLSRAQGGLFETLCDQLLDIPGTIRKQTFMAMLLKLRQRVLFLLDGYNEFKPQNCPE
CLANB	-----
CLANA	IEALIKENHREKNNMVIVTTTTECLRHIRQFGALTAEVGDMTEDSAQALIREVLIKELAEGLLLQI
CLANB	-----
CLANA	QKSRCCLRNLKMTPLFVVITCAIQMGESSEFHSHTQTTLFHTFYDLLIQKNKHKHKGVAAADFIRSL
CLANB	-----
CLANA	DHRGDLALEGVFESHKFDDELQDVSSVNEVDLLTTGLLCKYTAQREFKPKYKFFHKSEFQEYTAGRRL
CLANB	-----
CLANA	SSLTSHEPEEVTKGNGYLQKMVSISDITSTYSSLLRYTCGSSVEATRAVMKHLAAVYQHGCCLLG
CLANB	-----
CLANA	LSIAKRPLWRQESLQSVKNTTEQEILKAININSFVECGIHLVQESTSKSALSQEFEEAFFQGSLSY
CLANB	-----
CLANA	INSGNIPDYLFDFFEHLPNCASALDFIKLDFYGCAMASWEKAAEDTGGIHMEEAPEYYIPSRVVS
CLANB	-----
CLANA	LFENWKQEFRTLEVTLRDFSKLNKQDIRYLGKIFSSATSLRLQIKRCAGVAGSLSLVLSTCKNIY
CLANB	-----
CLANA	SLMVEASPLTIEDERHITSVTNLKTLSTHDLQNQRLPGLTDSLGNLKNLTKLIMDNIKMNEEDA
CLANB	-----GLTDSLGNLKNLTKLIMDNIKMNEEDA
CLANA	IKLAEGCLKNLKKMCLFHLTHLSDIGEGMDYIVKSLSSSEPCDLEEIQLVSCCLSANAVKILAQNLH
CLANB	IKLAEGCLKNLKKMCLFHLTHLSDIGEGMDYIVKSLSSSEPCDLEEIQLVSCCLSANAVKILAQNLH
CLANA	NLVKLSILDLSENYLEKDGNEALHELIDRMNVLEQLTALMLPWGCDVQGSLSLLKHLEEVPLV
CLANB	NLVKLSILDLSENYLEKDGNEALHELIDRMNVLEQLTALMLPWGCDVQGSLSLLKHLEEVPLV
CLANA	KLGKKNWRLTDTEIRILGAFFGKNPLKNFQQNLNLAGNRVSSDGLAFMGVFENLKQLVFFDFESTK
CLANB	KLGKKNWRLTDTEIRILGAFFGKNPLKNFQQNLNLAGNRVSSDGLAFMGVFENLKQLVFFDFESTK
CLANA	EFLPDPALVRKLSQVLSKLTFLQEARLVGNQFDDDDLSVITGAFKLVTA
CLANB	EFLPDPALVRKLSQVLSKLTFLQEARLVGNQFDDDDLSVITGAFKLVTA

Fig. 2




Figure 3

4/5

COP	MADKVLKEKRKLFIH	SMGEGTINGLLDELL	30
caspase-1	MADKVLKEKRKLFI	RSMGEGTINGLLDELL	30
	QTRVLNQ	EEMEKVKRENATVMDKTRALIDS	60
	QTRVLN	K EEMEKVKRENATVMDKTRALIDS	60
	VIPKGAQACQICITYICEEDSYLA	ETLGLS	90
	VIPKGAQACQICITYICEEDSYLA	G T L G L S	90
	AGPIRGN		97
	ADQTSGN		97

Figure 4

	MADKVLLEKRRKLLINS	LGEGTINGLLDELL	ETNVLSQEDM	Majority	
	10	20	30	40	
1	MADKVLKEKRRKLFIRSM	GEGTINGLLDELLQ	TRVLNKEEM	cas-1	
1	M - - ILLKRRRL	LLINS	LGEGTINGLLDELL	ETNVLSQEDT	cop-2
	EIVKRENATVIDKAR	ALLDSVIRKGAGACE	ICITYICEED	Majority	
	50	60	70	80	
41	EKVKRENATVM	DKTRALIDS	VIPKGAQACQ	ICITYICEED	cas-1
38	EIVKCENVT	VIDKARDL	LLDSVIRKGAGACE	ICITYICEED	cop-2
	SYLAGTLGLSAGNAVQ	AGGACSTSSGQDL		Majority	
	90	100			
81	SYLAGTLGLSAPQ	AVQDNPA	MPTSSG	cas-1	
78	RYLAGTLGLSAGN	DYRAGGI	CSPPRAQDL	cop-2	

Figure 5




Figure 6

